SUMO Protocols
Series Editor John M. Walker School of Life Sciences University of Hertfordshire Hatfield, Hertfordshir...
29 downloads
935 Views
5MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
SUMO Protocols
Series Editor John M. Walker School of Life Sciences University of Hertfordshire Hatfield, Hertfordshire, AL10 9AB, UK
For other titles published in this series, go to www.springer.com/series/7651
METHODS
IN
MOLECULAR BIOLOGY™
SUMO Protocols
Edited by
Helle D. Ulrich Cancer Research UK, London Research Institute, Clare Hall Laboratories, Blanche Lane, South Mimms Hertfordshire, United Kingdom
Editor Helle D. Ulrich Cancer Research UK London Research Institute Clare Hall Laboratories Blanche Lane South Mimms EN6 3LD Herts United Kingdom
ISBN: 978-1-934115-80-0 e-ISBN: 978-1-59745-566-4 ISSN: 1064-3745 e-ISSN: 1940-6029 DOI: 10.1007/978-1-59745-566-4 Library of Congress Control Number: 2008931471 © Humana Press 2009, a part of Springer Science+Business Media, LLC All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science + Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. Cover illustration: Chapter 8, Figure 1: The SBMs of RanBP2 and PIAS-X-P bind SUMO-1 in opposite orientations. Printed on acid-free paper springer.com
Preface Post-translational protein modifications by members of the ubiquitin family are widely recognized as important regulatory control systems for a variety of biological pathways. Their influence on eukaryotic cellular metabolism is comparable to that of other modifications such as phosphorylation, acetylation and methylation. The small ubiquitin-related modifier SUMO uses a conjugation and de-conjugation system closely related to that of ubiquitin itself; yet, the functions of the SUMO system are highly diverse and largely independent of the ubiquitin system. SUMO modification controls the activity of transcription factors and can influence protein stability, but it also contributes to nucleo-cytoplasmic transport, chromosome segregation and DNA damage repair. As a consequence, the SUMO system pervades virtually all areas of basic molecular and cell biology, and scientists from different backgrounds, including medical researchers, are likely to encounter SUMO in the course of their studies. This volume, SUMO Protocols, therefore aims at presenting a collection of methods relevant to SUMO research in order to make these tools available to biochemists, molecular and cell biologists as well as research-oriented clinicians not yet familiar with the system. In contrast to the ubiquitin system, which has been the subject of several reviews and methods collections, no practical compendium entirely devoted to SUMO has been published. Although some of the protocols described here are related to analogous techniques pertaining to the ubiquitin system, SUMO Protocols is intended to highlight important features unique to the biochemistry of SUMO, necessitating a distinction from other ubiquitin-like modifiers. For example, conjugation and de-conjugation assays require different components, and some technology, such as the identification of target proteins by mass spectrometry, is more difficult with SUMO than with ubiquitin due to the structure and sequence of the modifier. On the other hand, the preparation of sumoylated substrates in vitro or even in bacterial systems is generally more straightforward than in the case of ubiquitin. This volume presents a collection of methods for the in vivo and in vitro manipulation of the SUMO system. Part I provides an introduction to the SUMO system for researchers new to the field, giving an overview of the most important components and regulatory concepts (Chap. 1). Part II describes several approaches for the identification and verification of SUMO substrates. Whereas Chaps. 2 and 3 review different mass spectrometrybased techniques for the isolation and identification of target proteins from total cell extracts, Chap. 4 presents an orthogonal approach based on the use of in vitro translated protein libraries and in vitro sumoylation reactions. This is followed by two chapters describing strategies that facilitate the detection of specific SUMO targets in vivo: Chap. 5 details a method to enhance native sumoylation by fusion of candidate substrates to the SUMO-conjugating enzyme Ubc9, and Chap. 6 gives a step-by-step account of isolating SUMO targets by affinity chromatography under denaturing conditions, a method that is often applied in conjunction with mass spectrometry, but is also useful for the verification and characterization of specific target proteins. Part III is devoted to the downstream effectors of the SUMO pathway, i.e. factors that interact with sumoylated target proteins
v
vi
Preface
via SUMO-interacting motifs. Two chapters describe methodology for the identification and characterization of SUMO interactors by means of two-hybrid analysis (Chap. 7) and NMR (Chap. 8). The functional consequences of SUMO modification are too manifold to be thoroughly covered in a protocols collection. After all, they will most likely be unique to the SUMO target in question and therefore require specialized methodology. Nevertheless, Part IV of this volume covers two generally applicable strategies useful for the functional analysis of sumoylation in vivo. Chap. 9 uses linear fusions of SUMO to a given target protein in order to mimic its sumoylation. Although it is presented in the context of transcriptional repression, thus reflecting the predominant influence of the SUMO system on this area of cell biology, the approach can easily be adapted to the study of other SUMO targets. Chap. 10 describes a tool to mimic reversible, ligand-induced sumoylation that allows an assessment of the consequences of the modification for a given target protein by comparing its properties in the modified and un-modified state. The second half of the book brings together essential methods for the study and manipulation of the enzymatic components of the SUMO system. Part V comprises methodology for the purification and kinetic characterization of the SUMO conjugation enzymes (Chaps. 11 and 12) as well as the preparation of quantitatively sumoylated proteins for biochemical analysis in vitro (Chap. 13) and in a bacterial expression system (Chap. 14). The reverse reaction, de-conjugation by dedicated SUMO-specific proteases, is covered in Part VI, which presents a protocol for the preparation and purification of the relevant enzymes (Chap. 15) and a range of alternative approaches for the kinetic analysis of de-conjugation (Chaps. 15–18), applicable to endogenous as well as synthetic test substrates and SUMO precursors and using detection systems based on gel mobility, fluorescence resonance energy transfer (FRET) and an enzymatic reporter system. Finally, Part VII reviews two strategies of how the SUMO system can be manipulated and exploited experimentally. Chap. 19 describes the viral protein Gam1 and its uses as an inhibitor of the SUMO conjugation machinery, and the application of SUMO as a tool to enhance the efficiency of recombinant protein production is detailed in Chap. 20. I am grateful to the authors who have contributed their expertise to make this book possible. I thank John Walker, the series editor, for his advice, and the colleagues at Humana Press for producing this book.
Helle D. Ulrich
Contents Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Contributors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
v ix
PART I: INTRODUCTION 1.
The SUMO System: An Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Helle D. Ulrich
3
PART II: IDENTIFICATION OF SUMO TARGETS 2.
3.
4.
5.
6.
Identification of SUMO Target Proteins by Quantitative Proteomics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Jens S. Andersen, Ivan Matic, and Alfred C.O. Vertegaal Identification of SUMO-Conjugated Proteins and their SUMO Attachment Sites Using Proteomic Mass Spectrometry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . James A. Wohlschlegel Identification of SUMO Targets Through In Vitro Expression Cloning . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Christian B. Gocke and Hongtao Yu Enhanced Detection of In Vivo SUMO Conjugation by Ubc9 Fusion-Dependent Sumoylation (UFDS). . . . . . . . . . . . . . . . . . . . . . . . Rainer Niedenthal In Vivo Detection and Characterization of Sumoylation Targets in Saccharomyces cerevisiae . . . . . . . . . . . . . . . . . . . . . . . . Helle D. Ulrich and Adelina A. Davies
19
33
51
63
81
PART III: IDENTIFICATION OF SUMO INTERACTORS 7.
8.
Identification of SUMO-Interacting Proteins by Yeast Two-Hybrid Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107 Mary B. Kroetz and Mark Hochstrasser Identification of SUMO-Binding Motifs by NMR . . . . . . . . . . . . . . . . . . . . . . . . 121 Candace S. Seu and Yuan Chen
PART IV: FUNCTIONAL ANALYSIS OF SUMOYLATION IN VIVO 9.
Regulation of Transcription Factor Activity by SUMO Modification . . . . . . . . . . 141 Jian Ouyang, Alvaro Valin, and Grace Gill 10. Characterization of the Effects and Functions of Sumoylation Through Rapamycin-Mediated Heterodimerization. . . . . . . . . . . 153 Shanshan Zhu and Michael J. Matunis
vii
viii
Contents
PART V: BIOCHEMICAL STUDIES OF SUMO CONJUGATION 11. Purification of SUMO Conjugating Enzymes and Kinetic Analysis of Substrate Conjugation . . . . . . . . . . . . . . . . . . . . . . . . . . . Ali A. Yunus and Christopher D. Lima 12. Performing In Vitro Sumoylation Reactions Using Recombinant Enzymes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Andreas Werner, Marie-Christine Moutty, Ulrike Möller, and Frauke Melchior 13. Preparation of Sumoylated Substrates for Biochemical Analysis . . . . . . . . . . . . . Puck Knipscheer, Helene Klug, Titia K. Sixma, and Andrea Pichler 14. Strategies for the Expression of SUMO-Modified Target Proteins in Escherichia coli . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hisato Saitoh, Junsuke Uwada, and Azusa Kawasaki
167
187
201
211
PART VI: BIOCHEMICAL STUDIES OF SUMO DECONJUGATION 15. Preparation of SUMO Proteases and Kinetic Analysis Using Endogenous Substrates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . David Reverter and Christopher D. Lima 16. An In Vitro FRET-Based Assay for the Analysis of SUMO Conjugation and Isopeptidase Cleavage. . . . . . . . . . . . . . . . . . . . . . . Nicolas Stankovic-Valentin, Lukasz Kozaczkiewicz, Katja Curth, and Frauke Melchior 17. FRET-Based In Vitro Assays for the Analysis of SUMO Protease Activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Michael H. Tatham and Ronald T. Hay 18. Detection and Characterization of SUMO Protease Activity Using a Sensitive Enzyme-Based Reporter Assay . . . . . . . . . . . . . . . . . . Craig A. Leach, Xufan Tian, Michael R. Mattern, and Benjamin Nicholson
225
241
253
269
PART VII: MANIPULATION AND ALTERNATIVE USES OF THE SUMO SYSTEM 19. Inhibition of the SUMO Pathway by Gam1. . . . . . . . . . . . . . . . . . . . . . . . . . . . Mariaelena Pozzebon, Chiara V. Segré, and Susanna Chiocca 20. SUMO Fusion Technology for Enhanced Protein Production in Prokaryotic and Eukaryotic Expression Systems. . . . . . . . . . . . . . Tadas Panavas, Carsten Sanders, and Tauseef R. Butt Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
285
303 319
Contributors JENS S. ANDERSEN • Center for Experimental Bioinformatics (CEBI), Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark TAUSEEF BUTT • LifeSensors Inc., Malvern, PA, USA YUAN CHEN • Division of Immunology, Beckman Research Institute of the City of Hope, Duarte, CA, USA SUSANNA CHIOCCA • Department of Experimental Oncology, European Institute of Oncology, Milan, Italy KATJA CURTH • Department of Biochemistry I, Faculty of Medicine, Georg-August University of Göttingen, Germany ADELINA A. DAVIES • Cancer Research UK London Research Institute, Clare Hall Laboratories, South Mimms, United Kingdom GRACE GILL • Department of Anatomy and Cellular Biology, Tufts University School of Medicine, Boston, MA, USA CHRISTIAN B. GOCKE • Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, TX, USA RONALD T. HAY • Wellcome Trust Centre for Gene Regulation and Expression, College of Life Sciences, University of Dundee, United Kingdom MARK HOCHSTRASSER • Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT, USA AZUSA KAWASAKI • Department of Biological Sciences, Graduate School of Science and Technology, Kumamoto University, Kumamoto, Japan HELENE KLUG • Max F. Perutz Laboratories, Medical University of Vienna, Austria PUCK KNIPSCHEER • Department of Biological Chemisty and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA LUKASZ KOZACZKIEWICZ • Department of Biochemistry I, Faculty of Medicine, Georg-August University of Göttingen, Germany MARY B. KROETZ • Department of Cell Biology, Yale University, New Haven, CT, USA CRAIG A. LEACH, Progenra Inc., Malvern, PA, USA CHRISTOPHER D. LIMA • Structural Biology Program, Sloan-Kettering Institute, New York, NY, USA IVAN MATIC • Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany MICHAEL R. MATTERN • Progenra Inc., Malvern, PA, USA MICHAEL J. MATUNIS • Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA FRAUKE MELCHIOR • Department of Biochemistry I, Faculty of Medicine, Georg-August University of Göttingen, Germany ULRIKE MÖLLER • Department of Biochemistry I, Faculty of Medicine, Georg-August University of Göttingen, Germany MARIE-CHRISTINE MOUTTY • Department of Biochemistry I, Faculty of Medicine, Georg-August University of Göttingen, Germany BENJAMIN NICHOLSON • Progenra Inc., Malvern, PA, USA RAINER NIEDENTHAL • Institute of Biochemistry/Physiological Chemistry, Medical School Hannover, Germany
ix
x
Contributors
JIAN OUYANG • Department of Anatomy and Cellular Biology, Tufts University School of Medicine, Boston, MA, USA TADAS PANAVAS • LifeSensors Inc., Malvern, PA, USA MARIAELENA POZZEBON • FIRC Institute of Molecular Oncology, European Institute of Oncology (IFOM-IEO), Milan, Italy DAVID REVERTER • Institut de Biotecnologia i de Biomedicina. Universitat Autonoma de Barcelona, Barcelona, Spain HISATO SAITOH • Department of Biological Sciences, Graduate School of Science and Technology, Kumamoto University, Kumamoto, Japan CARSTEN SANDERS • LifeSensors Inc., Malvern, PA, USA CHIARA V. SEGRE • FIRC Institute of Molecular Oncology, European Institute of Oncology (IFOM-IEO), Milan, Italy CANDACE S. SEU • Department of Chemistry and Biochemistry, University of California, San Diego, CA, USA TITIA K. SIXMA • The Netherlands Cancer Institute and Center for Biomedical Genetics, Amsterdam, The Netherlands NICOLAS STANKOVIC-VALENTIN • Department of Biochemistry I, Faculty of Medicine, Georg-August University of Göttingen, Germany MICHAEL H. TATHAM • Wellcome Trust Centre for Gene Regulation and Expression, College of Life Sciences, University of Dundee, United Kingdom XUFAN TIAN • Progenra Inc., Malvern, PA, USA HELLE D. ULRICH • Cancer Research UK London Research Institute, Clare Hall Laboratories, South Mimms, United Kingdom JUNSUKE UWADA • Department of Biological Sciences, Graduate School of Science and Technology, Kumamoto University, Kumamoto, Japan ALVARO VALIN • Department of Anatomy and Cellular Biology, Tufts University School of Medicine, Boston, MA, USA ALFRED C.O. VERTEGAAL • Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, The Netherlands ANDREAS WERNER • Department of Biochemistry I, Faculty of Medicine, Georg-August University of Göttingen, Germany JAMES A. WOHLSCHLEGEL • Department of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, CA, USA HONGTAO YU • Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, TX, USA ALI A. YUNUS • Structural Biology Program, Sloan-Kettering Institute, New York, NY, USA SHANSHAN ZHU • Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
Chapter 1 The SUMO System: An Overview Helle D. Ulrich Abstract Post-translational modification by SUMO is now recognized as an important regulatory method employed by the cell to reversibly modulate the activity, stability, or localization of intracellular proteins. A dedicated enzymatic machinery is involved in the processing, attachment, and removal of the modifier with high selectivity. SUMO modification generally alters the properties of the modified target by influencing—either positively or negatively—its interactions with other cellular factors. As a consequence, the SUMO system contributes to the regulation of numerous biological pathways, ranging from nucleocytoplasmic transport to the repression of transcriptional activity and the maintenance of genome stability by its influence on DNA recombination and repair. This chapter gives a brief overview over the enzymes of the SUMO system, its regulation, and its functions. Key words: SUMO, SUMO-activating enzyme (E1), SUMO-conjugating enzyme (E2), SUMO ligase (E3), SUMO-specific isopeptidase (SENP), SUMO interaction motif (SIM), SUMO-binding motif (SBM).
1. Introduction The small ubiquitin-like modifier SUMO belongs to a family of structurally related proteins, of which ubiquitin is the most prominent member (1,2). These proteins operate according to a common principle, which involves their covalent attachment to other cellular factors. A dedicated enzymatic machinery is used to afford conjugation of the modifier by its conserved carboxy (C)terminal glycine residue to an amino group, usually of an internal lysine residue, on the target. In this way, ubiquitin-like proteins change the properties or interactions of the modified substrate and elicit a downstream response, often by the recognition of the modifier through specific interaction domains of an effector protein. Conjugation requires energy and is readily reversible, and an Helle D. Ulrich (ed.), Methods in Molecular Biology: SUMO Protocols, vol. 497 © 2009 Humana Press, a part of Springer Science + Business Media, New York, NY Book doi: 10.1007/978-1-59745-566-4
3
4
Ulrich
ensemble of specialized enzymes conveys selectivity and dynamic regulation to both the forward and the reverse reactions. In this way, modification by the members of the ubiquitin family can be compared to any other post-translational protein modification, such as phosphorylation or acetylation. The functional implications of the modification are similarly manifold and complex. The biological functions of the SUMO system have been the subject of many excellent reviews (1–4). This chapter will only provide a brief overview of the SUMO pathway. Its intention is to give an account of the enzymes involved in SUMO conjugation and deconjugation, highlight the concepts of how sumoylation can affect its target proteins, and point out possible mechanisms of how the process is regulated in vivo. For further information, the reader will be referred to appropriate review articles that discuss each aspect of the SUMO system individually and in greater detail. Hence, this introductory chapter should serve as a starting point for an exploration of the SUMO system, providing a background for the more practical aspects of manipulating the pathway that will be discussed in the following chapters.
2. SUMO Isoforms SUMO has been identified in a variety of different contexts and has consequently received many alternative names, such as sentrin, Ubl1, Pic1, Gmp1, and Smt3 (3). Like ubiquitin, SUMO is produced as an immature precursor protein with a C-terminal appendage that needs to be processed in order to expose the mature C-terminal di-glycine motif for conjugation. Despite its overall structural similarity to ubiquitin, however, sequence and surface properties of SUMO are quite distinct, and the protein bears an unstructured amino (N)-terminal extension that is not shared by other ubiquitin-related modifiers. In addition, higher eukaryotes harbor several paralogs of SUMO, which differ significantly in sequence (Fig. 1.1). Whereas yeast cells express only one form of SUMO, encoded by the SMT3 gene, mammalian cells encode four isoforms, SUMO-1, -2, -3, and -4 (see Table 1.1). A unique proline residue at position 90 prevents the processing of SUMO-4, which makes it unlikely that the protein
Fig. 1.1. Sequence alignment of yeast and mammalian SUMO paralogs. Sumoylation consensus sequences in the N termini of Smt3, SUMO-2, and SUMO-3, involved in poly-SUMO chain formation, and proline 90, which prevents processing in SUMO-4, are highlighted in bold. The cleavable C-terminal extensions of Smt3 and SUMO-1, -2, and -3 are indicated in italics.
The SUMO System – An Overview
5
Table 1.1 Components of the SUMO pathway in mammals and yeasts
Modifier
Mammals
S. cerevisiae
S. pombe
SUMO-1
Smt3
Pmt3
SUMO-2 SUMO-3 [SUMO-4]a Activating enzyme (E1)
Sae1 (Aos1)/Sae2 (Uba2)
Aos1/Uba2
Rad31/Fub2
Conjugating enzyme (E2)
Ubc9
Ubc9
Hus5
Ligase (E3)—SP-RING:
PIAS1
Siz1 (Ull1)
Pli1
PIAS3
Siz2 (Nfi1)
Nse2
PIASxα (ARIP3)
Mms21
PIASxβ (Miz1)
Zip3
PIASy Mms21 (Nse2) Ligase (E3)—Others:
RanBP2 (Nup358) Pc2b HDAC4b RSUMEc
Protease (SENP)
SENP1 (SuPr-2)
Ulp1 (Nib1)
Ulp1
SENP2 (AXAM2, SMT3IP2)
Ulp2 (Smt4)
Ulp2
SENP3 (SSP3, SMT3IP1) SENP5 SENP6 (SUSP1, SSP1) SENP7 Alternative names of individual enzymes are given in parentheses. a This SUMO isoform does not appear to be conjugated in vivo. b These factors act as substrate-selective enhancers of sumoylation, although their categorization as classical E3 enzymes is still a matter of debate. c This factor acts as a general enhancer of SUMO conjugation and stimulates the modification of selected model substrates in vitro, but substrate-specific E3 activity remains to be confirmed.
is ever conjugated in vivo (5). Its biological relevance is still a matter of debate, but it may fulfill a specialized function by means of noncovalent interactions. SUMO-2 and -3 are nearly identical in sequence and appear to act in a redundant fashion, but they differ significantly from SUMO-1, sharing only 50% sequence identity. Functional differences between SUMO-1 and SUMO-2
6
Ulrich
or -3 are implicated by their respective intracellular distributions, distinct changes in expression and conjugation patterns in the cellular stress response, and differences in their interactions with downstream effector proteins and SUMO-specific isopeptidases (6,7). For the purpose of this volume, SUMO will therefore serve as a general term applicable to all mammalian isoforms as well as the yeast protein, and individual forms will only be specified where necessary. Like ubiquitin, SUMO can form polymeric chains in vitro and in vivo (8). In mammals, this is primarily due to SUMO-2 and -3, which—like yeast Smt3—bear sumoylation consensus motifs in their N-terminal extensions (see below). Despite the fact that poly-SUMO chains are detectable in yeast and mammals (9–12), their biological function remains unclear. In yeast, they may contribute to the structural integrity of the synaptonemal complex during meiosis (13).
3. SUMO Conjugation, Processing, and Deconjugation
In analogy to the ubiquitin system, attachment of SUMO to a target protein is mediated by a cascade of enzymes responsible for energy-dependent activation, transfer, and substrate-selective conjugation of the modifier (Fig. 1.2). In contrast, removal of SUMO is accomplished in a single step that does not require energy. Yet, the diversity of the SUMO-specific proteases is comparable to that of the ligases, suggesting similar levels of complexity in the regulation of SUMO conjugation and deconjugation.
3.1. SUMO-Activating Enzyme (E1)
The SUMO-activating enzyme (E1) functions mechanistically similar to the ubiquitin-specific E1, and the two proteins are related in structure and sequence (14,15). SUMO E1 is a heterodimer; its subunits Aos1 (also called Sae1) and Uba2 (also called Sae2) resemble the N- and C-terminal halves of the ubiquitin-specific E1, Uba1. Uba2 carries a conserved active-site cysteine essential for catalysis. SUMO is activated by E1 in a three-step reaction: in the first step, a SUMO-adenylate intermediate is formed by attack of the C-terminal carboxylate of SUMO on ATP and release of pyrophosphate. In the second step, AMP is released as the SUMO C terminus is transferred to the catalytic cysteine of Uba2, forming a high-energy thioester intermediate. Finally, the SUMO thioester is transferred to the SUMO-conjugating enzyme.
3.2. SUMOConjugating Enzyme (E2)
In contrast to the ubiquitin system, a single, essential conjugating enzyme Ubc9 is responsible for all SUMO conjugations in eukaryotic cells (16). The structure and sequence of Ubc9 is closely related to that of the ubiquitin-specific E2s (17), and like
The SUMO System – An Overview
7
Fig. 1.2. The SUMO pathway of processing, conjugation, and deconjugation. SUMO is depicted as a grey lollipop symbol. The high-energy thioester bond between the mature C terminus of SUMO and the E1 (Aos1/Uba2) or E2 (Ubc9) enzyme is represented by a wavy line (∼).
these it bears a conserved cysteine residue in its active site that receives the modifier as a thioester from the E1. Attack of the ε-amino group of a substrate lysine residue then results in the formation of an isopeptide linkage between the C terminus of SUMO and the target protein. In vitro, this reaction often proceeds with significant specificity in the absence of a ligase, because in contrast to most ubiquitin-specific E2s Ubc9 often directly participates in substrate recognition. Ubc9 recognizes and modifies a consensus sequence motif, ΨKX(E/D) (where Ψ represents a bulky aliphatic residue, usually isoleucine, leucine, or valine, and X represents any amino acid), specifically when this motif is present in an unstructured region or a loop (18,19). The consensus sequence is found in many physiological SUMO targets as well as the N-terminal extensions of SUMO-2/3 and yeast Smt3, where it is used for the formation of poly-SUMO chains. In some SUMO targets, this motif is extended by a serine residue, whose phosphorylation enhances sumoylation (ΨKXEXXpSP), or a series of negatively charged residues (20,21). However, it is important to note that not all physiological SUMO acceptor sites adhere to this consensus. In fact, even in cases where a primary acceptor lysine can be identified, mutation of this site may result
8
Ulrich
in modification at other lysines that are not normally used for conjugation. This effect must be considered when trying to identify sumoylation sites by means of site-directed mutagenesis. 3.3. SUMO Ligases (E3)
SUMO ligases (E3s) fall into several classes (see Table 1.1). Most of the E3s known today harbor a RING finger-like domain, a so-called SP-RING motif (22). Like the RING finger in ubiquitinspecific E3s, this domain is required for ligase activity, although it does not appear to contribute any catalytic residues important for SUMO transfer. It is more likely to act as a binding platform that coordinates the contact between the E2 and the substrate. Among the SP-RING proteins, the PIAS (protein inhibitor of activated STAT) family is most prominent, comprising five distinct forms in mammals, some of them generated by alternative splicing: PIAS1, PIAS3, PIASxα, PIASxβ, and PIASy (23,24). S. cerevisiae encodes two PIAS proteins: Siz1 (also called Ull1) and Siz2 (also called Nfi1) (25). Additional SP-RING E3s are budding yeast Zip3, which functions during meiosis (13), and Mms21 (also called Nse2), a component of the chromatin-associated Smc5–Smc6 complex conserved from yeast to mammals (26–28). Generally, the SP-RING E3s appear to convey substrate selectivity to the SUMO conjugation reaction; however, there is evidence for functional overlap between different PIAS proteins (9), and in vitro sumoylation reactions often tend to be somewhat promiscuous with respect to the ligase. The SUMO ligase RanBP2 does not resemble any ubiquitin-specific enzyme or in fact any other SUMO E3 (29). A short, largely unstructured domain of RanBP2 is able to catalyze sumoylation by folding around the E2 and positioning the SUMO thioester on the Ubc9 surface in a conformation favorable for attack by a substrate lysine (30). In this way, RanBP2 promotes SUMO conjugation in a substrate-independent manner. A nonspecific stimulation of the sumoylation reaction has also been reported in the case of RSUME, a small protein capable of enhancing Ubc9–SUMO interaction and thioester formation (31). Another category of SUMO E3s is represented by the polycomb group protein Pc2, which promotes the sumoylation of the transcriptional corepressor CtBP in vivo and in vitro (32). However, its stimulating activity on sumoylation in vitro is modest, and other ligases can also enhance CtBP modification. Hence, it remains unclear whether Pc2 can be considered a genuine SUMO E3 or rather an ancillary factor that promotes sumoylation of CtBP indirectly by stabilizing the target or promoting protein–protein interactions (33). Similarly, the histone deacetylase HDAC4, itself a sumoylation target, was shown to stimulate SUMO conjugation in some contexts, but again, it remains to be determined whether this activity fits the criteria of an E3 (34).
The SUMO System – An Overview
3.4. SUMO-Specific Proteases (SENPs)
4. Biological Functions of Sumoylation
9
Cleavage at the C terminus of SUMO serves two distinct purposes (Fig. 1.2): on one hand, the SUMO precursors need to be converted to mature SUMO by removal of the C-terminal extension; this obviously requires the cleavage of a linear peptide bond, which is also called C-terminal hydrolase activity. On the other hand, removal of SUMO from target proteins or the processing of poly-SUMO chains, i.e., the reversal of the conjugation reaction, requires the cleavage of an isopeptide bond, or isopeptidase activity. A single class of enzymes that is responsible for both types of activities (see Table 1.1) has been identified. In humans, there are six so-called “sentrin-specific proteases” (SENPs): SENP1-3 and SENP5-7 (6,35). The proteins exhibit distinct preferences in terms of their activities not only towards SUMO maturation versus deconjugation but also with respect to the different SUMO isoforms. Their intracellular localizations indicate nonoverlapping functions, and the consequences of deleting or silencing individual SENPs suggest that their contributions to the dynamic regulation of sumoylation may be at least as important as those of the E3s. In S. cerevisiae, the two SENPs Ulp1 and Ulp2 (also called Smt4) are also distinct in terms of their localization and function (36,37). Ulp1 is solely responsible for precursor cleavage and localizes to the nuclear pores. A ulp1∆ deletion is inviable and cannot fully be rescued by concomitant expression of the mature form of SMT3, indicating that a lack of precursor processing is not primarily responsible for the phenotype. Ulp2 localizes to the nucleus and is nonessential. Thus, the two isopeptidases appear to process distinct sets of substrates and cannot compensate for each other.
The SUMO system plays an essential role in most organisms. Deletion of mutants of either the modifier or the E1 or E2 is inviable in budding yeast and shows severe growth defects in fission yeast, and deletion of Ubc9 in mice causes early embryonic lethality (14,38–41). Yet, it is still unclear whether there is one single essential function of SUMO, and no common theme can be ascribed to the effects that the modifier exerts on its target proteins. Similar to other post-translational modifications, such as phosphorylation, the SUMO system is involved in the regulation of a variety of distinct biological pathways that have been the subject of several excellent reviews (42–48). Despite this functional variety, however, a few general concepts are beginning to emerge for the mechanism of action of the SUMO system. It has become apparent that SUMO most often acts by modulating the
10
Ulrich
interactions of its target proteins with other cellular factors. In many cases the SUMO moiety will provide an additional binding site for another protein, thus causing the recruitment of a downstream effector (see below) or the targeting of the substrate to a specific location within the cell (44,49). Alternatively, SUMO may prevent protein–protein interactions by blocking interaction sites. A sumoylation-induced conformational change by means of an intramolecular interaction with the SUMO moiety has also been reported (50). Finally, it is possible that sumoylation may interfere with other post-translational modifications, such as ubiquitylation on the same lysine or phosphorylation at a nearby site (45). As a consequence, SUMO modification can affect the intracellular localization of a target protein, its enzymatic activity, its stability, or its interactions with other proteins or DNA. Two aspects of SUMO function that have been studied in particular detail are briefly discussed below. 4.1. SUMO and the Regulation of Transcription
In mammalian cells, a regulatory effect on gene expression is perhaps the best-studied area of SUMO function, as many of the sumoylation targets identified in this system have turned out to be transcription factors. In many, but not all cases, sumoylation causes a repression of transcription, resulting in hyperactivation of transcription upon mutation of the sumoylation sites in the target proteins (42,51). In fact, a linear fusion of SUMO to the Gal4 DNA-binding domain was shown to exert a negative effect on transcription, provided that a cognate DNA sequence was present in the promoter region of the reporter gene (52). There are, however, several different mechanisms by which SUMO can repress transcription, apparently dependent on the respective target protein. Some transcription factors were found to be sequestered into nuclear PML bodies upon sumoylation, thus making them unavailable for transcriptional activation. In other cases, sumoylation was shown to recruit histone deacetylases (HDACs), thus causing transcriptional repression via chromatin modifications at the relevant promoters. In addition, sumoylation of HDAC proteins themselves was found to enhance their repressive activity. Likewise, the transcriptional corepressor Daxx, itself a sumoylation target, is recruited by sumoylation of several transcription factors, although the downstream events leading to repression are still unclear (53). Finally, the PIAS proteins themselves, by interaction with sumoylated transcription factors, may play a role in the repression of transcription independent of their E3 activity (23,24).
4.2. SUMO and the Maintenance of Genome Stability
Another area of metabolism that is heavily influenced by the SUMO system is the maintenance of genome stability (43,46,47). This aspect of SUMO function has been studied most extensively in lower eukaryotes. On one hand, the ease
The SUMO System – An Overview
11
of genetic manipulations in the yeast system has allowed the phenotypic analysis of yeast mutants deficient in components of the SUMO pathway, which has revealed the importance of the modifier for protection from genome instability: ubc9ts and mms21 mutants are sensitive to DNA-damaging agents and spontaneously accumulate abnormal recombination intermediates during DNA replication (26–28,54); ulp2 mutants are characterized by DNA damage sensitivity, plasmid loss, and chromosome segregation defects (36); and zip3 mutants exhibit abnormal synaptonemal complex architecture, thus implying a function of SUMO in meiosis (13). On the other hand, global analysis of SUMO conjugates by mass spectrometry (10,55–59) has identified many potential sumoylation targets relevant to DNA metabolism, such as helicases (Sgs1), topoisomerases, and recombination factors (Rad52). In some cases, modification of a particular target protein can be attributed to a specific phenomenon in vivo. For example, sumoylation of topoisomerase II has been linked to the fidelity of chromosome transmission (60–63), sumoylation of Rad52 was shown to regulate recombination events in the ribosomal DNA locus (64), and sumoylation of the replication clamp protein PCNA is known to inhibit the association of the recombination factor Rad51 with replication forks by means of recruiting the antirecombinogenic helicase Srs2 (65,66). More often, however, the relevance of sumoylation for a given target protein remains unclear, and the target proteins responsible for many of the effects of mutants in the SUMO conjugation or deconjugation factors have not been identified.
5. SUMOInteracting Proteins
SUMO has emerged as an interaction partner from numerous two-hybrid screens. In some cases, this has turned out to be due to covalent modification of the bait protein, but noncovalent interactors have likewise been identified, where—in contrast to the covalent situation—binding does not depend on the presence of the C-terminal glycines of SUMO (67). Accordingly, a loose consensus motif, now termed SUMO-binding or SUMOinteracting motif (SBM or SIM), has been identified in many of these noncovalent interaction partners, consisting of a short hydrophobic stretch that is preceeded or followed by acidic and hydrophilic (mostly serine) residues (49). The SBM interacts with SUMO by forming a β-strand that aligns with a β-sheet on the surface of the modifier. Interestingly, there are examples of both parallel and antiparallel orientations. SBMs are found in downstream effector proteins whose recruitment depends
12
Ulrich
on their preferential interaction with a sumoylated target, but also in some SUMO E3s, where the motif is actually required for catalytic activity. Many SUMO-binding proteins, such as Daxx and PML, are at the same time subject to sumoylation themselves, and this often requires an intact SBM. Finally, SBMs can apparently serve to target sumoylated proteins for other post-translational modifications, as exemplified by the identification of a ubiquitin ligase (RNF4 in mammals and a heterodimeric complex of Slx8 with Slx5 or Rfp1 in S. cerevisiae and S. pombe, respectively), which, by means of a series of SBMs, recognizes sumoylated proteins and linear SUMO fusions as ubiquitylation targets (68–71).
6. Regulation of SUMO Modification
Compared to the number of ubiquitin-specific E2s and E3s, the repertoire of the SUMO conjugation machinery is rather limited, raising the question of how substrate selectivity and spatiotemporal regulation are achieved in the SUMO pathway. Intriguingly, most SUMO targets are modified at a very low level at any given time, suggesting dynamic control of sumoylation. In analogy to the ubiquitin system, phosphorylation has emerged as an important means to control SUMO conjugation at the level of individual substrates. As mentioned above, sumoylation of some target proteins, such as the heat-shock factor HSF1, is enhanced by the phosphorylation of its extended sumoylation motif, YKXEXXpSP (20). In contrast, phosphorylation of the NFκB inhibitor IκBα inhibits sumoylation (72). However, control over sumoylation can also be exerted at the level of the conjugation factors. Hence, activation of several kinase-mediated signaling cascades results in changes in the expression levels and activities of PIAS proteins (73,74). At least in the case of Pc2, phosphorylation has been demonstrated to enhance its E3 activity (75). Alternatively, post-translational modifications may regulate the intracellular localization of E3s and thereby promote the modification in a site-selective manner. For example, budding yeast Siz1 resides in the nucleus during most of the cell cycle, but relocalizes to the bud neck in G2/M, where it then sumoylates the septins, which are proteins that contribute to yeast cytokinesis (25). Although there is no direct evidence yet, it is likely that post-translational modifications, such as phosphorylation, regulate this change in Siz1 localization. Regulation of sumoylation can also occur on a global level. A reduction in overall sumoylation is observed
The SUMO System – An Overview
13
upon infection with a chicken adenovirus, due to a virus-encoded protein, Gam1, which induces the loss of E1 and E2 proteins (76). The ensuing derepression of transcriptional activity is believed to promote viral propagation. Oxidative stress results in a loss of SUMO conjugates by means of a reversible oxidative crosslinking and inactivation of the SUMO-conjugating enzymes (77). Other cellular stresses, such as heat shock, cause a global increase in sumoylation (78).
7. Outlook Since the discovery of SUMO a decade ago, a wealth of information has been gathered about the properties and functions of this modifier. Advances in mass spectrometry technology have allowed the identification of hundreds of SUMO targets, and many more will undoubtedly emerge in the future. The mechanism of SUMO conjugation and deconjugation has been studied in detail with a number of representative model substrates, but important questions concerning substrate recognition and selectivity remain unanswered. In vivo analysis will need to be combined with biochemical approaches in order to gain insight into the dynamic regulation of the SUMO system by cellular and extracellular signals. Importantly, much more is to be learned about the ways in which SUMO and, in particular, poly-SUMO chains affect the properties of the modified targets. The identification of additional SUMOinteracting proteins and motifs is expected to reveal important downstream effectors of the SUMO pathway and may help to provide the missing links between individual SUMO substrates and cellular phenotypes associated with defects in SUMO conjugation. As new areas of SUMO function are still being revealed, it is certain that the SUMO pathway will eventually be recognized as an important and flexible regulatory system in most aspects of cellular metabolism.
Acknowledgments I apologize to those researchers whose work could not be cited directly in this review due to space constraints. Work in this laboratory is supported by Cancer Research UK.
14
Ulrich
References 1. Schwartz, D. C. and Hochstrasser, M. (2003) A superfamily of protein tags: ubiquitin, SUMO and related modifiers. Trends Biochem. Sci. 28, 321–328. 2. Kerscher, O., Felberbaum, R., and Hochstrasser, M. (2006) Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev. Biol. 22, 159–180. 3. Johnson, E. S. (2004) Protein modification by SUMO. Annu. Rev. Biochem. 73, 355–382. 4. Geiss-Friedlander, R. and Melchior, F. (2007) Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell. Biol. 8, 947–956. 5. Owerbach, D., McKay, E. M., Yeh, E. T., Gabbay, K. H., and Bohren, K. M. (2005) A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. Biochem. Biophys. Res. Commun. 337, 517–520. 6. Mukhopadhyay, D. and Dasso, M. (2007) Modification in reverse: the SUMO proteases. Trends Biochem. Sci. 32, 286–295. 7. Saitoh, H. and Hinchey, J. (2000) Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J. Biol. Chem. 275, 6252–6258. 8. Vertegaal, A. C. (2007) Small ubiquitinrelated modifiers in chains. Biochem. Soc. Trans. 35, 1422–1423. 9. Bylebyl, G. R., Belichenko, I., and Johnson, E. S. (2003) The SUMO isopeptidase Ulp2 prevents accumulation of SUMO chains in yeast. J. Biol. Chem. 278, 44113–44120. 10. Matic, I., van Hagen, M., Schimmel, J., Macek, B., Ogg, S. C., Tatham, M. H., Hay, R. T., Lamond, A. I., Mann, M., and Vertegaal, A. C. (2008) In vivo identification of human small ubiquitin-like modifier polymerization sites by high accuracy mass spectrometry and an in vitro to in vivo strategy. Mol. Cell. Proteomics 7, 132–144. 11. Tatham, M. H., Jaffray, E., Vaughan, O. A., Desterro, J. M., Botting, C. H., Naismith, J. H., and Hay, R. T. (2001) Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J. Biol. Chem. 276, 35368–35374. 12. Windecker, H. and Ulrich, H. D. (2008) Architecture and assembly of poly-SUMO chains on PCNA in Saccharomyces cerevisiae. J. Mol. Biol. 376, 221–231. 13. Cheng, C. H., Lo, Y. H., Liang, S. S., Ti, S. C., Lin, F. M., Yeh, C. H., Huang, H. Y., and Wang, T. F. (2006) SUMO modifications control assembly of synaptonemal complex and polycomplex in meiosis of Saccharomyces cerevisiae. Genes Dev. 20, 2067–2081.
14. Johnson, E. S., Schwienhorst, I., Dohmen, R. J., and Blobel, G. (1997) The ubiquitinlike protein Smt3p is activated for conjugation to other proteins by an Aos1p/Uba2p heterodimer. EMBO J. 16, 5509–5519. 15. Lois, L. M. and Lima, C. D. (2005) Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1. EMBO J. 24, 439–451. 16. Johnson, E. S. and Blobel, G. (1997) Ubc9p is the conjugating enzyme for the ubiquitin-like protein Smt3p. J. Biol. Chem. 272, 26799–26802. 17. Tong, H., Hateboer, G., Perrakis, A., Bernards, R., and Sixma, T. K. (1997) Crystal structure of murine/human Ubc9 provides insight into the variability of the ubiquitin-conjugating system. J. Biol. Chem. 272, 21381–21387. 18. Bernier-Villamor, V., Sampson, D. A., Matunis, M. J., and Lima, C. D. (2002) Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1. Cell 108, 345–356. 19. Johnson, E. S. and Blobel, G. (1999) Cell cycle-regulated attachment of the ubiquitinrelated protein SUMO to the yeast septins. J. Cell Biol. 147, 981–994. 20. Hietakangas, V., Anckar, J., Blomster, H. A., Fujimoto, M., Palvimo, J. J., Nakai, A., and Sistonen, L. (2006) PDSM, a motif for phosphorylation-dependent SUMO modification. Proc. Natl. Acad. Sci. USA 103, 45–50. 21. Yang, S. H., Galanis, A., Witty, J., and Sharrocks, A. D. (2006) An extended consensus motif enhances the specificity of substrate modification by SUMO. EMBO J. 25, 5083–5093. 22. Hochstrasser, M. (2001) SP-RING for SUMO: new functions bloom for a ubiquitin-like protein. Cell 107, 5–8. 23. Palvimo, J. J. (2007) PIAS proteins as regulators of small ubiquitin-related modifier (SUMO) modifications and transcription. Biochem. Soc. Trans. 35, 1405–1408. 24. Sharrocks, A. D. (2006) PIAS proteins and transcriptional regulation–more than just SUMO E3 ligases? Genes Dev. 20, 754–758. 25. Johnson, E. S. and Gupta, A. A. (2001) An E3-like factor that promotes SUMO conjugation to the yeast septins. Cell 106, 735–744. 26. Andrews, E. A., Palecek, J., Sergeant, J., Taylor, E., Lehmann, A. R., and Watts, F. Z. (2005) Nse2, a component of the Smc5–6 complex, is a SUMO ligase required for the response to DNA damage. Mol. Cell. Biol. 25, 185–196.
The SUMO System – An Overview 27. Potts, P. R. and Yu, H. (2005) Human MMS21/NSE2 is a SUMO ligase required for DNA repair. Mol. Cell. Biol. 25, 7021–7032. 28. Zhao, X. and Blobel, G. (2005) A SUMO ligase is part of a nuclear multiprotein complex that affects DNA repair and chromosomal organization. Proc. Natl. Acad. Sci. USA 102, 4777–4782. 29. Pichler, A., Knipscheer, P., Saitoh, H., Sixma, T. K., and Melchior, F. (2004) The RanBP2 SUMO E3 ligase is neither HECT- nor RINGtype. Nat. Struct. Mol. Biol. 11, 984–991. 30. Reverter, D. and Lima, C. D. (2005) Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex. Nature 435, 687–692. 31. Carbia-Nagashima, A., Gerez, J., Perez-Castro, C., Paez-Pereda, M., Silberstein, S., Stalla, G. K., Holsboer, F., and Arzt, E. (2007) RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell 131, 309–323. 32. Kagey, M. H., Melhuish, T. A., and Wotton, D. (2003) The polycomb protein Pc2 is a SUMO E3. Cell 113, 127–137. 33. Wotton, D. and Merrill, J. C. (2007) Pc2 and SUMOylation. Biochem. Soc. Trans. 35, 1401–1404. 34. Zhao, X., Sternsdorf, T., Bolger, T. A., Evans, R. M., and Yao, T. P. (2005) Regulation of MEF2 by histone deacetylase 4- and SIRT1 deacetylase-mediated lysine modifications. Mol. Cell. Biol. 25, 8456–8464. 35. Hay, R. T. (2007) SUMO-specific proteases: a twist in the tail. Trends Cell Biol. 17, 370–376. 36. Li, S. -J. and Hochstrasser, M. (2000) The yeast ULP2 (SMT4) gene encodes a novel protease specific for the ubiquitin-like Smt3 protein. Mol. Cell. Biol. 20, 2367–2377. 37. Li, S. J. and Hochstrasser, M. (1999) A new protease required for cell-cycle progression in yeast. Nature 398, 246–251. 38. Hayashi, T., Seki, M., Maeda, D., Wang, W., Kawabe, Y., Seki, T., Saitoh, H., Fukagawa, T., Yagi, H., and Enomoto, T. (2002) Ubc9 is essential for viability of higher eukaryotic cells. Exp. Cell Res. 280, 212–221. 39. Nacerddine, K., Lehembre, F., Bhaumik, M., Artus, J., Cohen-Tannoudji, M., Babinet, C., Pandolfi, P. P., and Dejean, A. (2005) The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev. Cell 9, 769–779. 40. Seufert, W., Futcher, B., and Jentsch, S. (1995) Role of a ubiquitin-conjugating enzyme in degradation of S- and M-phase cyclins. Nature 373, 78–81.
15
41. Tanaka, K., Nishide, J., Okazaki, K., Kato, H., Niwa, O., Nakagawa, T., Matsuda, H., Kawamukai, M., and Murakami, Y. (1999) Characterization of a fission yeast SUMO-1 homologue, pmt3p, required for multiple nuclear events, including the control of telomere length and chromosome segregation. Mol. Cell. Biol. 19, 8660–8672. 42. Girdwood, D. W., Tatham, M. H., and Hay, R. T. (2004) SUMO and transcriptional regulation. Semin. Cell Dev. Biol. 15, 201–210. 43. Muller, S., Ledl, A., and Schmidt, D. (2004) SUMO: a regulator of gene expression and genome integrity. Oncogene 23, 1998–2008. 44. Melchior, F., Schergaut, M., and Pichler, A. (2003) SUMO: ligases, isopeptidases and nuclear pores. Trends Biochem. Sci. 28, 612–618. 45. Ulrich, H. D. (2005) Mutual interactions between the SUMO and ubiquitin systems: a plea of no contest. Trends Cell Biol. 15, 525–532. 46. Seeler, J. S., Bischof, O., Nacerddine, K., and Dejean, A. (2007) SUMO, the three Rs and cancer. Curr. Top. Microbiol. Immunol. 313, 49–71. 47. Watts, F. Z. (2007) The role of SUMO in chromosome segregation. Chromosoma 116, 15–20. 48. Gill, G. (2004) SUMO and ubiquitin in the nucleus: different functions, similar mechanisms? Genes Dev. 18, 2046–2059. 49. Kerscher, O. (2007) SUMO junction-what’s your function? New insights through SUMO-interacting motifs. EMBO Rep. 8, 550–555. 50. Steinacher, R. and Schar, P. (2005) Functionality of human thymine DNA glycosylase requires SUMO-regulated changes in protein conformation. Curr. Biol. 15, 616–623. 51. Gill, G. (2005) Something about SUMO inhibits transcription. Curr. Opin. Genet. Dev. 15, 536–541. 52. Ross, S., Best, J. L., Zon, L. I., and Gill, G. (2002) SUMO-1 modification represses Sp3 transcriptional activation and modulates its subnuclear localization. Mol. Cell 10, 831–842. 53. Lin, D. Y., Huang, Y. S., Jeng, J. C., Kuo, H. Y., Chang, C. C., Chao, T. T., Ho, C. C., Chen, Y. C., Lin, T. P., Fang, H. I. et al. (2006) Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol. Cell 24, 341–354. 54. Branzei, D. and Foiani, M. (2005) The DNA damage response during DNA replication. Curr. Opin. Cell Biol. 17, 568–575.
16
Ulrich
55. Denison, C., Rudner, A. D., Gerber, S. A., Bakalarski, C. E., Moazed, D., and Gygi, S. P. (2005) A proteomic strategy for gaining insights into protein sumoylation in yeast. Mol. Cell. Proteomics 4, 246–254. 56. Panse, V. G., Hardeland, U., Werner, T., Kuster, B., and Hurt, E. (2004) A proteome-wide approach identifies sumoylated substrate proteins in yeast. J. Biol. Chem. 279, 41346–41351. 57. Vertegaal, A. C., Ogg, S. C., Jaffray, E., Rodriguez, M. S., Hay, R. T., Andersen, J. S., Mann, M., and Lamond, A. I. (2004) A proteomic study of SUMO-2 target proteins. J. Biol. Chem. 279, 33791–33798. 58. Wohlschlegel, J. A., Johnson, E. S., Reed, S. I., and Yates, J. R. 3rd. (2004) Global analysis of protein sumoylation in Saccharomyces cerevisiae. J. Biol. Chem. 279, 45662–45668. 59. Zhou, W., Ryan, J. J., and Zhou, H. (2004) Global analyses of sumoylated proteins in Saccharomyces cerevisiae. Induction of protein sumoylation by cellular stresses. J. Biol. Chem. 279, 32262–32268. 60. Takahashi, Y., Yong-Gonzalez, V., Kikuchi, Y., and Strunnikov, A. (2006) SIZ1/SIZ2 control of chromosome transmission fidelity is mediated by the sumoylation of topoisomerase II. Genetics 172, 783–794. 61. Bachant, J., Alcasabas, A., Blat, Y., Kleckner, N., and Elledge, S. J. (2002) The SUMO-1 isopeptidase Smt4 is linked to centromeric cohesion through SUMO-1 modification of DNA topoisomerase II. Mol. Cell 9, 1169–1182. 62. Azuma, Y., Arnaoutov, A., and Dasso, M. (2003) SUMO-2/3 regulates topoisomerase II in mitosis. J. Cell Biol. 163, 477–487. 63. Liu, L. F., Desai, S. D., Li, T. K., Mao, Y., Sun, M., and Sim, S. P. (2000) Mechanism of action of camptothecin. Ann. N. Y. Acad. Sci. 922, 1–10. 64. Torres-Rosell, J., Sunjevaric, I., De Piccoli, G., Sacher, M., Eckert-Boulet, N., Reid, R., Jentsch, S., Rothstein, R., Aragon, L., and Lisby, M. (2007) The Smc5-Smc6 complex and SUMO modification of Rad52 regulates recombinational repair at the ribosomal gene locus. Nat. Cell Biol. 9, 923–931. 65. Papouli, E., Chen, S., Davies, A. A., Huttner, D., Krejci, L., Sung, P., and Ulrich, H. D. (2005) Crosstalk between SUMO and ubiquitin on PCNA is mediated by recruitment of the helicase Srs2p. Mol. Cell 19, 123–133. 66. Pfander, B., Moldovan, G. L., Sacher, M., Hoege, C., and Jentsch, S. (2005) SUMOmodified PCNA recruits Srs2 to prevent recombination during S phase. Nature 436, 428–433.
67. Hannich, J. T., Lewis, A., Kroetz, M. B., Li, S. J., Heide, H., Emili, A., and Hochstrasser, M. (2005) Defining the SUMOmodified proteome by multiple approaches in Saccharomyces cerevisiae. J. Biol. Chem. 280, 4102–4110. 68. Prudden, J., Pebernard, S., Raffa, G., Slavin, D. A., Perry, J. J., Tainer, J. A., McGowan, C. H., and Boddy, M. N. (2007) SUMOtargeted ubiquitin ligases in genome stability. EMBO J. 26, 4089–4101. 69. Sun, H., Leverson, J. D., and Hunter, T. (2007) Conserved function of RNF4 family proteins in eukaryotes: targeting a ubiquitin ligase to SUMOylated proteins. EMBO J. 26, 4102–4112. 70. Uzunova, K., Gottsche, K., Miteva, M., Weisshaar, S. R., Glanemann, C., Schnellhardt, M., Niessen, M., Scheel, H., Hofmann, K., Johnson, E. S. et al. (2007) Ubiquitindependent proteolytic control of SUMO conjugates. J. Biol. Chem. 282, 34167–34175. 71. Xie, Y., Kerscher, O., Kroetz, M. B., McConchie, H. F., Sung, P., and Hochstrasser, M. (2007) The yeast HEX3-SLX8 heterodimer is a ubiquitin ligase stimulated by substrate sumoylation. J. Biol. Chem. 282, 34176–34184. 72. Desterro, J. M., Rodriguez, M. S., and Hay, R. T. (1998) SUMO-1 modification of IκBα inhibits NF-κB activation. Mol. Cell 2, 233–239. 73. Bossis, G. and Melchior, F. (2006) SUMO: regulating the regulator. Cell Div. 1, 13. 74. Guo, B., Yang, S. H., Witty, J., and Sharrocks, A. D. (2007) Signalling pathways and the regulation of SUMO modification. Biochem. Soc. Trans. 35, 1414–1418. 75. Roscic, A., Moller, A., Calzado, M. A., Renner, F., Wimmer, V. C., Gresko, E., Ludi, K. S., and Schmitz, M. L. (2006) Phosphorylation-dependent control of Pc2 SUMO E3 ligase activity by its substrate protein HIPK2. Mol. Cell 24, 77–89. 76. Boggio, R., Colombo, R., Hay, R. T., Draetta, G. F., and Chiocca, S. (2004) A mechanism for inhibiting the SUMO pathway. Mol. Cell 16, 549–561. 77. Bossis, G. and Melchior, F. (2006) Regulation of SUMOylation by reversible oxidation of SUMO conjugating enzymes. Mol. Cell 21, 349–357. 78. Kurepa, J., Walker, J. M., Smalle, J., Gosink, M. M., Davis, S. J., Durham, T. L., Sung, D. Y., and Vierstra, R. D. (2003) The small ubiquitin-like modifier (SUMO) protein modification system in Arabidopsis. Accumulation of SUMO1 and -2 conjugates is increased by stress. J. Biol. Chem. 278, 6862–6872.
Chapter 2 Identification of SUMO Target Proteins by Quantitative Proteomics Jens S. Andersen, Ivan Matic, and Alfred C.O. Vertegaal Abstract The identification of target proteins for small ubiquitin-like modifiers (SUMOs) is a critical step towards a detailed understanding of the cellular functions of SUMOs. Substrate protein identification for SUMOs is hampered by the low abundance of SUMO targets, the finding that only a small fraction of these target proteins is sumoylated, and the high activity of deconjugating enzymes. Quantitative proteomics is a powerful tool to overcome these challenges, because it allows discrimination between contaminating proteins in SUMO-enriched preparations and true target proteins. In this chapter, the methodological details of the application of stable isotope labeling of amino acids in cell culture (SILAC) for the identification of target proteins for SUMOs are described. In addition to steady state sumoylation, the sumoylated proteome undergoes dynamic rearrangements in response to a diverse array of stimuli. SILAC also allows the study of sumoylation dynamics in response to these stimuli. Key words: SUMO-1, SUMO-2, SUMO-3, SILAC, quantitative proteomics, mass spectrometry.
1. Introduction The ubiquitin family includes small ubiquitin-like modifiers (SUMOs) that regulate the activity of a wide variety of cellular target proteins via covalent modification of lysine residues on these targets (1). A diverse set of SUMO target proteins has been identified, including factors that regulate transcription, replication, DNA repair, RNA metabolism, translation, and transport (2). Sumoylation is a reversible process; SUMO proteases can remove SUMOs from target proteins. Currently, specific inhibitors of these proteases are unavailable. To block SUMO protease activity, the purification of SUMO conjugates is carried out in Helle D. Ulrich (ed.), Methods in Molecular Biology: SUMO Protocols, vol. 497 © 2009 Humana Press, a part of Springer Science + Business Media, New York, NY Book doi: 10.1007/978-1-59745-566-4
19
20
Andersen, Matic, and Vertegaal
denaturing buffers (3,4). The use of denaturing buffers also prevents the copurification of noncovalent SUMO-interacting proteins. However, due to a limited choice of affinity tags that can be used under denaturing conditions, the purified fractions usually contain significant numbers of contaminating proteins (see Note 1). To discriminate between bona fide SUMO target proteins and contaminants, the use of quantitative proteomics is a prerequisite. Stable isotope labeling of amino acids in cell culture (SILAC) is a powerful quantitative proteomics method (5–7) (see Note 2). It is based on the labeling of proteins in populations of cells with normal and stable isotope variants of amino acids (Fig. 2.1) (see Notes 3 and 4). For example, after the purification of pro-
Fig. 2.1. A SILAC strategy to identify SUMO target proteins. Parental cells were labeled with Arg0 and Lys0, and cells stably expressing His6-SUMO-2 were labeled with Arg10 and Lys8. Equal amounts of cells from the two different populations were mixed and lysed and His6-SUMO-2 conjugates were purified by Immobilized Metal Affinity Chromatography. The SUMO-enriched fraction was digested in solution and analyzed by mass spectrometry. Peptide mass spectra of proteins were quantified to identify proteins potentially conjugated to SUMO-2.
Identification of SUMO Targets by SILAC
21
tein complexes or subcellular fractions, proteins are digested by trypsin into smaller peptides that are subsequently identified and quantified by mass spectrometry. The resulting data contain information about the identity of the purified proteins and their relative abundance in the different pools of cells (see Note 5). SILAC has been used to study the dynamics of the nucleolar proteome in response to metabolic inhibitors (8), to compare the related signaling pathways of epidermal growth factor and platelet-derived growth factor (9), and to identify PP1α- and –γ-binding proteins (10). Here, we describe how SILAC can be applied to investigate the sumoylated proteome. Since purified sumoylated proteins often contain contaminants, preparations of experiments are designed to contain a control cell population to eliminate false positives. Cells that express tagged SUMOs and control cells that lack exogenous SUMOs are used. After full incorporation of isotopic variants of amino acids, cells are lysed in a denaturing buffer to inactivate SUMO proteases, and tagged SUMOs are subsequently purified. After trypsin digestion and identification and quantification of peptides in the purified fraction by mass spectrometry, the ratio between the isotopic variants of these peptides is determined to distinguish between SUMO target proteins and copurified contaminating proteins (see Note 6). We have used SILAC previously to investigate the target protein preferences of the mammalian SUMO family members SUMO-1 and SUMO-2 (4). SUMO-1 and SUMO-2 were shown to function largely nonredundantly but were also conjugated to a common set of targets. In the past the SUMO field has largely focused on steadystate sumoylation. Interestingly, sumoylation can also occur in a stimulus-dependent manner (11). The SILAC method is suitable for studying stimulus-dependent sumoylation, because it can determine increases and decreases in sumoylation of target proteins in a quantitative manner. Nonquantitative methods are inherently less suitable for studying conditional sumoylation.
2. Materials 2.1. SILAC Medium and Cell Culture
1. Dulbecco’s modified eagle’s medium (DMEM) without arginine, lysine, and glutamine (available from SAFC Biosciences, Lenexa, Kansas; cat. no. 63190) (see Notes 7 and 8). 2. Dialysed fetal bovine serum (e.g., Invitrogen, cat. no. 26400–044) (see Note 9). 3.
L-Arginine-12C614N4
(Arg0; Sigma-Aldrich, cat. no. A6969).
22
Andersen, Matic, and Vertegaal
4.
L-Lysine-12C614N2
5.
L-Arginine-13C615N4
6.
L-Lysine-13C615N2
(Lys0; Sigma-Aldrich, cat. no. L8662). (Arg10; Sigma-Isotec, cat. no. 608033).
(Lys8; Sigma-Isotec, cat. no. 608041).
7. Amino acids: arginine (84 mg/ml) and lysine (146 mg/ml) are prepared as 3000x concentrated stocks in phosphatebuffered saline (PBS) for labeling HeLa cells. Solutions are filtered through a 0.22-µm filter and stored in aliquots at 4°C for up to 6 months. Add amino acids to DMEM shortly before use as required for the cell line of choice (see Note 10). 8. Antibiotics: Penicillin or Streptomycin stock solution (100x). 9.
L-Glutamine:
200 mM stock solution (100x).
10. 0.22 µm vacuum filter flasks. 11. Cell line of choice stably expressing His6-SUMO-1, -2, or -3. HeLa cells stably expressing His6-SUMO-1 or SUMO-2 have been described previously (4). 2.2. Cell Lysis
1. PBS: store at 4°C. 2. Cell scrapers. 3. Lysis buffer: 6 M Guanidinium-HCl, 100 mM NaH2PO4/ Na2HPO4, 10 mM Tris-HCl, pH 8.0. Shortly before use add β-mercaptoethanol to 10 mM and imidazole to 20 mM. 4. Sonicator.
2.3. Purification of SUMO Targets
1. Ni2+-NTA agarose beads (Qiagen). 2. Empty columns (BioSpin columns, Bio-Rad, or equivalent). 3. Wash buffer A: 6 M Guanidinium-HCl, 100 mM NaH2PO4/ Na2HPO4, 10 mM Tris-HCl, pH 8.0. Shortly before use add β-mercaptoethanol to 10 mM and Triton-X-100 to 0.2%. 4. Wash buffer B: 8 M urea, 100 mM NaH2PO4/Na2HPO4, 10 mM Tris-HCl, pH 8.0. Shortly before use add β-mercaptoethanol to 10 mM and Triton-X-100 to 0.2%. 5. Wash buffer C: 8 M urea, 100 mM NaH2PO4/Na2HPO4, 10 mM Tris-HCl, pH 6.3. Shortly before use add β-mercaptoethanol to 10 mM and Triton-X-100 to 0.2%. 6. Wash buffer D: 8 M urea, 100 mM NaH2PO4/Na2HPO4, 10 mM Tris-HCl, pH 6.3. Shortly before use add β-mercaptoethanol to 10 mM and Triton-X-100 to 0.1%. 7. Wash buffer E: 8 M urea, 100 mM NaH2PO4/Na2HPO4, 10 mM Tris-HCl, pH 7.0. 8. Elution buffer: 6.4 M urea, 80 mM NaH2PO4/Na2HPO4, 8 mM Tris-HCl, pH 7.0, 200 mM imidazole. 9. NuPAGE Novex 4–12% Bis-Tris gradient gels (Invitrogen).
Identification of SUMO Targets by SILAC
2.4. Protein Digestion and Mass Spectrometry
23
1. Ammonium bicarbonate (ABC buffer): 50 mM NH4HCO3, pH 8.0; store at room temperature. 2. Dithiothreitol (DTT): 10 mM DTT in 50 mM ABC buffer; store in small aliquots at −20°C. 3. Iodoacetamide: prepare 55 mM iodoacetamide in 50 mM ABC, store in small aliquots at −20°C, protected from light. 4. Trifluoroacetic acid (TFA). 5. Formic acid. 6. Acetonitrile. 7. Endopeptidase Lys-C (Wako Chemicals GMBH, cat. no. 129–02541): 0.5 µg/µl LysC in 50 mM ABC. Store in small aliquots at −20°C. 8. Sequencing grade modified trypsin for proteomics (Promega, cat. no. V5111): 0.5 µg/µl trypsin in 50 mM ABC. Store in small aliquots at −20°C. 9. Reprosil C18-AQ, 3 µm beads. 10. Material for C18 microcolumns (12). 11. Fused silica capillary with a 75 µm inner diameter and an 8-µm tip opening (New Objective, Woburn, MA) packed with Reprosil C18 beads (Dr. Maisch, Ammerbuch, Germany). 12. High accuracy mass spectrometer such as a linear ion trap (LTQ)-FT-ICR mass spectrometer or an Orbitrap (Thermo Fisher Scientific). 13. Nanoflow HPLC (Agilent Technologies or equivalent). 14. Buffer X: 0.5% acetic acid in H2O. 15. Buffer Y: 80% acetonitrile (toxic), 0.5% acetic acid in H2O.
2.5. Data Analysis and Confirmation
1. Software to identify proteins and peptide, such as Mascot (Matrix Science, London, U.K.). 2. Software to automatically quantify the identified peptides, such as MSQuant (available through http://msquant. sourceforge.net), SpectrumMill (available through Matrix Science), or other software capable of automatically quantifying SILAC data.
3. Methods The experiment described here is aimed at identifying target proteins for His6-SUMO-2 (Fig. 2.1). The same method can also be applied to identify target proteins for His6-SUMO-1 or His6-SUMO-3 (see Note 11). It is important to use a cell line
24
Andersen, Matic, and Vertegaal
stably expressing tagged SUMO and the parental cell line that lacks exogenous SUMOs as a negative control. After preparing the cell culture media containing either light or heavy amino acids, cell cultures are set up in these media. The parental cells are grown in medium containing light amino acids and the cells stably expressing His6-SUMO-2 are grown in medium containing heavy amino acids for at least five cell doublings. The cell line that we have used in this experiment is the widely used HeLa cell line. For this cell line it takes five cell doublings to fully replace proteins labeled with light amino acids with proteins labeled with heavy amino acids. This period of time should be experimentally verified (see Note 12). Cells are harvested and, after verifying that equal amounts of cells are used from the differently labeled populations, all cells are mixed and a single lysate is prepared. This minimizes errors introduced due to differential handling of the different populations—a unique advantage of the SILAC method. Sumoylated proteins are inherently labile due to the activity of intracellular SUMO proteases. It is therefore important to rapidly lyse the cells in denaturing lysis buffer. The resulting lysate is very viscous and needs to be sonicated to make it suitable for the purification of sumoylated proteins. After purification of the sumoylated proteome, proteins are digested in solution (see Note 13) with trypsin, which is a protease that cleaves proteins after lysines and arginines. Each resulting peptide will be labeled with either light or heavy lysine or arginine, except for the very C-terminal peptides of proteins (unless of course the C-terminal amino acid of a protein is a lysine or arginine). The resulting peptide mixture is subsequently bound to a column of reverse-phase material and eluted by a gradient buffer to fractionate the usually very complex mixture of peptides based on hydrophobicity. Parent ion masses of the eluted peptides are measured in the mass spectrometer, and peptides are further analyzed by collision-induced fragmentation to obtain fragment ion mass spectra. The corresponding proteins are subsequently identified by searching protein sequence databases using the obtained peptide data. Protein ratios are then calculated for each arginine- or lysine-containing peptide as the peak area of the heavy labeled peptide divided by the peak area of the light labeled peptide for each peptide. The peptide ratios are averaged for all peptides sequenced for each protein using available open source software. Significantly enriched proteins represent SUMO-2 target proteins (see Note 14). Examples of a SUMO-2 target protein and contaminating proteins are shown in Fig. 2.2. Novel SUMO target proteins can further be confirmed by immunoblotting. 3.1. SILAC Medium and Cell Culture
1. Cells that stably express His6-tagged SUMOs are established. In this experiment, we have used a CMV-driven His6-SUMO-2 expression construct that also renders cells
Identification of SUMO Targets by SILAC
25
Fig. 2.2. Examples of a SUMO-2 target protein, an endogenous contaminating protein, and an exogenous contaminating protein. These examples are depicted here to illustrate the different classes of proteins that are identified in SILAC experiments. (A) The peptide NTLETSSLNFK, which corresponds to the protein SAF-B2, was found preferentially in the Lys8-labeled form, indicating that this is a bona fide SUMO-2 target protein. (B) The peptide NMMAACDPR, which corresponds to β-tubulin, was found in the Arg0- and Arg10-labeled form in equal amounts, indicating that this is a copurified contaminating protein. (C) The peptide LGEHNIDVLEGNEQFINAAK, which corresponds to trypsin, was found exclusively in the Lys0-labeled form because it does not originate from the cells, but was introduced on purpose during sample handling.
26
Andersen, Matic, and Vertegaal
resistant to puromycin to enable the selection of stable transfectants. The expression level of exogenous SUMO is compared to the expression level of endogenous SUMO to minimize overexpression. HeLa cells stably expressing His6SUMO-1 or SUMO-2 have been described previously (4). 2. If needed, add common amino acids to light and heavy SILAC dropout medium. When labeling with arginine and lysine, add regular stable isotope versions of other amino acids not present in the dropout medium. 3. Divide SILAC dropout medium into two equal volumes. 4. Light and heavy arginine and lysine are added to the light and heavy media, respectively (see Note 10). 5. Dropout DMEM containing heavy or light amino acids is filter sterilized. 6. Add glutamine, 10% fetal bovine serum, and antibiotics to both bottles of medium. This medium can be stored for a maximum of 2 months at 4°C. 7. Parental cells are passaged in DMEM containing light amino acids, and cells stably expressing tagged-SUMOs are passaged in DMEM containing heavy amino acids for at least five cell doublings to ensure complete incorporation of the labels (see Notes 12 and 15). 3.2. Lysis
1. Wash cells three times with ice-cold PBS and scrape in icecold PBS. 2. Spin down the cells and determine the weight of the cell pellets of the different populations. Adjust precisely to a oneto-one ratio. 3. Confirm the one-to-one ratio by determining the protein concentration of equal small aliquots lysed in 8 M urea. 4. Combine all the cells in ice-cold PBS into 10 million cells a single sample and split this sample again into aliquots of 107 cells per 15 ml tube. 5. Spin down the cells, keep the aliquots on ice, and lyse them one by one as follows: 6. Remove PBS, vortex for 2 s at maximum setting, and immediately add 3 ml lysis buffer (room temperature) while vortexing. Mix vigorously for another 10 s. 7. Sonicate the samples on ice to reduce the viscosity. Avoid heating the samples during this procedure. 8. Spin the lysate at 15,000–20,000g for 10 min at room temperature. Use the supernatant for subsequent purification of SUMO targets.
Identification of SUMO Targets by SILAC
3.3. Purification of SUMO Targets
27
1. Combine the lysates into a single sample and incubate with 100 µl Ni-NTA-agarose beads for 1–2 h while mixing at room temperature. 2. Spin down the beads at 500 g for 1 min. 3. Resuspend the beads in 20 bead volumes of wash buffer A and load the mixture on an empty column. 4. Wash with 20 bead volumes of wash buffer B. 5. Wash with 20 bead volumes of wash buffer C. 6. Wash with 20 bead volumes of wash buffer D. 7. Wash five times with wash buffer E. 8. Elute the proteins in one bead volume of elution buffer for 5 min at room temperature. 9. Repeat Step 8 twice. 10. Determine the protein concentration and the total amount of purified material. Samples in urea buffer should not be heated. 11. Run a small aliquot on a 4–12% gradient-gel and check the conjugation status of the SUMOs by immunoblotting. Most of the immunoreactive material should be present in high molecular weight conjugates. For an example, see (4).
3.4. Protein Digestion and Mass Spectrometry
1. Add DTT to 1 mM to reduce the sample. Incubate for 30 min at room temperature. 2. Add iodoacetamide to 5 mM to alkylate the sample. Vortex and incubate for 20 min at room temperature in the dark. 3. Add ABC buffer to reduce the final concentration of urea to 3 M. 4. Add 0.2 µg endopeptidase Lys-C per 10 µg of protein present in the sample. 5. Incubate at 37°C for 2–3 h. 6. Dilute the sample 2-fold with 50 mM ammonium bicarbonate. 7. Add 0.2 µg of trypsin per 10 µg of protein present in the sample. 8. Incubate at 37°C overnight. 9. Add trifluoroacetic acid to 1% to stop digestion. 10. Purify the peptides using C18 microcolumns (12) according to the manufacturer’s protocol (New Objective). 11. Elute the peptides from the columns using 80% acetonitrile/0.1% formic acid. 12. Dry the samples in a vacuum centrifuge.
28
Andersen, Matic, and Vertegaal
13. Resuspend the peptides in 10 µl of 2.5% acetonitrile/1% trifluoroacetic acid. 14. Load the peptide mixture onto the silica capillary. Use approximately 2–5 µg of peptide as determined in Sect. 3.3, Step 10. 15. Elute peptides with a 140 min linear gradient of 95% buffer X to 50% buffer Y. 16. Acquire high resolution precursor ion spectra and tandem mass spectra. 3.5. Data Analysis and Confirmation
1. Search the peak list with high stringency in the International Protein Index (IPI) database (www.ebi.ac.uk/IPI/IPIhelp. html) using an appropriate program such as Mascot (Matrix Science, London, UK). 2. Calculate the peptide ratios for each arginine- or lysine-containing peptide and average the ratios of the sequenced peptides per proteins using suitable software such as MSQuant (http://msquant.sourceforge.net). 3. Plot the obtained ratios to determine an appropriate cut-off ratio. This ratio should not be smaller than 1.5-fold and ideally should be at least 2-fold. 4. Confirm the sumoylation status of a number of identified proteins by immunoblotting (see Note 16).
4. Notes 1. Due to the high activity of SUMO proteases in cells and in lysates, the use of denaturing buffers is essential, which severely limits the choice of the affinity tag that can be used. The His6-tag is compatible with buffers containing very large amounts of guanidinium or urea, but many proteins contain stretches of histidines, which results in their copurification in Immobilized Metal Affinity Chromatography procedures. 2. ICAT and iTRAQ are other quantitative proteomics method that are alternatives to SILAC (13,14). 3. It is important to note that these heavy amino acids are not radioactive. 4. The enzyme trypsin, which cleaves carboxy-terminal of lysines and arginines, is extensively used in proteomics. It is therefore particularly useful to label proteins in cells with isotopic variants of lysine and arginine. This results in the presence of a single labeled amino acid in each peptide, with
Identification of SUMO Targets by SILAC
29
the exception of the very carboxy-terminal tryptic peptide of a protein. Although it is desirable to label both arginines and lysines in proteins, it is possible to use only arginine encoding, or only lysine encoding, or encoding with other amino acids such as leucine (5). 5. An added advantage of the SILAC method is that exogenous contaminants such as keratins, which can be introduced during sample handling, are encoded by light amino acids only and are thus easily distinguishable from proteins labeled by heavy amino acids. 6. Other types of post-translational modifications such as phosphorylation and acetylation as well as amino acid methylation can directly be identified by mass spectrometry. It is also desirable to positively identify the sumoylated lysines in target proteins by mass spectrometry, although complex overlapping MS/MS spectra of SUMO-modified peptides makes this type of modification difficult to detect (15). Direct identification of modified lysines is easier for ubiquitin target proteins, because tryptic fragments of ubiquitylated lysines contain an indivisible diglycine signature (16). 7. As an alternative to buying individual components for preparing SILAC medium, kits are available from Invitrogen that contain all the required components. 8. If the cell line of choice requires another medium formulation, custom-synthesized medium without arginine and lysine should be used. 9. A small number of cell lines fail to thrive in medium containing commercially available dialyzed serum. Potentially, you can also dialyze a particular type of serum required in your own laboratory using a low molecular weight cut-off to avoid the loss of low-molecular-weight growth factors. 10. A potential problem that arises from the use of labeled arginine is the capacity of some cell types to metabolically convert arginines to prolines. This is especially the case when excessive concentrations of arginine are used. This challenge can be overcome by titrating the amount of arginine without reaching amino acid starvation levels. Note that the same amounts of arginine should be used for both light and heavy SILAC media. Conversion can be monitored in the cell lines of choice by MS analysis. If conversion occurs, prolinecontaining peptides will have heavier satellite clusters. 11. In the described protocol, two populations of cells are used: cells that stably express a tagged SUMO and parental cells that serve as a negative control. It is also possible to use three populations of cells and triply encode proteins (4), using intermediate L-Arg6 (13C614N4-Arginine, avail-
30
Andersen, Matic, and Vertegaal
able from Cambridge Isotope labs, Andover, MA; cat. no. CLM-2265) and L-Lys4 (2H412C614N2-Lysine, available from Sigma-Isotec, St. Louis, MO; cat no. 616192). This method is particularly useful to investigate stimulus-induced changes in the sumoylated proteome. 12. When applying the SILAC method for the first time, it is important to verify complete replacement of light amino acids with heavy amino acids in proteins by analyzing a small aliquot of total lysate prepared in 6 M urea/2 M thiourea after five cell doublings. Digest 25–50 µg protein in solution. 13. When analyzing complex samples containing more than 300 proteins, SUMO-enriched samples can also be separated on a one-dimensional gel, stained with Coomassie and sliced into small slices to reduce sample complexity. When gel slices corresponding to less than 14 KDa size differences are prepared, it is theoretically possible to separate sumoylated proteins from nonsumoylated contaminating counterparts. 14. Using the SILAC method, relative standard deviations are usually less than 20%. Therefore, quantitative changes of 1.5-fold can be significant, although a 2-fold change is a more conservative cut-off. 15. Depending on the sensitivity of the mass spectrometer that is used, a sample derived from 50 million cells of each SILAC population is optimal. 16. Gradient gels are particularly useful to assess the ratio of free to conjugated SUMOs in purified samples, because they allow the visualization of small and large proteins simultaneously. Note that the blotting time influences the amount of free SUMOs that are visualized, because a significant amount of small proteins can be lost upon prolonged blotting.
Acknowledgments The authors would like to thank Professor Matthias Mann for comments on the manuscript. This work was supported by the Netherlands Organisation for Scientific Research (NWO) to ACOV as part of the Innovational Research Incentives Scheme and by a generous grant from the Danish National Research Foundation to Matthias Mann and JSA.
Identification of SUMO Targets by SILAC
31
References 1. Hay, R. T. (2005) SUMO: a history of modification. Mol. Cell 18, 1–12. 2. Xu, P., and Peng, J. (2006) Dissecting the ubiquitin pathway by mass spectrometry. Biochim. Biophys. Acta 1764, 1940–1947. 3. Vertegaal, A. C., Ogg, S. C., Jaffray, E., Rodriguez, M. S., Hay, R. T., Andersen, J. S., Mann, M., and Lamond, A. I. (2004) A proteomic study of SUMO-2 target proteins. J. Biol. Chem. 279, 33791–33798. 4. Vertegaal, A. C., Andersen, J. S., Ogg, S. C., Hay, R. T., Mann, M., and Lamond, A. I. (2006) Distinct and overlapping sets of SUMO-1 and SUMO-2 target proteins revealed by quantitative proteomics. Mol. Cell Proteomics 5, 2298–2310. 5. Ong, S. E., Blagoev, B., Kratchmarova, I., Kristensen, D. B., Steen, H., Pandey, A., and Mann, M. (2002) Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell Proteomics 1, 376–386. 6. Ong, S. E., Kratchmarova, I., and Mann, M. (2003) Properties of 13C-substituted arginine in stable isotope labeling by amino acids in cell culture (SILAC). J. Proteome Res. 2, 173–181. 7. Ong, S. E., and Mann, M. (2006) A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat. Protoc. 1, 2650–2660. 8. Andersen, J. S., Lam, Y. W., Leung, A. K., Ong, S. E., Lyon, C. E., Lamond, A. I., and Mann, M. (2005) Nucleolar proteome dynamics. Nature 433, 77–83. 9. Kratchmarova, I., Blagoev, B., HaackSorensen, M., Kassem, M., and Mann, M. (2005) Mechanism of divergent growth fac-
10.
11.
12.
13.
14.
15.
16.
tor effects in mesenchymal stem cell differentiation. Science 308, 1472–1477. Trinkle-Mulcahy, L., Andersen, J., Lam, Y. W., Moorhead, G., Mann, M., and Lamond, A. I. (2006) Repo-Man recruits PP1 gamma to chromatin and is essential for cell viability. J. Cell Biol. 172, 679–692. Saitoh, H., and Hinchey, J. (2000) Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J. Biol. Chem. 275, 6252–6258. Rappsilber, J., Ishihama, Y., and Mann, M. (2003) Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal. Chem. 75, 663–670. Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H., and Aebersold, R. (1999) Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17, 994–999. Mann, M. (2006) Functional and quantitative proteomics using SILAC. Nat. Rev. Mol. Cell Biol. 7, 952–958. Matic, I., van Hagen, M., Schimmel, J., Macek, B., Ogg, S. C., Tatham, M. H., Hay, R. T., Lamond, A. I., Mann, M., and Vertegaal, A. C. (2008) In vivo identification of human SUMO polymerization sites by high accuracy mass spectrometry and an in-vitro to in vivo strategy. Mol. Cell. Proteomics 7, 132–144. Peng, J., Schwartz, D., Elias, J. E., Thoreen, C. C., Cheng, D., Marsischky, G., Roelofs, J., Finley, D., and Gygi, S. P. (2003) A proteomics approach to understanding protein ubiquitination. Nat. Biotechnol. 21, 921–926.
Chapter 3 Identification of SUMO-Conjugated Proteins and their SUMO Attachment Sites Using Proteomic Mass Spectrometry James A. Wohlschlegel Abstract The covalent modification of cellular factors by the small ubiquitin-like modifier (SUMO) has emerged as a key regulatory pathway for many biological processes. One recent advance in the field of SUMO modification that has provided important insights into SUMO-mediated regulatory networks is the ability to use proteomic mass spectrometry to identify the substrates of SUMO modification as well as their sites of conjugation (1–10). In this chapter, we describe a global strategy for affinity purifying and identifying a broad spectrum of SUMO-conjugated proteins and a focused approach for purifying a selected SUMO target and mapping its SUMO attachment site(s). Although both methods were initially developed for use in S. cerevisiae, they can be readily adapted to study the SUMO pathway in higher eukaryotes. Key words: Mass spectrometry, proteomics, post-translational modifications, Smt3⋅SUMO.
1.Introduction The ability to identify the proteins that are post-translationally modified and the exact sites of those modifications is an important step in understanding the biological role of covalent modifications. Mass spectrometry has emerged as a powerful technology capable of performing these tasks and has been successfully applied to the study of a number of different post-translational modifications, including phosphorylation, acetylation, and ubiquitylation. In this chapter, we focus on proteomic methods for analyzing the covalent modification of proteins by SUMO—a member of the ubiquitin family of protein modifiers. The first Helle D. Ulrich (ed.), Methods in Molecular Biology: SUMO Protocols, vol. 497 © 2009 Humana Press, a part of Springer Science + Business Media, New York, NY Book doi: 10.1007/978-1-59745-566-4
33
34
Wohlschlegel
method was successfully used in Wohlschlegel et al. (8) and is a global proteomic approach for purifying and characterizing the entire pool of SUMO-conjugated proteins isolated from the budding yeast S. cerevisiae with the primary goal of identifying all of the SUMO-modified components present in the sample. The second method is focused on the mapping of SUMO attachment sites in a selected target and involves the tandem affinity purification of the sumoylated fraction of a specific substrate and the identification of SUMO-modified lysines in the purified substrate by mass spectrometry. The general strategy for globally analyzing SUMO substrates is depicted in Fig. 3.1. Briefly, SUMO-conjugated proteins are purified under denaturing conditions using Ni-NTA affinity chromatography from a yeast strain expressing Smt3 (the yeast homologue of SUMO) fused to an octahistidine tag. The denaturing conditions of this purification are extremely important to limit the activity of SUMO deconjugation enzymes in the extract as well as to ensure that only factors covalently attached to SUMO, and not the associated proteins, are purified. The affinity-purified mixture is then digested by the sequential addition of Lys-C and trypsin proteases and loaded onto a triphasic microcapillary column consisting of strong cation exchange (SCX) resin flanked by segments of reverse-phase (RP) material. Peptides are fractionated using a multidimensional separation strategy and eluted directly into a mass spectrometer, where they are fragmented using collision-induced dissociation (CID), and the resulting MS/MS
Fig. 3.1. Flowchart of methods for identifying SUMO-modified proteins (left) and for mapping SUMO attachment sites (right).
SUMO and Mass Spectrometry
35
spectra are recorded (see Note 1). This online multidimensional fractionation and mass spectrometry approach is also known as MudPIT (Multidimensional Protein Identification Technology) or 2D-LC-MS/MS (11, 12). Finally, the data is analyzed using a series of algorithms to identify the proteins present in the sample. Proteins identified from the SUMO-purified sample are compared to proteins identified from a control sample purified from an untagged yeast strain to determine the factors that are likely to be bona fide SUMO substrates as opposed to nonspecific contaminants. In addition to identifying the proteins that are modified by SUMO, it is also sometimes necessary to map the exact residues in those substrates that are covalently linked to the SUMO protein. This mapping information can guide subsequent mutational analyses where nonmodifiable mutants of those substrates are generated and the ability of those mutants to perform their cellular duties is assessed. The strategy for mapping SUMO attachment sites is based on an approach first devised for mapping ubiquitylation sites and is shown in Fig. 3.2 (13–15). The tryptic digestion of a SUMO-modified protein results in the five C-terminal amino acids from Smt3 (EQIGG) remaining covalently attached to the modified lysine reside in the substrate. The presence of these additional amino acids leads to a mass shift of 484.2282 Daltons that can be measured using mass spectrometry. Although this approach is conceptually straightforward, the mapping of SUMO conjugation sites is still technically challenging. This is due mainly to the extremely low abundance of the majority of the sumoylated subtrates where the stoichiometry of the modification is typically less than 1% (see Note 2). To address this challenge, we perform a two-step purification method to specifically
Fig. 3.2. Strategy for mapping SUMO modification sites. While tryptic digestion of an unmodified protein yields only tryptic fragments (left), tryptic digestion of a sumoylated protein by trypsin results in the generation of modified peptide containing a skipped tryptic cleavage site and a diagnostic mass fragment (484.2822 Da) corresponding to the C-terminal EQIGG sequence from Smt3 that remains attached to the modified lysine after digestion (right ). This mass shift allows the modified peptide to be identified using mass spectrometry.
36
Wohlschlegel
enrich the sumoylated version of the substrate of interest, which is then analyzed by tandem mass spectrometry to identify the conjugation sites as described above. For this tandem purification method, we generate a yeast strain expressing both His8-Smt3 and the protein of interest fused to an in vivo biotinylation peptide. SUMO conjugates are first purified using Ni-NTA chromatography, and then the biotinylated SUMO-modified substrate of interest is further purified from this fraction using immobilized streptavidin. The sequential purification of the sumoylated target in this manner results in a high level of enrichment that greatly facilitates the modification site mapping by mass spectrometry. A protocol for this method is described in Sect. 3.5.
2. Materials 2.1. Affinity Purification of SUMO Conjugates
1. Yeast culture medium: YPD or selective media if required. 2. Yeast strain EJ337: yeast strain in which HIS8-SMT3 is integrated into its endogenous locus and expresses His8-Smt3 under the control of its endogenous promoter (strain available by request from the author). 3. Control untagged yeast strain. 4. Lysis buffer: 1.85 N NaOH, 1.85% β-mercaptoethanol. This buffer should be prepared freshly before use. 5. Trichloacetic acid: Prepare a 50% (w/v) solution in water and store at 4°C. 6. Ice-cold acetone. 7. Guanidine binding buffer: 6 M guanidine hydrochloride, 100 mM sodium phosphate, 10 mM Tris-HCl, pH 8.5. 8. Nickel-NTA agarose (Qiagen, Valencia, CA). 9. Poly-Prep chromatography column (Bio-Rad, Hercules, CA). 10. Urea washing buffer: 8 M urea, 100 mM sodium phosphate, 10 mM Tris-HCl, pH 6.3. 11. Urea elution buffer: 8 M urea, 100 mM sodium phosphate, 10 mM Tris-HCl, pH 4. 12. Urea binding buffer: 8 M urea, 100 mM sodium phosphate, 10 mM Tris-HCl, pH 8.0. 13. Rabbit α-His polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA).
2.2. Proteolytic Digest of SUMO Conjugates
1. Digestion buffer: 8 M urea, 100 mM Tris-HCl, pH 8.5. 2. Tris(2-Carboxyethyl) phosphine hydrochloride (TCEPHCl): dissolved in water at 200 mM and stored in aliquots at −20°C.
SUMO and Mass Spectrometry
37
3. Iodoacetamide: 500 mM stock solution dissolved in H2O, prepared immediately before use. Iodoacetamide is light sensitive and should be stored in the dark after preparation. 4. Sequencing-grade endoprotease Lys-C (Princeton Separations, Adelphia, NJ): dissolve in water at a concentration of 0.1 µg/µL and store in aliquots at −80°C 5. 100 mM Tris-HCl, pH 8.5. 6. 1 M CaCl2. 7. Sequencing-grade endoprotease trypsin (Promega, Madison, WI): dissolve in water at a concentration of 0.5 µg/µl and store in aliquots at −80°C. 2.3. Microcapillary Column Construction and Sample Loading
1. Fused silica capillary tubing with 100 µm inner diameter and 360 µm outer diameter (Polymicro Technologies, Phoenix AZ) (see Note 3). 2. Aqua C18 reverse phase resin: 5-µm-sized particles (Phenomenex, Torrance, CA). 3. Luna strong-cation exchange (SCX) resin: 5-µm-sized particles (Phenomenex, Torrance, CA). 4. Sutter P-2000 laser puller (Sutter Instruments, Novato, CA). 5. 100% ethanol. 6. 100% methanol. 7. Helium pressure loading cell (Brechbuhler, Houston, TX; alternatively, material transfer agreement for blueprints can be requested from John Yates, The Scripps Research Institute, La Jolla, CA).
2.4. Analysis of SUMOConjugated Proteins Using Mass Spectrometry
1. Agilent HP1200 quaternary HPLC (Agilent Technologies, Santa Clara, CA) (see Note 4). 2. Thermofisher Linear Ion Trap - Orbitrap hybrid mass spectrometer (LTQ-Orbitrap) equipped with a nano-ESI source (Thermofisher Scientific, Waltham, MA). 3. HPLC buffer A: 95% water, 5% acetonitrile, 0.1% formic acid. 4. HPLC buffer B: 20% water, 80% acetonitrile, 0.1% formic acid. 5. HPLC buffer C: 95% water, 5% acetonitrile, 0.1% formic acid, 500 mM ammonium acetate. 6. Database search algorithm such as SEQUEST (Thermofisher Scientific, Waltham, MA) and other algorithms including RawXtract, DTASelect2, and Contrast2 for data analysis (algorithms are available through software transfer agreement from John Yates at The Scripps Research Institute, La Jolla, CA).
38
Wohlschlegel
2.5. Modified Protocol for BiotinSteptavidin Purification of Selected Sumoylated Substrate
1. Yeast strain expressing His8-Smt3 and the substrate of interest fused to an in vivo biotinylation peptide. 2. Guanidine elution buffer: 6 M guanidine hydrochloride, 100 mM sodium phosphate, 10 mM Tris-HCl, 250 mM imidazole. 3. Streptavidin agarose. 4. Streptavidin-conjugated horseradish peroxidase (streptavidin-HRP) (Pierce Biotechnology, Rockford, IL).
3. Methods The procedures outlined in Sects. 3.1–3.4 are used to affinity purify the entire pool of SUMO-conjugated proteins from a yeast culture and identify the components of that mixture using mass spectrometry. Section 3.5 describes modifications to the original protocol that allow the selective purification of a single sumoylated protein of interest in order to map its modification sites. 3.1. Affinity Purification of SUMO Conjugates
1. Affinity purifications should be carried out independently from two different yeast strains: a yeast strain expressing His8-Smt3 and an untagged control strain. 2. Grow 6 l of either the yeast strain expressing His8-Smt3 or the untagged control strain in YPD medium to an A600 = 2.0 and collect cells by centrifugation (2000g, 3 min, 4°C). 3. Wash the cells with 0.025 volumes of water (25 ml water per liter of starting culture) and spin cells as before. 4. Store the cell pellet at −80°C or proceed with lysis (see Note 5). 5. Resuspend the cell pellet in 150 ml of lysis buffer (25 ml lysis buffer per liter of starting culture) and incubate on ice for 30 min (see Note 6). 6. Add 150 ml 50% TCA to the sample (final concentration of TCA = 25%) and incubate on ice for 30 min. 7. Centrifuge at 27000g for 15 min at 4°C to collect the precipitate. 8. Resuspend the precipitate in 200 ml ice-cold acetone and centrifuge as before. 9. Resuspend the precipitate in 100 ml of binding buffer and incubate at room temperature for 30 min on a shaking platform. 10. Centrifuge at 27,000g and distribute the supernatant to two 50 ml conical tubes.
SUMO and Mass Spectrometry
39
11. Adjust the pH of sample in each tube to ∼8 using pH indicator paper and a few drops of 10 N NaOH. 12. Add 2 ml of Ni-NTA resin (50% slurry, 1 ml bead volume) pre-equilibrated with guanidine binding buffer to each tube and rotate at room temperature for 2 h. 13. Centrifuge the tubes at 2000g for 2 min to pellet resin. 14. Remove the supernatant and resuspend the resin in a small volume of binding buffer. 15. Pool the slurries from the two conical tubes and pour into a Poly-Prep column. 16. Wash the beads with 20 ml of guanidine binding buffer. 17. Wash the beads with 20 ml of urea washing buffer (check the pH of washing buffer before use and adjust if necessary; see Note 7). 18. Elute bound material with 5 ml of urea elution buffer. 19. As described in Note 8, we find it helpful to perform a second round of Ni-NTA purification on this eluate to further concentrate the sample before proteolytic digestion. The steps for this second round of purification are described below. 20. Adjust the pH of the eluate to ∼8 using 4 N NaOH. 21. Add 100 µl of Ni-NTA agarose (50% slurry, 50 µl bead volume) equilibrated in urea binding buffer. 22. Rotate the sample at room temperature for 2 h. 23. Centrifuge the tube at 2000g for 2 min to pellet resin. 24. Remove the supernatant, resuspend the resin in 1 ml of urea binding buffer, and transfer to a 1.7 ml microcentrifuge tube. 25. Centrifuge the tube at 2000g rpm for 1 min in a microcentrifuge. 26. Remove the supernatant and resuspend the resin in 500 µl of urea binding buffer. 27. Wash the beads three more times (Steps 25–26) for a total of four washes (500 µl per wash) and then proceed to proteolytic digestion (see Note 9). 28. A small aliquot of beads may be analyzed at this stage by SDS-PAGE followed by immunoblotting with α-Smt3 or α-His6 to monitor the effectiveness of the purification. 3.2. Proteolytic Digest of SUMO Conjugates
1. Wash the beads twice (500 µl per wash) as described in Sect. 3.1, Steps 25–26, but using digestion buffer. 2. Remove the supernatant until the digestion buffer barely covers the beads. 3. Reduce the sample by adding 0.75 µl of 200 mM TCEP and agitating the beads at room temperature for 20 min (see Note 10).
40
Wohlschlegel
4. Add 1.1 µl of freshly prepared 500 mM iodoacetamide to the sample and incubate for 20 min at room temperature in the dark while agitating (see Note 11). 5. Add 1 µl of endoprotease lys-C and incubate the sample at 37°C for at least 4 h. Lys-C is normally added at an enzyme:substrate ratio of 1:100, but since the concentration of the sample is known to be very low and hard to measure while attached to the beads, we have empirically determined 1 µl to be an effective amount of enzyme to add to the reaction. Continue to agitate the beads to prevent them from settling in the tube. 6. Add 150 µl of 100 mM Tris-HCl, pH 8.5, to the sample to reduce the concentration of urea from 8 to 2 M. 7. Add 2 µl of 100 mM CaCl2 and 1 µl of sequencing-grade trypsin (0.5 µg/µl) to the sample and incubate at 37°C with agitation. We typically add trypsin to the reaction at an enzyme:substrate ratio of 1:20, but since the concentration of the sample is known to be very low and hard to measure while attached to the beads, we have empirically determined 1 µl to be an effective amount of trypsin to add to the reaction. This step is typically performed overnight but should be allowed to proceed for at least 4 h. 8. Centrifuge sample for 1 min at 2000g. 9. Carefully transfer the supernatant to a separate centrifuge tube, using a gel-loading pipette tip to avoid transferring any of the resin. 10. Add 12 µl of 88% formic acid to the supernatant (final concentration ∼5%). 11. Resuspend the resin in 100 µl of 5% formic acid and incubate at room temperature for 10 min with agitation. 12. Centrifuge the sample for 1 min at 2000g and pool the supernatant with the supernatant from Step 9. 13. Centrifuge the pooled supernatants for 2 min at 14,000g and transfer the resulting supernatant to a new microcentrifuge tube. 14. Repeat Step 13 until no resin is visible at the bottom of the tube after centrifugation. 15. The digested sample can be stored at −20°C until it is analyzed. 3.3. Microcapillary Column Construction and Sample Loading
1. Use an alcohol burner to blacken a 3–4 cm section in the center of a 50-cm piece of fused silica capillary tubing of 100 µm inner diameter and 360 µm outer diameter (see Note 3 and Fig. 3.3).
SUMO and Mass Spectrometry
41
2. Remove the blackened coating from the fused silica tubing by wiping with a kimwipe wetted with 100% ethanol until a clear section of the tubing remains. 3. Place the fused silica capillary tubing into a Sutter P-2000 laser puller with the clear section of the tubing centered in the optical pathway of the laser beam. 4. Operate the laser puller so that the 50-cm piece of fused silica capillary is pulled and separated into two 25-cm long columns with a tip containing 5 µm orifice on one end (see Note 12). 5. Place a 1.5 ml microcentrifuge tube containing the slurry of Luna C18 reverse-phase (RP) resin wetted in methanol into the pressure loading cell. 6. Insert the flat end of the pulled microcapillary column into the pressure loading cell through a Swagelok fitting containing a 0.4 mm teflon ferrule until the end of the column is submerged in the slurry. 7. Pressurize the pressure loading device to 800–1000 psi using helium gas to force the RP material into the column until the column contains ∼8 cm of packed RP material. 8. Repeat the packing procedure using the slurry of Luna SCX resin wetted in methanol to pack ∼3 cm of SCX material below the RP resin. 9. Repeat the packing procedure to pack an additional 3 cm of RP material below the SCX material. 10. Wash the packed column with HPLC Buffer A for at least 20 min to equilibrate the column. 11. Place the digested sample into the pressure loading cell and load the sample onto the packed and equilibrated microcapillary column. 12. After loading is completed, wash the column with HPLC Buffer A for at least 20 min. 3.4. Identification of SUMO-Conjugated Proteins Using Mass Spectrometry
1. Install the loaded and washed column into the nanoelectrospray stage so that the blunt end of the column is attached to the HPLC and the spray tip is 2–3 mm from the inlet of the mass spectrometer (see Note 4). 2. Operate the HPLC at a flow rate of 0.15 ml/min and use a 50 µm inner diameter waste line to split the flow and reduce the flow rate at the tip of the column to 200–300 nl/min (see Note 13). 3. Use the HPLC controlled by the Xcalibur instrument control software to deliver a series of seven chromatographic gradients to the column. The first step, whose purpose is to
42
Wohlschlegel
Fig. 3.3. Preparation of fused silica capillary columns. Electrospray tips with a 5-µm orifice are generated at one end of a capillary column using a Sutter P-2000 laser puller. The column is then packed with the appropriate chromatography resins using a pressure loading device, followed by loading of the proteolytically digested sample of interest onto the column, fractionation of the sample by liquid chromatography, and analysis of the peptides by tandem mass spectrometry.
desalt the column and move peptides from the RP segment at the back of the column to the SCX phase, consists of a 20 min linear gradient from 100% Buffer A to 100% Buffer B, followed by 5 min of 100% Buffer B, a 1 min linear gradient from 100% Buffer B to 100% Buffer A, and 4 min at 100% Buffer A. Gradients for Steps 2–7 consist of 5 min of 100% Buffer A, 3 min of x% Buffer C, a 90 min linear gradient from 100% Buffer A to 40% Buffer A/60% Buffer B, a 10 min linear gradient from 40% Buffer A/60% Buffer B to 100% Buffer B, 8 min at 100% Buffer B, a 1 min linear gradient to 100% Buffer A, and 3 min at 100% Buffer A (x = 10, 25, 40, 60, 80, and 100% Buffer C for Step 2–7, respectively). Steps 2–7 serve to move subpopulations of peptides from the SCX phase to the long RP segment and then resolve those peptides using a long gradient of increasing acetonitrile. 4. Peptides are eluted from the microcapillary column and electrosprayed directly into the mass spectrometer by the application of a 2.5 kV spray voltage. This can be accomplished by using a liquid-metal junction created by connecting the waste line to a microtee containing a gold wire that is attached the mass spectrometer’s high voltage source (see Note 13). 5. Data-dependent acquisition of peptide tandem mass spectra is controlled by the Xcalibur data system as peptides enter the mass spectrometer. This data collection strategy is based on a cycle in which the Orbitrap mass analyzer records a
SUMO and Mass Spectrometry
43
full MS scan (m/z range = 400–1600, resolution = 60000) consisting of all ions eluting into the mass spectrometer at a given point in time while the linear ion trap mass analyzer (LTQ) performs seven rounds of MS/MS analysis at 35% collision energy to collect peptide fragmentation spectra for the seven most abundant ions from the Orbitrap full MS scan. This cycle is repeated over the course of the entire chromatographic separation. 6. Spectra are initially collected and saved by Xcalibur data system in the RAW binary file format. The program RawXtract is used to convert the RAW files to ms2 files—a text-based format. SEQUEST is then used to search the ms2 files against a database that contains all S. cerevisiae protein sequences obtained from the Saccharomyces genome database (SGD) and is concatenated to a reversed database in which the primary sequence of each yeast protein is reversed. The false positive rate for a given scoring threshold is calculated by comparing the number of peptides matching the correct forward databases versus the reversed decoy database (16). The DTASelect2 algorithm is run on the dataset and uses a linear discriminant analysis to adjust the scoring cutoffs so that the false positive rate is less than 5%. 7. Mass spectrometric analysis should be carried out on both the Smt3 affinity purification and the control purification. The Contrast2 algorithm can be used to compare proteins identified from the Smt3 affinity purification and the control purification to identify proteins uniquely identified in the Smt3 sample. 3.5. Modified Protocol Used for Mapping SUMO Attachment Sites In a Specific Cellular Substrate
1. Purify SUMO conjugates using Ni-NTA chromatography as described in Sect. 3.1, Steps 1–16. 2. Elute the SUMO conjugates using 5 ml of guanidine elution buffer. 3. Add 100 µl of streptavidin agarose (50% slurry, 50 µl bead volume) equilibrated in guanidine binding buffer. 4. Rotate the sample at room temperature for 2 h. 5. Wash the beads as described in Sect. 3.1, Steps 23–27, using guanidine binding buffer, and then proceed to proteolytic digestion. 6. A small aliquot of beads may be analyzed at this stage by SDS-PAGE followed by Western blotting using streptavidin-HRP to monitor the effectiveness of the purification. It should be noted that the guanidine in the sample must be removed prior to analysis by SDS-PAGE in order to prevent the precipitation of SDS. This can be done by TCA or acetone precipitation.
44
Wohlschlegel
7. Protease digestion is performed as described in Sect. 3.2. 8. Microcapillary columns are fabricated as described in Sect. 3.3, except that the column is packed with a single, 10-cm segment of RP material instead of the three phases of packing material described previously (see Note 14). 9. The seven-step multidimensional separation described in Sect. 3.4, Step 3, is replaced by a single-step 120-min gradient consisting of 5 min of 100% Buffer A, a 90-min linear gradient from 100% Buffer A to 40% Buffer A/60% Buffer B, a 10-min linear gradient from 40% Buffer A/60% Buffer B to 100% Buffer B, 5 min at 100% Buffer B, a 5-min linear gradient to 100% Buffer A, and 5 min at 100% Buffer A. 10. The mass spectrometer settings are identical to those described in Sect. 3.4, Steps 4–5. 11. Data analysis is identical to that described in Sect. 3.4, Step 6, except that SEQUEST searches are modified to consider potential mass shifts of 484.2282 on lysine residues corresponding to a SUMO-modified peptide (see Note 15).
4. Notes 1. The approach described in this protocol utilizes an online multidimensional separation method to fractionate the peptide mixture on a triphasic column and elute the peptides directly into the mass spectrometer. We find that this strategy is extremely effective when attempting to analyze very low amounts of a complex mixture such as the sample of affinity-purified SUMO conjugates analyzed here. Alternative fractionation methods could also be employed including a GeLC-MS/MS approach in which the proteins are separated by SDS-PAGE; the entire lane corresponding to the sample is excised into a series of gel slices, and individual gel slices are digested with trypsin and analyzed using singledimension LC-MS/MS (17). 2. Although some modification sites can be identified directly from the complex mixture of SUMO-conjugated proteins, the high complexity and dynamic range of SUMO substrates in this purified sample severely limits the ability to identify SUMO attachment sites in all but the most abundant proteins in the mixture. In those cases where SUMO modification sites need to be determined for a single protein of interest, we specifically purify the sumoylated fraction of that protein away from all other SUMO conjugates using
SUMO and Mass Spectrometry
45
a tandem denaturing purification procedure similar to that originally described by Tagwerker et al. and then analyze the highly purified sample by mass spectrometry (18, 19). 3. This section describes a procedure for constructing and packing microcapillary columns that is cost-effective over the long term and offers flexibility in terms of column lengths and resin types. Prepacked columns are commercially available from New Objective, Inc. (Woburn, MA) and would also be suitable for the experiments described here. 4. Although the proteomic methods described in this section have been optimized for the instrumentation present in the author’s laboratory, the overall strategy is general in nature and could be adapted to other platforms. Any mass spectrometer capable of acquiring tandem mass spectra (Applied Biosystems Qstar, Waters Q-Tof, etc.) as well any algorithm able to perform differential modification searches (Pep_ probe, Mascot, etc.) can also be used. 5. Preserving the SUMO modification during the purification procedure by inhibition of the SUMO proteases is critical for the success of this approach. Although the use of denaturing buffers for lysis and purification is normally very effective at inhibiting protease activity, we have occasionally noted significant losses of SUMO conjugates during the course of the purification. If this is observed, the addition of N-ethylmaleimide (NEM) to the water washes in Sect. 3.1, Step 3, the lysis buffer, and the guanidine binding buffer can help to further preserve the modification. NEM is added to a final concentration of 10 mM from a 1 M stock prepared in DMSO. 6. The yeast cells can be lysed using a number of different methods. In addition to the chemical lysis procedure used here, bead beating, grinding the cells under liquid N2, or high-pressure homogenization are all effective means of cell disruption. The requirements for choosing a lysis method are that the lysate can be generated under denaturing conditions and that the conditions are compatible with Ni-NTA affinity chromatography. 7. Long-term storage of urea-containing buffers leads to the dissociation of the urea and alteration of the pH of the buffer. The pH of urea-containing buffers should be checked immediately before use and adjusted if necessary. 8. For unknown reasons, we and others have consistently observed that Ni-NTA agarose has a significantly lower than predicted binding capacity in yeast whole cell lysates, requiring a large amount of the resin to be used in initial binding reaction (20). Consequently, the bead and elution volumes
46
Wohlschlegel
from the initial purification are quite large, making further manipulations (tryptic digestion, etc.) more difficult. To concentrate the protein for digestion, we typically use a second round of Ni-NTA purification using a small amount of resin. The components present in the yeast whole cell lysate that diminish the binding capacity of the Ni-NTA are absent in the second round of purification, allowing a much smaller volume of Ni-NTA resin to be used. 9. The digestion of samples by trypsin and other proteases is greatly facilitated by having a high protein concentration in the sample, which is typically achieved by concentration of the sample as much as possible. Although protein concentration methods such as TCA precipitation can be used here, we have noticed a significant amount of sample loss when attempting to precipitate low amounts of protein. In this particular purification, we take advantage of the high concentration of the protein on the Ni-NTA resin or streptavidin-sepharose during the second round of purification and perform the tryptic digestion directly off the beads. 10. Samples should be agitated through the course of the digestion to prevent the beads from settling at the bottom of the tube. We use a thermomixer for this purpose (Eppendorf, Westbury, NY) where both the rate of agitation and the temperature can be accurately controlled. It is also possible to perform these digestions using a tube rotator placed in an appropriate incubator. 11. Iodoacetamide is light sensitive. It should be freshly prepared before use, and all incubations should be carried out in the dark (wrap tubes or thermomixer in foil). 12. The settings required for creating electrospray tips using the Sutter P-2000 laser puller vary from instrument to instrument and must be individually determined. More details regarding determining and optimizing the settings can be found in the manufacturer’s instructions. An example program that can serve as the starting point for optimization can be found in Florens et al. (21). 13. Many of the parameters described here for flow-splitting and the application of voltage are dependent on the type of HPLC and electrospray source used and must be adjusted accordingly. 14. The sequential purification of a sumoylated factor by NiNTA agarose and streptavidin agarose leads to a high degree of enrichment and the final sample typically has very few components (low complexity). For this reason, we typically fractionate this type of sample using a single-dimension reverse-phase separation instead of the multidimensional separation described previously.
SUMO and Mass Spectrometry
47
15. Mapping of SUMO attachments sites is technically difficult even when using the strategy described here. If no SUMO attachments sites are identified using this method, a number of alternative approaches may be employed to increase the chance of success. Overexpression of SUMO or the introduction of a temperature-sensitive allele of the SUMO protease Ulp1 into the yeast strain can increase the abundance of the sumoylated substrate and help facilitate the mapping studies (22). We have also found that different C-terminal SUMO mutants can improve mapping studies by generating sumoylated peptides that are more amenable to mass spectrometry as well as enabling the use of different protease digestion strategies to observe regions of the protein that may be difficult to identify using only trypsin (15, 23). An algorithm that uses a modified scoring scheme optimized for identifying sumoylated peptides has recently been described and may prove to be a useful addition to these basic strategies (24). Finally, in those cases where the amount of sumoylated substrate that can be purified is still extremely prohibitive, the sumoylated substrate can either be produced in vitro or in a heterologous system for generating sumoylated proteins and then used for the mapping procedures (15, 23). This alternative has the major drawback that any sites identified in vitro must be examined further in an in vivo system to confirm their biological authenticity. 16. Although the procedures described here focus on analyzing SUMO conjugation in S. cerevisiae, the strategies themselves can be adapted to study the SUMO pathway in higher eukaryotes. One important consideration for the mapping of SUMO attachment sites in higher eukaryotes is the choice of protease to be used in order to generate a SUMO-specific mass signature for the modified peptide. For example, human SUMO-1 does not possess a tryptic cleavage site near its C-terminus and the digestion of a protein modified by human SUMO-1 leaves a 19 amino acid residue fragment from the C-terminus of SUMO attached to the modified target lysine. Although peptides containing this large fragment have been successfully identified using a specialized algorithm, the identification of peptides in this manner remains extremely challenging (24). As an alternative approach for mapping modification sites in higher eukaryotes, it is also possible to use site-directed mutagenesis to introduce a tryptic cleavage site near the C-terminus of human SUMO or to use an alternate protease such as Glu-C that does contain a cleavage site near the SUMO C-terminus (15, 23). Either of these strategies can be used to generate modified peptides that possess a SUMO-specific mass signature that can be readily monitored using mass spectrometry.
48
Wohlschlegel
References 1. Denison, C., Kirkpatrick, D. S., and Gygi, S. P. (2005) Proteomic insights into ubiquitin and ubiquitin-like proteins. Curr. Opin. Chem. Biol. 9, 69–75. 2. Hannich, J. T., Lewis, A., Kroetz, M. B., Li, S. J., Heide, H., Emili, A., and Hochstrasser, M. (2005) Defining the SUMOmodified proteome by multiple approaches in Saccharomyces cerevisiae. J. Biol. Chem. 280, 4102–4110. 3. Li, T., Evdokimov, E., Shen, R. F., Chao, C. C., Tekle, E., Wang, T., Stadtman, E. R., Yang, D. C., and Chock, P. B. (2004) Sumoylation of heterogeneous nuclear ribonucleoproteins, zinc finger proteins, and nuclear pore complex proteins: a proteomic analysis. Proc. Natl. Acad. Sci. USA 101, 8551–8556. 4. Manza, L. L., Codreanu, S. G., Stamer, S. L., Smith, D. L., Wells, K. S., Roberts, R. L., and Liebler, D. C. (2004) Global shifts in protein sumoylation in response to electrophile and oxidative stress. Chem. Res. Toxicol. 17, 1706–1715. 5. Panse, V. G., Hardeland, U., Werner, T., Kuster, B., and Hurt, E. (2004) A proteomewide approach identifies sumoylated substrate proteins in yeast. J. Biol. Chem. 279, 41346–41351. 6. Rosas-Acosta, G., Russell, W. K., Deyrieux, A., Russell, D. H., and Wilson, V. G. (2005) A universal strategy for proteomic studies of SUMO and other ubiquitin-like modifiers. Mol. Cell. Proteomics 4, 56–72. 7. Vertegaal, A. C., Ogg, S. C., Jaffray, E., Rodriguez, M. S., Hay, R. T., Andersen, J. S., Mann, M., and Lamond, A. I. (2004) A proteomic study of SUMO-2 target proteins. J. Biol. Chem. 279, 33791–33798. 8. Wohlschlegel, J. A., Johnson, E. S., Reed, S. I., and Yates, J. R., 3rd (2004) Global analysis of protein sumoylation in Saccharomyces cerevisiae. J. Biol. Chem. 279, 45662– 456628. 9. Zhao, Y., Kwon, S. W., Anselmo, A., Kaur, K., and White, M. A. (2004) Broad spectrum identification of cellular small ubiquitin-related modifier (SUMO) substrate proteins. J. Biol. Chem. 279, 20999–21002. 10. Zhou, W., Ryan, J. J., and Zhou, H. (2004) Global analyses of sumoylated proteins in Saccharomyces cerevisiae. Induction of protein sumoylation by cellular stresses. J. Biol. Chem. 279, 32262–32268. 11. Florens, L., and Washburn, M. P. (2006) Proteomic analysis by multidimensional
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
protein identification technology. Methods Mol. Biol. 328, 159–175. Washburn, M. P., Wolters, D., and Yates, J. R., 3rd (2001) Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 19, 242–247. Denison, C., Rudner, A. D., Gerber, S. A., Bakalarski, C. E., Moazed, D., and Gygi, S. P. (2005) A proteomic strategy for gaining insights into protein sumoylation in yeast. Mol. Cell. Proteomics 4, 246–254. Peng, J., Schwartz, D., Elias, J. E., Thoreen, C. C., Cheng, D., Marsischky, G., Roelofs, J., Finley, D., and Gygi, S. P. (2003) A proteomics approach to understanding protein ubiquitination. Nat. Biotechnol. 21, 921–926. Wohlschlegel, J. A., Johnson, E. S., Reed, S. I., and Yates, J. R., 3rd (2006) Improved identification of SUMO attachment sites using C-terminal SUMO mutants and tailored protease digestion strategies. J. Proteome Res. 5, 761–770. Peng, J., Elias, J. E., Thoreen, C. C., Licklider, L. J., and Gygi, S. P. (2003) Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/ MS) for large-scale protein analysis: the yeast proteome. J. Proteome Res. 2, 43–50. Schirle, M., Heurtier, M. A., and Kuster, B. (2003) Profiling core proteomes of human cell lines by one-dimensional PAGE and liquid chromatography-tandem mass spectrometry. Mol. Cell. Proteomics 2, 1297–1305. Tagwerker, C., Flick, K., Cui, M., Guerrero, C., Dou, Y., Auer, B., Baldi, P., Huang, L., and Kaiser, P. (2006) A tandem affinity tag for two-step purification under fully denaturing conditions: application in ubiquitin profiling and protein complex identification combined with in vivo cross-linking. Mol. Cell. Proteomics 5, 737–748. Tagwerker, C., Zhang, H., Wang, X., Larsen, L. S., Lathrop, R. H., Hatfield, G. W., Auer, B., Huang, L., and Kaiser, P. (2006) HB tag modules for PCR-based gene tagging and tandem affinity purification in Saccharomyces cerevisiae. Yeast 23, 623–632. Kaiser, P., and Wohlschlegel, J. (2005) Identification of ubiquitination sites and determination of ubiquitin-chain architectures by mass spectrometry. Methods Enzymol. 399, 266–277. Florens, L., Carozza, M. J., Swanson, S. K., Fournier, M., Coleman, M. K., Workman,
SUMO and Mass Spectrometry J. L., and Washburn, M. P. (2006) Analyzing chromatin remodeling complexes using shotgun proteomics and normalized spectral abundance factors. Methods 40, 303–311. 22. Li, S. J., and Hochstrasser, M. (1999) A new protease required for cell-cycle progression in yeast. Nature 398, 246–251. 23. Knuesel, M., Cheung, H. T., Hamady, M., Barthel, K. K., and Liu, X. (2005) A method of mapping protein sumoylation
49
sites by mass spectrometry using a modified small ubiquitin-like modifier 1 (SUMO-1) and a computational program. Mol. Cell. Proteomics 4, 1626–1636. 24. Pedrioli, P. G., Raught, B., Zhang, X. D., Rogers, R., Aitchison, J., Matunis, M., and Aebersold, R. (2006) Automated identification of SUMOylation sites using mass spectrometry and SUMmOn pattern recognition software. Nat. Methods 3, 533–539.
Chapter 4 Identification of SUMO Targets Through In Vitro Expression Cloning Christian B. Gocke and Hongtao Yu Abstract Covalent modification of proteins by small ubiquitin-like modifier (SUMO) regulates diverse cellular processes. While many SUMO substrates are identified through individual efforts, affinity-based approaches followed by mass spectrometry are also used to identify in vivo SUMO substrates in yeast and in mammals. Because of low steady-state levels of sumoylation and biases towards abundant targets, identifying sumoylated proteins in vivo can be challenging. The in vitro expression cloning (IVEC) method for SUMO target identification circumvents these challenges and complements the affinity-based approaches. IVEC allows for immediate validation and analysis of substrates through in vitro reconstitution. Furthermore, this method can be easily adapted to identify substrates of specific SUMO ligases. Key words: In vitro expression cloning, SUMO, sumoylation, SUMO ligase, Ubc9.
1. Introduction The small ubiquitin-like modifier (SUMO) is conserved from yeast to man and regulates diverse cellular processes (1–4). Sumoylation refers to the covalent attachment of SUMO to the ε-amino group of a lysine residue in a substrate or target, forming an isopeptide bond. Sumoylation is catalyzed by a cascade of enzymes, including the E1 SUMO-activating enzyme (the Aos1– Uba2 heterodimer), the E2 SUMO-conjugating enzyme (Ubc9), the E3 SUMO ligases, and the SUMO isopeptidases and proteases (SENPs). Many SUMO substrates have been identified by candidate-based approaches (2, 4). Affinity-based approaches in conjunction with mass spectrometry have also been used to systematically identify in vivo SUMO substrates in yeast and
Helle D. Ulrich (ed.), Methods in Molecular Biology: SUMO Protocols, vol. 497 © 2009 Humana Press, a part of Springer Science + Business Media, New York, NY Book doi: 10.1007/978-1-59745-566-4
51
52
Gocke and Yu
mammals (5–10). These approaches have several shortcomings and challenges, including low steady-state levels of sumoylation in the cell and biases towards abundant proteins. Furthermore, once substrates are identified using mass spectrometry, validation of these putative SUMO substrates requires cloning of the corresponding genes or obtaining antibodies against them. The in vitro expression cloning (IVEC) method was developed by Kirschner and coworkers (11). In this method, small pools of cDNA plasmids are transcribed in vitro and translated in rabbit reticulocyte lysate in the presence of 35S-methionine. The mixture of radiolabeled proteins is subjected to posttranslational modifications, such as phosphorylation, ubiquitylation, sumoylation, or proteolysis, by purified recombinant enzymes. The modified proteins are analyzed by SDS-PAGE to identify pools that contain targets of these modifications. The pools of cDNAs are then divided to identify the genes encoding each target. The IVEC method is thus ideal for the identification of enzyme substrates. It has been successfully used to identify substrates of kinases (12), ubiquitin ligases (13), and caspases (14). We had previously adapted IVEC to identify SUMO substrates (15). IVEC avoids the biases and complications associated with affinity-based techniques discussed above. In our protocol, 35 S-labeled in vitro translated proteins from a pooled cDNA plasmid library are subjected to control or sumoylation reactions. SDS-PAGE and autoradiography are used to visualize changes in gel mobility consistent with sumoylation. The cDNAs encoding individual substrates are then isolated from the corresponding pools and sequenced. This technique is specific and sensitive in identifying in vitro SUMO substrates (15).
2. Materials 2.1. Purification of Recombinant Sumoylation Enzymes
1. Plasmids: pET28a-SUMO1, pET28a-SUMO2, pET11c-Aos1, pET28b-Uba2, pET28b-Ubc9, and pGEX-4T-Ulp1 (15). 2. Competent BL21(DE3) bacterial cells. 3. Isopropyl β-D-1-thiogalactopyranoside (IPTG): dissolve in water at a concentration of 1 M. 4. 1 l culture flasks and centrifuge bottles. 5. LB broth and agar supplemented with 100 µg/ml ampicillin or 30 µg/ml kanamycin. 6. Lysozyme: dissolve in Tris-buffered saline (TBS) at a concentration of 100 mg/ml. 7. 0.45 µm filters and syringes.
In Vitro Expression Cloning of SUMO Targets
53
8. Bradford protein detection reagent (Bio-Rad; Cat#: 5000006): dilute 1:5 with water before use. 9. Coomassie Blue staining solution: 2 g Coomassie Blue, 2 l methanol, 1.6 l water, 400 ml of glacial acetic acid. 10. Destaining solution: 200 ml glacial acetic acid, 400 ml methanol, 3.4 l water. 11. Chromatography columns (Bio-Rad, Econo-Pac columns, Cat#: 732-1010). 12. Glutathione Sepharose-4B (GE Healthcare). 13. Ni2+-NTA agarose beads (Qiagen). 14. Amicon Ultra −15 (10 kDa cut-off) concentrators. 15. Superdex 200 (HiLoad 16/60) gel-filtration column (GE Healthcare). 16. PD-10 desalting columns (GE Healthcare). 17. Branson Sonifier 450 or equivalent. 18. Lysis Buffer: 50 mM Tris-HCl (pH 7.7), 150 mM KCl, and 0.1% Triton X-100. Store at 4°C. Add 15 mM β-mercaptoethanol before use. 19. Wash Buffer: 50 mM Tris-HCl (pH 7.7), 300 mM KCl, and 0.1% Triton X-100. Store at 4°C. Add 15 mM β-mercaptoethanol before use. 20. Storage Buffer: 20 mM Tris-HCl (pH 7.7), 100 mM KCl, and 10% glycerol. Store at 4°C. Add 1 mM DTT before use. 2.2. In Vitro Expression Cloning of SUMO Substrates
1. ProteoLink Human Adult Brain cDNA library (Promega, Cat#: L6500) (see Note 1). 2. Gold TNT SP6 Express 96-well plate (Promega, Cat#: L6501). 3.
35
S-Methionine (GE Healthcare, Cat#: SJ1015, 1000 Ci/ mmol).
4. Energy Mix: 150 mM phosphocreatine, 20 mM ATP, 2 mM EGTA, and 20 mM MgCl2. Adjust to pH 7.7. Store at −80°C. 5. XB buffer: 10 mM HEPES (pH 7.7), 1 mM MgCl2, 0.1 mM CaCl2, 100 mM KCl, and 50 mM Sucrose. Store at −80°C. 6. 2X SDS Sample Buffer: 2.9 g SDS, 0.4 g Tris-base, 12 ml glycerol, 40 mg bromophenol blue, and 620 mg DTT. Add distilled water to 40 mL. Store at −20°C. 7. 1X SDS running buffer: 60 g Tris base, 144 g glycine, and 10 g SDS. Add distilled water to 10 l. 8. Gel dryer (Bio-Rad model 583 and HydroTech vacuum pump or equivalent). 9. DH5α competent cells. 10. Multichannel pipettes/tips.
54
Gocke and Yu
11. 96-well reaction plates (Rainin, Cat#: R96-OAPV-1CO or similar). 12. SealPlate adhesive (EXCEL Scientific; Cat#: 100-SEALPLT). 13. Criterion Precast gels and 4 Criterion cells (Bio-Rad). Use 26-well Tris-HCl gels, 1.0 mm thickness. 14. Fujifilm BAS cassette2 2040 and FLA-5100 image reader. 15. Flat-Bottom blocks. 96-well blocks with 2 ml wells plus lids (Qiagen, Cat#: 19579). Autoclave before use. 16. Mini-prep kits.
3. Methods The overall scheme for identifying SUMO substrates by IVEC and the results for the identification of a representative substrate are shown in Figs. 4.1 and 4.2. The two most important steps in preparing for IVEC are given as follows: (1) choosing the appropriate cDNA library, and (2) purification of high-quality SUMO enzymes for the biochemical assay. We used a commercial library that contained about 50 cDNAs in each pool. Alternatively, a homemade library could be used. It is important that there is broad representation of the genome and that repetitiveness based on mRNA abundance is minimized. Once the SUMO enzymes are purified, one should perform reactions on a known substrate for quality control. Reactions and techniques can be optimized at this time before starting the large-scale experiment. Unlike most ubiquitylation reactions, efficient in vitro sumoylation does not require a SUMO ligase (E3 ligase) because Ubc9 directly binds to the consensus motif ΨKXE (Ψ, a large hydrophobic residue; X, any amino acid) on the substrate (16). One could, however, modify this procedure and identify substrates of a given SUMO ligase by comparing samples with and without the SUMO ligase of interest. 3.1. Purification of Recombinant Sumoylation Enzymes
1. Transform the appropriate plasmids (see Sect. 2.1.1 or similar constructs) into BL21(DE3) bacteria. Cotransform the Uba2 and Aos1 plasmids and use different antibiotic resistances to ensure selection of cotransformants. 2. Seed a single colony in 100 ml of LB and the appropriate antibiotic(s) and shake at 37°C for 10–14 h at 250 rpm. 3. Dilute approximately 1:100 to 1:50 in fresh LB and antibiotics and shake at 250 rpm at 37°C until the OD600 is between 0.5 and 0.7. Add IPTG to a final concentration of 250 µM and
In Vitro Expression Cloning of SUMO Targets
55
Fig. 4.1. In vitro expression cloning of SUMO substrates: primary screen. A cDNA library with multiple cDNAs per well in a 96-well format is in vitro transcribed and translated in the presence of 35S-methionine. In vitro expressed proteins are then subjected to control (−) or sumoylation (+) reactions followed by SDS-PAGE and autoradiography. The gel of samples from row E in plate B is shown in the bottom panel. Well E12 displays new high molecular weight bands that appear after sumoylation (indicated by a bracket). A disappearing substrate band (indicated by an asterisk) was also observed, although this is often less clear unless sumoylation is very efficient.
incubate for another 4–6 h at room temperature. Harvest bacteria using centrifugation. Wash the pellet once with phosphate-buffered saline (PBS). Confirm protein expression by comparing samples with and without IPTG on SDS-PAGE followed by Coomassie Blue staining and destaining. 4. Store the bacterial pellet at −80°C (stable for several months). Alternatively, resuspend the pellet in lysis buffer and then freeze.
56
Gocke and Yu
Fig. 4.2. In vitro expression cloning of SUMO substrates: secondary screen and validation. (A) Once putative hits have been identified in the primary screen, cDNAs from that well are transformed into E. coli and single colonies are cultured in 96-well blocks. Bacteria culture from individual rows (R1–8) or columns (C1–12) are combined. After plasmid purification, cDNAs are tested for sumoylation as in Fig. 4.1. Substrates are identified by a matrix-assisted technique. The individual clone is isolated, confirmed for sumoylation, and sequenced. (B, C) Secondary screen to identify the substrate in E12 on plate B as shown in Fig. 4.1. The dashed boxes mark the same substrate (BRD8) found in C11 and R5, indicating the exact location of the positive clone in the 96-well culture block.
5. Resuspend the pellet in 5 pellet volumes of ice-cold lysis buffer by vortexing. Add lysozyme to a final concentration of 1 mg/mL. Incubate on ice for 20–30 min with intermittent mixing. 6. Transfer the lysate to a glass beaker. Sonicate the lysate in an ice-water bath for 2 min with a duty cycle of 50% and a power output of 5 (these settings apply to the Branson Sonifier 450 and may have to be adjusted when using other models). Repeat the procedure until the lysate is no longer viscous as determined by pipetting with a 1 ml microtip. 7. Spin the lysate at 30,000g at 4°C for 1 h. Filter the supernatant using a syringe attached to a 0.45 µm filter (see Note 2). 8. Depending on the specific protein to be purified, add 1 mL of Ni2+-NTA or glutathione Sepharose beads to the supernatant. Beads should be pre-equilibrated with 20 ml of lysis buffer. Incubate the supernatant with beads for 1 h at 4°C with constant but gentle mixing. Pour beads and supernatant into a 30 ml Econo-Pac column and allow the supernatant to drain.
In Vitro Expression Cloning of SUMO Targets
57
9. Wash the beads with 50 ml of wash buffer or until the washes are negative for proteins as determined by adding one drop of the wash solution into 200 µl of Bradford protein detection reagent solution. 10. Elute protein with wash buffer containing 10 mM glutathione for GST fusion proteins or 200 mM imidazole for Histagged proteins. Collect three fractions of 3 ml each. 11. Confirm size, purity, and quantity of the eluted proteins on SDSPAGE followed by Coomassie Blue staining and destaining. 12. Concentrate the eluate to approximately 2.5 ml using Centriprep concentrators. Apply the eluate to a PD-10 column pre-equilibrated with storage buffer. Elute protein with 3.5 ml of storage buffer. For the His6-Aos1–Uba2 complex, concentrate the eluate and directly apply to a Superdex 200 column pre-equilibrated with two column volumes of storage buffer. 13. Concentrate all enzymes to 1–2 mg/ml. Aliquot, flash freeze, and store at −80°C. 3.2. In Vitro Expression Cloning of SUMO Substrates
1. Test and optimize sumoylation reactions using a known substrate using procedures similar to that described below. This step is extremely important, because it determines the sensitivity and feasibility of the screen (see Note 3). 2. In vitro express cDNA libraries in 96-well plates (Fig. 4.1). Pipette 2 µl of each cDNA pool into a 96-well plate containing 20 µl of Gold TNT lysate supplemented with 2 µl of distilled water and 1 µL of 35S-Methionine in each well. Mix by gently vortexing. 3. Incubate at 30°C for 90 min. 4. Store at −80°C. Avoid multiple cycles of freezing and thawing. 5. Thaw in vitro expressed protein on ice. In a 96-well reaction plate, add 2 µl of in vitro expressed protein to 8 µl of control mix or sumoylation mix. The control mix contains XB buffer only. The sumoylation mix contains 2 µg of Aos1– Uba2, 0.5 µg of Ubc9, 1 µg of SUMO, 1 µl of energy mix, and is adjusted to 8 µl with XB buffer. Prepare these reactions on ice, and add the energy mix finally (see Note 4). It is prudent to run a test plate of sumoylation reactions for quality control before expression and sumoylation of the entire library. 6. Apply the adhesive film and mix 96-well plate reactions by gentle vortexing. 7. Incubate at 30°C for 2 h. 8. Stop the reactions by applying 10 µl of 2X-SDS sample buffer to each well. Denature the proteins by placing the 96-well plates on heat blocks at 100°C for 2–3 min.
58
Gocke and Yu
9. Load 10 µl of sample into wells of precast Bio-Rad gels (see Notes 5 and 6). 10. Run gels at 30 mA for approximately 2 h in 1 X SDS running buffer. 11. Stain with Coomassie Blue for 30 min and destain for approximately 1 h (see Note 7). 12. Dry gels at 80°C for 2 h (see Note 8). 13. Place the dried gels in a phosphorimager cassette. Label molecular weight markers by blotting 35S samples on the filter paper next to markers and expose overnight (see Note 9). 14. Analyze the images using a phosphorimager. Identify high molecular weight bands that appear in the sumoylation lane, but are absent in the control lane (Fig. 4.1, see bracket in lane E12). The band belonging to the unsumoylated substrate may not always be clear. However, bands that disappear specifically in the sumoylation lane are of interest, as detection of smears can sometimes be difficult. Set your own standards for characterizing “hits,” depending on the sensitivity and specificity of your particular assay (see Note 10). 15. Once positive hits are identified, transform the cDNA pools from these wells into DH5α so that approximately 500 colonies are obtained (Fig. 4.2A). 16. Pick colonies (see Note 11) using autoclaved microtips. Inoculate 1 ml of LB-ampicillin in each well of a 96-well block (Fig. 4.2A). Tips should be removed only after all colonies are inoculated to avoid inoculating the same well twice. Shake overnight at 37°C. 17. Combine 0.4 ml of culture from each well within a row or a column (R1-8 and C1-12) (see Note 12) so that only 20 mini-preps are necessary to identify the hit (Fig. 4.2A). Bacteria can be combined into a single tube simply by releasing cultures from a multichannel pipettor onto a clean spatula that feeds into a 15-ml culture tube. Store the rest of the bacterial culture in the 96-well culture block at 4°C while performing the secondary sumoylation screens. 18. Repeat steps 2–14 described in Section 3.2. but use 1 µl of each DNA miniprep, 0.5 µl of 35S-Methionine, and 10 µl of TNT lysate. Identify the specific well in the 96-well bacterial culture block (Fig. 4.2B, see C11, R5) that contains the substrate. 19. Repeat steps 2–14 described in Section 3.2. but with a single plasmid encoding the sumoylated substrate identified in Step 18. Use 1 µl of miniprep DNA, 0.5 µl of 35S-Methionine, and 10 µl of TNT lysate for in vitro translation. 20. Once sumoylation of the substrate is confirmed, sequence the plasmid.
In Vitro Expression Cloning of SUMO Targets
59
21. Validate at least some of the substrates by repeating the sumoylation reactions. Omit individual components of the sumoylation machinery from or add Ulp1 (a SENP) to the reactions to demonstrate specificity (see Note 13).
4. Notes 1. The cDNA library can be custom made or purchased. It is preferable that the library is normalized and pooled into approximately 100 cDNAs per well in a 96-well format. Expression of each cDNA can be driven by Sp6 or T7 promoters. While the quality of the library used in our screen was generally good, only 15–20 identifiable bands on average (instead of the about 100 proteins expected) were obtained after in vitro translation of each cDNA pool (Fig. 4.1). In addition, as this library is made from brain tissues that contain mostly terminally differentiated cells, substrates involved in the active cell division cycle may be underrepresented. 2. Filtration may be difficult, but will save time later because it removes particulate material that will clog your column. 3. The quality of the purified recombinant SUMO enzymes should be tested using a known substrate. MEF2C is a suitable substrate for this purpose. Do not use substrates that are too efficiently sumoylated in vitro, e.g., SUMO ligases, which are known to undergo efficient autosumoylation. The use of efficient SUMO substrates may provide false assurance of the quality of the recombinant enzymes. Sumoylation reactions should also be optimized by varying the quantity of enzymes and the length of the incubation. Finally, while we used SUMO1 in our screen, SUMO2 can be used instead to identify substrates that are conjugated to SUMO2. 4. The sumoylation reactions need to be prepared on ice, because autosumoylation of the sumoylation machinery at room temperature may deplete certain reactants before the addition of substrates. This is especially important if the screen is adapted to search for substrates of E3 ligases. We typically make a master reaction mix, aliquot it into 8 wells, and then distribute 8 µl per well in a 96-well plate using a multichannel pipettor. 5. It is important to load samples onto SDS-PAGE immediately after boiling. Freeze-thawing requires reboiling of samples prior to loading and decreases the quality of autoradiography. If samples are boiled for too long, water will evaporate and cause SDS to precipitate, making loading difficult and unreliable. 6. We used 10% gels in our screen. Higher percentage gels or gradient gels can also be used. However, in our experience, these gels tend to crack more easily during the drying process.
60
Gocke and Yu
7. Staining and destaining does not need to be complete before gel drying. This step simply washes away excess free 35S-methionine, fixes the gel, and allows visualization of bands to confirm equal loading and the quality of the sample. Bands should be sharp and equal across lanes. If running multiple gels, cut corners off to keep track of the gels. We recommend running a maximum of 8 gels at a time (enough to screen one 96-well plate). 8. To decrease cracking of gels during the drying process, submerge a sheet of filter paper underneath the gel in a large dish of water to capture the gel on top of the paper. Make sure that the gels are completely dry before releasing vacuum. 9. The benefit of analyzing data at various intensities and with a digital format using a phosphorimager outweighs the better resolution of film. 10. New substrates not seen in the primary screen may be identified during the secondary screens (Fig. 4.2B, lanes C8, R7). This could be due to crowding in the lanes during the primary screen or because of reduced competition among the expressed proteins (8 in the secondary screen versus 100 in the primary screen). The intensity ratio of the sumoylated and unsumoylated bands can be used to measure the sumoylation efficiency of a substrate. Hits identified in the primary screen are typically more efficient substrates. 11. If 96 colonies per positive pool are picked for the secondary screen, it is possible that the original substrate will not be identified. In this case, another 96 colonies should be picked and screened to identify the hit. 12. Although mini-prep kits in 96-well format are available, we still recommend the use of the matrix-assisted method to identify substrates described above. This method reduces the work load of the secondary screen by nearly 5-fold. 13. The specificities of isopeptidases should be kept in mind for such assays. For example, Ulp1 shows little activity toward the SUMO2-conjugated substrates, but is very active against SUMO1 (K. Orth, personal communication).
Acknowledgments We thank Dr. Jungseog Kang for assistance in developing the IVEC SUMO screen and Joshua Bembenek for the purification of SUMO enzymes. We also thank Frauke Melchior, Kim Orth, and Stefan Muller for providing expression constructs and purification protocols of SUMO enzymes.
In Vitro Expression Cloning of SUMO Targets
61
References 1. Johnson, E. S. (2004) Protein modification by SUMO. Annu. Rev. Biochem. 73, 355–382. 2. Seeler, J. S., and Dejean, A. (2003) Nuclear and unclear functions of SUMO. Nat. Rev. Mol. Cell Biol. 4, 690–699. 3. Melchior, F., Schergaut, M., and Pichler, A. (2003) SUMO: ligases, isopeptidases and nuclear pores. Trends Biochem. Sci. 28, 612–618. 4. Muller, S., Ledl, A., and Schmidt, D. (2004) SUMO: a regulator of gene expression and genome integrity. Oncogene 23, 1998–2008. 5. Li, T., Evdokimov, E., Shen, R. F., Chao, C. C., Tekle, E., Wang, T., Stadtman, E. R., Yang, D. C., and Chock, P. B. (2004) Sumoylation of heterogeneous nuclear ribonucleoproteins, zinc finger proteins, and nuclear pore complex proteins: A proteomic analysis. Proc. Natl. Acad. Sci. USA 101, 8551–8556. 6. Panse, V. G., Hardeland, U., Werner, T., Kuster, B., and Hurt, E. (2004) A Proteomewide Approach Identifies Sumoylated Substrate Proteins in Yeast. J. Biol. Chem. 279, 41346–41351. 7. Vertegaal, A. C., Ogg, S. C., Jaffray, E., Rodriguez, M. S., Hay, R. T., Andersen, J. S., Mann, M., and Lamond, A. I. (2004) A proteomic study of SUMO-2 target proteins. J. Biol. Chem. 279, 33791–33798. 8. Wohlschlegel, J. A., Johnson, E. S., Reed, S. I., and Yates, J. R., 3rd (2004) Global analysis of protein sumoylation in Saccharomyces cerevisiae. J. Biol. Chem. 279, 45662– 45668. 9. Zhao, Y., Kwon, S. W., Anselmo, A., Kaur, K., and White, M. A. (2004) Broad spectrum identification of cellular small ubiquitin-
10.
11.
12.
13.
14.
15.
16.
related modifier (SUMO) substrate proteins. J. Biol. Chem. 279, 20999–21002. Zhou, W., Ryan, J. J., and Zhou, H. (2004) Global analyses of sumoylated proteins in Saccharomyces cerevisiae. Induction of protein sumoylation by cellular stresses. J. Biol. Chem. 279, 32262–32268. Lustig, K. D., Stukenberg, P. T., McGarry, T. J., King, R. W., Cryns, V. L., Mead, P. E., Zon, L. I., Yuan, J., and Kirschner, M. W. (1997) Small pool expression screening: identification of genes involved in cell cycle control, apoptosis, and early development. Methods Enzymol. 283, 83–99. Stukenberg, P. T., Lustig, K. D., McGarry, T. J., King, R. W., Kuang, J., and Kirschner, M. W. (1997) Systematic identification of mitotic phosphoproteins. Curr. Biol. 7, 338–348. McGarry, T. J., and Kirschner, M. W. (1998) Geminin, an inhibitor of DNA replication, is degraded during mitosis. Cell 93, 1043–1053. Cryns, V. L., Byun, Y., Rana, A., Mellor, H., Lustig, K. D., Ghanem, L., Parker, P. J., Kirschner, M. W., and Yuan, J. (1997) Specific proteolysis of the kinase protein kinase C-related kinase 2 by caspase-3 during apoptosis. Identification by a novel, small pool expression cloning strategy. J. Biol. Chem. 272, 29449–29453. Gocke, C., Yu, H., and Kang, J. (2004) Systematic identification and analysis of mammalian small ubiquitin-like modifier substrates. J. Biol. Chem. 280, 5004–5012. Sampson, D. A., Wang, M., and Matunis, M. J. (2001) The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification. J. Biol. Chem. 276, 21664–21669.
Chapter 5 Enhanced Detection of In Vivo SUMO Conjugation by Ubc9 Fusion-Dependent Sumoylation (UFDS) Rainer Niedenthal Abstract The bottleneck in studying protein sumoylation—the conjugation of the small ubiquitin-like modifier (SUMO)—is the detection of the low level of in vivo sumoylated proteins. The Ubc9 fusion-directed sumoylation (UFDS) system strongly enhances the in vivo sumoylation of a substrate protein at its specific sumoylation site. UFDS utilizes an expression plasmid for the protein of interest fused to the SUMO-conjugating enzyme Ubc9. When expressed in HEK293, COS-7, HeLa, or CHO cells, the fused target protein is conjugated with endogenous or coexpressed SUMO at its native sumoylation sites. This sumoylation requires neither SUMO ligase nor any extracellular stimulation and is easily detectable by fusion protein- or Ubc9-specific Western blotting with commercially available antibodies. Key words: SUMO, Ubc9, sumoylation, Ubc9 fusion-directed sumoylation, UFDS, in vivo sumoylation.
1. Introduction Sumoylation is a protein conjugation process similar to ubiquitylation and conjugation of other ubiquitin-like proteins (Ubls). It is involved in the regulation of many different cellular processes, but, in contrast to ubiquitylation, it is most likely not involved in proteasomal protein degradation (1). Sumoylation first requires SUMO maturation, where one of five known SUMO-specific proteases cleaves the SUMO precursor protein (2). Subsequently, the SAE1–SAE2 complex (E1) activates SUMO (3–6) and transfers it to the SUMO-conjugating enzyme Ubc9 (E2) (7–8). SUMO-loaded Ubc9 in turn conjugates substrate proteins with SUMO directly (9) or is supported by SUMO ligases (10–13). Helle D. Ulrich (ed.), Methods in Molecular Biology: SUMO Protocols, vol. 497 © 2009 Humana Press, a part of Springer Science + Business Media, New York, NY Book doi: 10.1007/978-1-59745-566-4
63
64
Niedenthal
Sumoylation can be reverted by SUMO-specific proteases (2). In contrast to other Ubl-conjugating processes, most SUMO ligases act mainly as adaptors between Ubc9 and the sumoylation substrates. Furthermore, they do not appear to be absolutely essential for most sumoylations as shown by efficient in vitro or E. coli sumoylation systems (14) that function without SUMO ligases. Depending on the small amount of a specific sumoylated protein in the cell, it is difficult to study sumoylation of a protein of interest in vivo. We therefore tested whether the SUMO ligase adaptor function can be replaced by the direct fusion of Ubc9 to the substrate proteins (Fig. 5.1A). To this end, we developed eukaryotic protein expression vectors allowing the fusion of Ubc9 to the N- or the C-terminus of a protein (Fig. 5.1B). The use of such expression vectors for Ubc9 fusion-directed sumoylation (UFDS, 15) is described in the following in detail. The expression vectors for Ubc9 fusion proteins are transfected
Fig. 5.1. The Ubc9 fusion-dependent sumoylation (UFDS) system. (A) Schematic representation of natural protein sumoylation (top) and Ubc9 fusion-directed sumoylation (bottom) (taken from Ref. (15) ). (B) The multicloning sites of pNU and pCU for fusion of Ubc9 to the protein of interest. Useful restriction sites are indicated. The Ubc9 reading frame is represented by a short translated part of the sequence.
Ubc9 Fusion-Dependent Sumoylation
65
to HEK293, COS-7, HeLa, or CHO cells alone or together with EGFP-SUMO1. The transfected cells are lysed in gel loading buffer, and the proteins are separated on SDS-PAGE and analyzed by Western blotting. Sumoylated Ubc9 fusion proteins can be detected with commercially available antibodies against the primary fusion protein or Ubc9 combined with HRP-conjugated secondary antibodies, a chemiluminescent reagent, and a detection system for the measurement of the chemiluminescent signal, such as Fuji LAS3000 (Fig. 5.2A–D). Using this simple method of UFDS, we have identified new SUMO substrate proteins and have analyzed the in vivo function of sumoylation of STAT1 (1, 16). Further study of the UFDS system shows that it is very helpful to verify whether a particular protein can be sumoylated in vivo, and to identify in vivo sumoylation sites by mutagenesis. In addition, UFDS can be applied to the study of protein–protein interactions (unpublished observations), and could possibly be improved using ligand-inducible protein–protein interaction between Ubc9 and the protein of interest (Zimnik et al., submitted and Chapter 10). Here we describe an analysis of the efficiency of UFDS, using STAT1-Ubc9 and p53-Ubc9 as model fusion proteins in COS-7, HeLa, and CHO cells in comparison to HEK293. In all four tested cell lines, UFDS induces sumoylation of the fusion proteins with specificity for the known sumoylation sites (Fig. 5.2). The Ubc9 fusion proteins are sumoylated with endogenous SUMO1 or with coexpressed EGFP-SUMO1 to a similar extent in HEK293 and COS-7 cells and with slightly reduced efficiency in HeLa cells. In CHO cells, sumoylation with endogenous SUMO appears weaker, possibly depending on a low amount of activated SUMO that is available in these cells, or possibly on a partial incombatibilty between mouse Ubc9 and Chinese hamster SUMO. In all cell lines, weak sumoylation at secondary sites is detected to varying degrees, dependent on the respective protein of interest. In addition, the strength of sumoylation by UFDS is sometimes influenced by unknown factors. While using UFDS, one should consider the restricted flexibility of a covalently fused Ubc9. Hence, not all natural sumoylation events will be possible even when both fusions to the N- and C-terminus have been tested. This will result in false negatives. On the other hand, weak sumoylations, probably without any function, are detectable as false positives, as is known for other modifications such as phosphorylation. Accordingly, the relevance of a newly identified sumoylation event will have to be confirmed by functional analysis. Overall, UFDS as a highly effective method in the in vivo sumoylation system can be very helpful in the analysis of the function of sumoylation in regulating other protein modifications, protein interactions, enzymatic function, protein stability, or cellular protein localization (15, 16). The contribution of
66
Niedenthal
Fig. 5.2. Sumoylation of p53-Ubc9 and STAT1-Ubc9 in HEK293 (A), in COS-7 (B), in HeLa (C), and in CHO (D) cells. The indicated Ubc9 fusion proteins were expressed alone or together with EGFP-SUMO-1. After 24 h, the protein extracts of the transfectants were analyzed by immunoblotting with antibodies specific for STAT1 or p53 and—after stripping—with anti-EGFP antibody. The protein-specific antibodies decorate the Ubc9 fusion protein, its conjugates to EGFP-SUMO-1
Ubc9 Fusion-Dependent Sumoylation
67
UFDS to both identifying sumoylation substrates and studying the function of protein sumoylation in vivo qualifies this method as a simple and valuable tool for analyzing protein sumoylation.
2. Materials 2.1. Cell Culture, Plasmids, and Cell Lysis
1. Dulbecco’s modified eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) for HEK293, COS-7, and HeLa cells. 2. Alpha-modified eagle’s medium (Alpha-MEM) supplemented with 10% fetal bovine serum (FBS) for CHO cells. 3. Solution of Penicillin and Streptomycin for supplementing growth media. 4. Polyethylenimine, 1 mg/ml (in H2O) solution, for transfection of HEK293, COS-7, and HeLa cells (see Note 1). 5. Lipofectamine Reagent and Plus Reagent (Invitrogen, Carlsbad, CA, USA). 6. Modified Laemmli (2 X) buffer for cell lysis: 160 mM TrisHCl, pH 6.8, 4% (w/v) sodium dodecyl sulphate (SDS), 20% (v/v) glycerol, 0.5% (v/v) β-mercaptoethanol, 0.008% (w/v) bromophenol blue. 7. Expression vectors: pcDNA3 (Invitrogen) for Ubc9 fusion proteins and pEGFP-C2 (Clontech Laboratories, Mountain View, CA, USA) for EGFP-SUMO-1.
2.2. SDSPolyacrylamide Gel Electrophoresis (SDS-PAGE)
1. Separating gel buffer: 1 M Tris-HCl, pH 8.8. Store at room temperature. 2. Stacking gel buffer: 1 M Tris-HCl, pH 6.8. Store at room temperature.
Fig. 5.2. (continued) and endogenous SUMO and—if detectable—the endogenous protein. The results in HEK293 (A) and COS-7 (B) cells are very similar: they show clear sumoylation both by endogenous SUMO (S-STAT1-Ubc9 and S-p53Ubc9) and coexpressed EGFP-SUMO-1 (E-S1-STAT1-Ubc9 and E-S1-p53-Ubc9). Sumoylation by endogenous SUMO is confirmed by a partial competition with coexpressed EGFP-SUMO-1 and the appearance of a new band of lower mobility (E-S1-STAT-Ubc9 and E-S1-p53-Ubc9). The results in HeLa (C) and CHO (D) cells are similar, but sumoylation with endogenous SUMO is weaker in HeLa cells and hardly detectable in CHO cells. In all cell lines, sumoylation is strongly reduced for the sumoylation site mutants STAT1(K703R) and p53(K386R). This shows that sumoylation in all cell lines takes place at the physiological sites. Nevertheless, in blots of the mutant proteins, there are weak signals of sumoylated proteins, which are stronger for p53 but also detectable for STAT1. While it is unclear why such bands are sometimes undetectable (STAT1, see Ref. (16 ) ) and sometimes clearly present, their presence does not prevent the identification of major sumoylation sites by UFDS. The second development of the blot with an EGFP or SUMO antibody is necessary to ensure that the same amount of EGFP-SUMO-1 was coexpressed with the wild type and mutant protein.
68
Niedenthal
3. Acrylamide solution: 30% (w/v) aqueous acrylamide/ bisacrylamide (37.5:1) in water. Acrylamid is a neurotoxin when unpolymerized and, hence, care should be taken to avoid exposure or incorporation. 4. N,N,N,N′-Tetramethyl-ethylenediamine (TEMED): store at 4°C. 5. Ammonium persulfate (APS): prepare a 10% (w/v) solution in water and immediately freeze and store in single-use aliquots (500 µl) at −20°C. 6. Water from a Millipore MQ system with a resistivity of 18.2 MΩ cm (see Note 2). 7. SDS solution: 20% (w/v) solution. Store at 30°C (see Note 3). 8. SDS-PAGE running buffer (10 X): 250 mM Tris, 1.9 M glycine, pH 8.8, 1% (w/v) SDS. Store at room temperature. 9. Molecular weight markers: MagicMarkXP Western Standard (Invitrogen, Carlsbad, CA, USA) or equivalent (see Note 4). 2.3. Detection of Ubc9 Fusion Proteins by Western Blotting
1. Transfer buffer: 48 mM Tris base (do not adjust pH), 39 mM glycine, 20% (v/v) methanol, 0.037% (w/v) SDS. Store at room temperature (see Note 5). 2. Supported PVDF membrane (see Note 6) and gel blotting paper (1.2 mm) (Carl Roth, Karlsruhe, Germany, or equivalent). 3. Tris-buffered saline with Tween 20 (TBS-T): Prepare a 10 X stock with 1.37 M NaCl, 200 mM Tris-HCl, pH 7.6. Dilute 100 ml with 900 ml water for use and add to 0.1% (v/v) Tween 20. 4. Blocking buffer: 5% (w/v) nonfat dry milk in TBS-T. 5. Primary antibody dilution buffer: Blocking buffer. 6. Primary antibodies: We recommend anti-STAT1, anti-p53, and anti-EGFP antibodies from Cell Signaling, but equally suitable antibodies are available from different suppliers (see Note 7). 7. Secondary antibody: HRP Goat Anti-Rabbit Igs. 8. Immobilon Western Chemiluminescent reagent (HRP substrate) (Millipore Corporation, Billerica, MA, USA) or equivalent. 9. LAS-3000 imaging system (Fuji Film, Düsseldorf, Germany) or equivalent.
2.4. Stripping and Reprobing Blots for Detection of Coexpressed EGFP-SUMO-1
1. Stripping buffer: 62 mM Tris-HCl, pH 6.8, 2% (w/v) SDS, 0.7% (v/v) β-mercaptoethanol. Store at room temperature. 2. Wash buffer: TBS-T. 3. Primary antibody: Anti-EGFP antibody (see Sect. 2.3, Item 6.)
Ubc9 Fusion-Dependent Sumoylation
69
3.Methods The following important points should be considered when studying sumoylation with Ubc9 fusion proteins: 1. Sumoylation of the protein of interest should be analyzed in both structural arrangements, with Ubc9 fused to the Nterminus and to the C-terminus. This is necessary because in some cases only one of the structural arrangements results in a protein sumoylation (e.g., for p53). 2. The transfection efficiency should be controlled to ensure a proper expression of the coexpressed proteins. Therefore, we always confirm the efficiency of transfection after 24 h by verifying the presence of cotransfected EGFP-SUMO-1 using fluorescence microscopy. 3. Because of the presence of SUMO-specific proteases, sumoylation in cells and cell extracts is often relatively unstable. Hence, it is necessary to inactivate the proteases as quickly and completely as possible during cell lysis. During preparation of crude cellular protein extracts, we minimize desumoylation by boiling the cells directly in SDS-gel loading buffer. Furthermore, we recommend loading the protein extracts directly onto a SDS-gel, as repeated thawing and refreezing might cause a loss of the modification. 4. Use of the correct blotting method for the protein to be analyzed is of considerable importance for successful detection of sumoylation (see Note 8). 3.1. Cloning the cDNA of Interest into Ubc9 Fusion Protein Expression Vectors
1. For the generation of the pcDNA-Ubc9-MCS vector (pNU) suited for fusions of Ubc9 to the N-terminus of proteins (Fig. 5.1B), the coding sequence of mouse Ubc9 containing the start but lacking the stop codon was inserted as a BamHI/EcoRI fragment into pcDNA3. When selecting the position in the multicloning site (MCS) for insertion of the cDNA of interest, it needs to be ensured that the coding sequence of the protein of interest is in frame with the Ubc9 coding sequence. We recommend adding a three glycine linker between the Ubc9 and the coding sequence of the protein of interest (Fig. 5.1B) (see Note 9). Furthermore, to reduce the possibility of an internal translation start, the start codon of the fused protein of interest should be absent. In contrast, the native stop codon should be present to prevent generation of an artificial sumoylation site by read-through of translation into the MCS. 2. For generation of the pcDNA-MCS-Ubc9 vector (pCU) suited for fusions of Ubc9 to the C-terminus of proteins (Fig. 5.1B), the coding sequence of mouse Ubc9, lacking
70
Niedenthal
the start but containing the stop codon, was inserted as an EcoRI/XbaI fragment into pcDNA3. When selecting the position in the MCS for insertion of the cDNA of interest, its coding sequence needs to be in frame with the Ubc9 coding sequence. It also has to carry the native start codon and a Kozak sequence, but must not contain a stop codon (see Note 9). 3.2. Transfection of HEK293, COS-7, HeLa, and CHO Cells 3.2.1. HEK293 and COS-7 Cells
Human embryonal kidney cells (HEK293) and African green monkey kidney cells (COS-7) are transfected using the following procedure to maximize the amounts of sumoylated protein: 1. Transfer a fresh confluent 10 cm plate of HEK293 (COS-7) cells to a 12-well plate. At this step, DMEM with or without antibiotics can be used. 2. Incubate for 12–24 h until the cells have reached about 70% confluence. 3. For each well, prepare the following transfection mixture: serum- and antibiotic-free α−MEM medium (∼45 µl) is mixed with 750 ng of the transfection-purity expression vector DNA in a 1.5 ml tube (total volume ∼45 µl) and vortexed. 4. Vortex the polyethylenimin stock solution (1 mg/ml), add 3 µl to the tube containing the DNA and DMEM medium, and mix by vortexing. 5. Incubate the mixture at room temperature for 10 min. 6. Add 450 µl fresh DMEM to the mixture and vortex. DMEM with or without antibiotics can be used. 7. Completely remove the medium covering the cells. 8. Immediately and carefully add the transfection mix (∼500 µl) to each well. 9. Carefully rock the 12-well plate to ensure proper distribution of the DNA–transfection reagent complex. 10. Incubate the cells for 24 h at a 37°C in a humidified CO2incubator (5% CO2) prior to lysis.
3.2.2. HeLa Cells
The transfection protocol for the human cervix carcinoma cells (HeLa) is very similar to the protocol for HEK293 and COS-7 cells but uses DMEM without antibiotics. To obtain satisfying transfection efficiencies with the PEI transfection reagent, use the following procedure: 1. Transfer a fresh confluent 10 cm plate of HeLa cells to a 12-well plate. Use DMEM without antibiotics. 2. Incubate for 12–24 h until the cells have reached about 70% confluence.
Ubc9 Fusion-Dependent Sumoylation
71
3. For each well, prepare the following transfection mixture: serum- and antibiotic-free DMEM medium (∼45 µl) is mixed with 1000 ng of the transfection-purity expression vector DNA in a 1.5 ml tube (total volume ∼47 µl) and vortexed. 4. Vortex the polyethylenimin stock solution (1 mg/ml), add 4 µl to the tube containing the DNA and DMEM medium, and mix by vortexing. 5. Incubate the mixture at room temperature for 10 min. 6. Add 450 µl fresh DMEM to the mixture and vortex. Use DMEM without antibiotics. 7. Completely remove the medium covering the cells. 8. Immediately and carefully add the transfection mix (∼500 µl) to each well. 9. Carefully rock the 12-well plate to ensure proper distribution of the DNA–transfection reagent complex. 10. Incubate the cells for 24 h at a 37°C in a humidified CO2incubator (5% CO2) prior to lysis. 3.2.3. CHO Cells
For the transfection of the Chinese hamster ovary cells (CHO), the Lipofectamine and the Plus reagent of Invitrogen is used according to the following protocol: 1. Transfer a fresh confluent 10 cm plate of CHO cells to a 12-well plate. Use Alpha-MEM without antibiotics. 2. Incubate for 12–24 h until the cells have reached about 70% confluence. 3. For each well, prepare the following transfection mixture: serum- and antibiotic-free Alpha-MEM medium (∼45 µl) is mixed with 750 ng of the transfection-purity expression vector DNA in a 1.5 ml tube (total volume ∼50 µl) and vortexed. 4. Vortex the Plus Reagent, add 8 µl to the tube containing the DNA and MEM medium, and mix by vortexing (mixture A). 5. Incubate this mixture A at room temperature for 15 min. 6. In a second 1.5 ml tube, mix serum- and antibiotic-free Alpha-MEM medium (48 µl) with 2 µl of Lipofectamine (mixture B). 7. Add mixture A to mixture B and mix by vortexing. 8. Incubate the combined transfection mixture (A+B) at room temperature for 15 min. 9. Completely remove the medium covering the cells. 10. Immediately add 400 µl fresh medium without antibiotics to each well.
72
Niedenthal
11. Carefully add the transfection mixture (∼100 µl) to each well. 12. Carefully rock the 12-well plate to ensure proper distribution of the DNA–transfection reagent complex. 13. Incubate the cells for 3 h at a 37°C in a humidified CO2incubator (5%). 14. Add 500 µl of medium with 20% serum to each well. 15. Incubate the cells for 24 h to 48 h at a 37°C in a humidified CO2-incubator (5% CO2) prior to lysis. 3.3. Cell Lysis and Preparation of Samples for Identifying in Vivo Sumoylated Proteins
1. The transfected cells in the 12-well plate are processed in groups of 4 wells. To this end, aspirate the medium from four wells each, add 1 mL of PBS (room temperature), and rock the plate briefly. 2. Aspirate PBS quantitatively from the wells, and immediately add 150 µl of gel loading buffer (room temperature) onto the cells in each of the four wells. Scrape the cells from the bottom of the wells with a cut yellow tip. 3. Transfer the viscous cell suspension to a 1.5 ml tube and briefly store on ice until all samples from the 12-well plate have been processed. 4. Heat the samples for 10 min at 96°C in a heat block. It is helpful to use safe lock reaction tubes to avoid unexpected opening of the tubes and potential loss of sample. 5. Cool the samples briefly on ice, vortex, and collect the solution at the bottom of the tube by a very short centrifugation. Samples are now ready for loading onto SDS-PAGE or can be stored at −20°C (see Note 10).
3.4. SDS-PAGE
1. The following instructions are specific for the use of the BioRad Mini-PROTEAN 3 gel system (BIO-RAD, Hercules, CA, USA), but other systems can be used according to the manufacturer’s instructions. First, clean the glass plates with a common detergent and then wash them extensively with deionised water. The clean glass plates are dried and stored until usage. Before assembling the plates for preparing the gels, clean them with 70–96% ethanol and air-dry. 2. Prepare six 7.5% separating gels (0.75 mm thick) by carefully mixing 7.5 ml acrylamide solution, 11.2 ml separating gel buffer, 13.7 ml water, 150 µl SDS solution, and 150 µl APS. Add 30 µl TEMED and mix again carefully. Pour the gel by filling the space between the glass plates up to 1.5 cm below the top of the smaller glass plate, leaving space for the stacking gel. Immediately overlay with water.
Ubc9 Fusion-Dependent Sumoylation
73
3. Once the gel is fully polymerized (after ∼30 min), the stacking gel can be prepared. Alternatively, the separating gel can be stored for up to 5 days in a closed plastic box and wrapped in moist paper to prevent drying (see Note 11). 4. Prepare six stacking gels (5%) by carefully mixing 1.7 ml acrylamide solution, 1.25 ml stacking gel buffer, 7.3 ml water, 50 µl SDS solution, and 50 µl APS. Pour off the water from the separating gel and remove residual water with blotting paper. Avoid touching the gel surface. Add 15 µl TEMED to the stacking gel solution and mix carefully. Pour the stacking gel up to the top of the smaller glass plate and insert the comb. 5. Once the gel is fully polymerized (after 30 min), it can be stored for 5 days in a closed plastic box and wrapped in moist paper to prevent drying (see Note 11). 6. Prepare the running buffer by diluting 500 ml of 10 X running buffer with 4500 ml of double distilled water and mix well. 7. Before placing the gel into the electrophoresis chamber or storage at 4°C, carefully remove the comb. 8. Assemble two gels, or one gel and a buffer dam, in the inner electrophoresis chamber and place this into the buffer tank. Fill the inner chamber completely with running buffer and ensure that the chamber is not leaky. Then fill the outer chamber such that the bottom of the gel is well immersed into the buffer. Wash away air bubbles that might be trapped in the outer chamber at the bottom of the gel using a syringe with a bent needle, filled with running buffer. 9. Before loading the samples use a 200 µl pipette to wash out the wells with running buffer, ensuring that the wells are not blocked by gel slices. 10. Load 15 µl of sample per well. Load the molecular weight marker to one well (see Note 4). 11. Carefully cover the gel chamber with its lid and connect it to the power supply. Run the gel at 100 V and stop the current when the blue dye front has reached the bottom of the gel. 3.5. Western Blot Analysis for Sumoylated Ubc9 Fusion Proteins
1. After separation by SDS-PAGE, proteins are electrophoretically transferred to a PVDF membrane by semi-dry blotting (see Note 12). To this end, a sheet of PVDF membrane slightly larger than the size of the separating gel (8.5 × 6 cm) is moistened by methanol for 2 min. Make sure that the membrane is completely submerged (see Note 13). Next, transfer the membrane into blotting buffer and briefly shake to completely wash away the methanol. Subsequently, immerse two sheets of gel blotting paper (1.2 mm thick) in blotting
74
Niedenthal
buffer. Disconnect the SDS-PAGE unit from the power supply, disassemble, and separate the glass plates. Remove the stacking gel and continue by processing the separating gel. 2. Place one sheet of gel blotting paper on the anode plate of the blotter and carefully rub with a glass pipette to remove air bubbles trapped between the anode and the blotting paper. Add 2 ml of blotting buffer onto the gel blotting paper, place the PVDF membrane into this buffer, and cover by a further 2 ml of blotting buffer. If the molecular weight marker was loaded asymmetrically, no further marking of the gel is necessary. Next, place the gel onto the PVDF membrane and cover with another 2 ml of blotting buffer. Place the second sheet of gel blotting paper, soaked with blotting buffer, on top of the gel, and complete the blotting stack by mounting the cathode plate (see Note 14). 3. Connect the blotting apparatus to a power supply and carry out the transfer for 90 min at 0.8 mA/cm2. 4. When the transfer is completed, switch off and disconnect the blotting apparatus from the power supply. Carefully disassemble the blotting stack, ensuring that the surface of the PVDF membrane is not damaged, which would cause artificial signals during development of the blot. Place the membrane in TBS-T to wash away the blotting buffer. Again, it is important that the membrane is completely submerged and is not allowed to dry out (see Note 13). The membrane is then placed into a 50 ml Falcon tube with 5 ml of blocking buffer. Ensure that there is no overlap between parts of the membrane. Incubate the blot for 30 min in a Falcon roller at room temperature. Then briefly wash the blot in the Falcon tube twice with 15 ml of TBS-T. 5. For incubation with the primary antibody, add 2 ml of blocking buffer and, subsequently, 1 µl of the respective antibody specific for the fusion protein into the Falcon tube containing the PVDF membrane. Incubate overnight in a Falcon roller at 4°C. The primary antibody solution can be stored and used for one to two additional blot developments. Wash the membrane in the Falcon roller three times for 5 min with 15 ml of TBS-T. 6. Dilute the secondary antibody 1:20,000 in 2 ml of blocking buffer, add to the blot membrane, and incubate for 1 h at room temperature. Wash the blot three times for 5 min with 15 ml of TBS-T buffer and store in TBS-T buffer until you are ready for development (see Note 15). 7. Development of the blot membrane is performed with 1 ml of freshly mixed development reagent warmed to room temperature. To this end, the reagents are removed from the
Ubc9 Fusion-Dependent Sumoylation
75
refrigerator 30 min prior to use. A total of 0.5 ml each of component A and component B are then mixed and stored in the dark until use. 8. Analysis of Western blot signals with the Fuji Film LAS3000 is performed as follows: Remove the blot from the TBS-T and allow the buffer to drain from the blot almost quantitatively, but do not allow the blot to dry up. Place the membrane into a tray with the gel side facing up, and distribute the developing reagent over the entire membrane by careful rocking (see Note 16). The chemiluminescence measurement by the LAS3000 is performed using the professional increment mode. This mode automatically stores blot pictures of increasing exposure times, which facilitates the selection of the most informative exposure (Fig. 5.2A–D). Furthermore, the digitized results can be used for a quantitative analysis of the blot. Alternatively, standard x-ray film exposure and development is possible. 3.6. Stripping and Reprobing the Blots for EGFP-SUMO1 Conjugation
1. Once a satisfactory result with the antibody specific for the fusion protein has been obtained, the membrane can be stripped of the signal and reprobed with an antibody that recognizes both free and conjugated EGFP-SUMO1 to verify the correct coexpression. 2. Warm the stripping buffer (50 ml per blot) to 50°C and add to the blot in a Falcon tube. Incubate the blot for 30 min in a Falcon roller at 50°C. 3. Wash the stripped blot three times with 30 ml of TBS-T for 5 min each and subsequently incubate another 30 min in blocking buffer at room temperature. Probe the membrane with an EGFP-specific antibody (1:2000 in TBS-T) as described in Sect. 3.5.
3.7. Interpretation of Ubc9- and EGFPWestern Blots
For the identification of sumoylation of the Ubc9 fusion protein, always compare the results obtained by the expression of the Ubc9 fusion protein alone with the results from its coexpression with EGFP-SUMO1. If the Ubc9 fusion protein is sumoylated, then one or several additional high molecular weight bands are detectable in the coexpression with EGFP-SUMO1 (Fig. 5.2A–D). These bands usually run more slowly than expected for the estimated combined molecular weight of the Ubc9 fusion protein and EGFP-SUMO1. Furthermore, the molecular weight shift induced by sumoylation appears to vary, depending on the localization of the sumoylation site within the fusion protein. Attachment of SUMO to the N- or C-terminus of the fusion protein generally induces a smaller shift than attachment to a central site. Consequently, the analysis of a protein of interest fused to Ubc9 at the N-terminus often gives a different band shift compared to the
76
Niedenthal
C-terminal fusion and provides a first hint about the localization of the sumoylation site. In addition, we often find that even without EGFP-SUMO1 coexpression there is a weaker band above the main band corresponding to the Ubc9 fusion protein. If this represents endogenous sumoylation of the Ubc9 fusion protein, the intensity of this band should be reduced due to competition when EGFP-SUMO1 is coexpressed. Whether the appearance of a band for the fusion protein conjugated by endogenous SUMO is indicative for a natural sumoylation is not yet clear. We also do not know whether the preference of some sumoylations sites for SUMO1 versus SUMO2 is valid in the UFDS system. Analysis of the sumoylation of the Ubc9 fusion proteins is possible with Ubc9 antibodies (15, 16) or with protein-specific antibodies (Fig. 5.2A–D), usually with identical results. Detection with the Ubc9 antibody allows a comparison of the sumoylation patterns of different Ubc9 fusion proteins on one blot. Using a protein-specific antibody allows a comparison of the expression level of the fusion protein with that of the endogenous protein. For further verification of a sumoylation event identified by UFDS, Ubc9 fusion proteins can be immunoprecipitated, and coprecipitated SUMO can be immunoblotted. It is also possible to use GST-SUMO for UFDS, which allows affinity purification of GST-SUMO and copurification of conjugated Ubc9 fusion proteins, thus demonstrating sumoylation of the respective fusion partner. Furthermore, site-directed mutagenesis can be performed on the Ubc9 fusion protein expression plasmids in order to identify sumoylation sites by UFDS. Finally, an advanced UFDS system will be available in the future (Zimnik et al., manuscript submitted), which renders sumoylation of a specific protein inducible to allow the kinetic analysis of the sumoylation reaction.
4. Notes 1. The polyethylenimine transfection reagent was used according to ref. (17). It is comparable in price to the calcium phosphate method, but simpler. Until now we have only used polyethylenimine from Sigma-Aldrich ( (# 408727) St. Louis, MO, USA), but equivalent products from different suppliers may also work. 2. While we use doubly distilled water for running and blotting buffer, all other solutions were prepared in water from a Millipore MQ system with a resistivity of 18.2 MΩ cm. 3. We store the 20% SDS stock solution at 30°C to prevent SDS precipitation.
Ubc9 Fusion-Dependent Sumoylation
77
4. This marker is very useful because it is detected along with the Ubc9 fusion proteins by immunoblotting. For use, the marker is diluted in the ratio 1:20 in SDS gel loading buffer, and 15 µl is loaded. Do not heat the stock solution or the diluted marker. 5. Transfer buffer is used only once. 6. The PVDF membrane of Carl Roth (Roti-PVDF) has properties very similar to Immobilon-P membrane (Millipore). We recommend the use of either of these two PVDF membranes. 7. These antibodies work well in our hands, but numerous comparable reagents are available from other commercial sources. 8. For the blotting of very large SUMO conjugates, a tank blotting system is preferable. However, we found that during tank blotting some proteins are quantitatively blotted through the membrane. This is avoided with semi-dry blotting. 9. The Ubc9 fusions cloned in pNU and pCU always contain a three-glycine linker between Ubc9 and the protein of interest, but we have never tested whether the presence or absence of the linker makes a difference in sumoylation. To construct a Ubc9-substrate fusion with a three-glycine linker in pNU, the coding sequence to be inserted has to include the sequence encoding the three glycines. In pCU, the sequence encoding the three glycines is present (Fig. 5.1B). 10. Although we have not analyzed this in detail, it appears from our experiments that the amount of sumoylated protein in the cell extract decreases with each cycle of freezing and thawing; the best results are obtained by loading the samples on a SDS-gel directly after heating at 96°C. Furthermore, storage of the proteins at room temperature is not recommended and could lead to loss of sumoylation. We have not analyzed the extent of decay of sumoylation in the samples frozen at −20°C. 11. Complete SDS gels with stacking gel can be stored up to 5 days at 4°C, but we recommend pouring fresh gels for highest quality. 12. We favor the use of a semi-dry blotting system, such as semidry blotter Z340502 (Sigma-Aldrich). 13. The moistened PVDF membrane should never be allowed to dry at any time during the blotting and developing procedure, as this can lead to artificial signals.
78
Niedenthal
14. One gel blotting paper (1.2 mm) on either side of the membrane works as well as three sheets of 3MM Whatmann paper. 15. After washing away surplus secondary antibody, the blot should be developed immediately. Storage of the washed blot in TBS-T reduces the signal strength. 16. The developing reagent should remain on the blot during the measurement. Do not discard the developing reagent until after the measurement is complete. If cloudy signals from the developing reagent disturb the exposure, remove the tray with the blot from the instrument for a careful rocking and restart the measurement.
Acknowledgements The author would like to thank Matthias Gaestel for critical reading of the manuscript, and Astrid Jakobs for preparing the figures shown for Ubc9 fusion-directed sumoylation. This work was supported by the Medical School Hannover, Institute of Physiological Chemistry.
References 1. Hay, R. T. (2005) SUMO: a history of modification. Mol. Cell 18, 1–12. 2. Melchior, F., Schergaut, M., and Pichler, A. (2003) SUMO: ligases, isopeptidases and nuclear pores. Trends Biochem. Sci. 28, 612–618. 3. Desterro, J. M., Rodriguez, M. S., Kemp, G. D., and Hay, R. T. (1999) Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1. J. Biol. Chem. 274, 10618–10624. 4. Gong, L., Li, B., Millas, S., and Yeh, E. T. (1999) Molecular cloning and characterization of human AOS1 and UBA2, components of the sentrin-activating enzyme complex. FEBS Lett. 448, 185–189. 5. Johnson, E. S., Schwienhorst, I., Dohmen, R. J., and Blobel, G. (1997a) The ubiquitinlike protein Smt3p is activated for conjugation to other proteins by an Aos1p/Uba2p heterodimer. EMBO J. 16, 5509–5519. 6. Okuma, T., Honda, R., Ichikawa, G., Tsumagari, N., and Yasuda, H. (1999) In vitro
7.
8.
9.
10.
11.
12.
SUMO-1 modification requires two enzymatic steps, E1 and E2. Biochem. Biophys. Res. Commun. 254, 693–698. Desterro, J. M., Thomson, J., and Hay, R. T. (1997) Ubch9 conjugates SUMO but not ubiquitin. FEBS Lett. 417, 297–300. Johnson, E. S., and Blobel, G. (1997b) Ubc9p is the conjugating enzyme for the ubiquitin-like protein Smt3p. J. Biol. Chem. 272, 26799–26802. Rodriguez, M. S., Dargemont, C., and Hay, R. T. (2001) SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J. Biol. Chem. 276, 12654–12659. Hochstrasser, M. (2001) SP-RING for SUMO: new functions bloom for a ubiquitin-like protein. Cell 107, 5–8. Kagey, M. H., Melhuish, T. A., and Wotton, D. (2003) The polycomb protein Pc2 is a SUMO E3. Cell 113, 127–137. Kirsh, O., Seeler, J. S., Pichler, A., Gast, A., Muller, S., Miska, E., Mathieu, M.,
Ubc9 Fusion-Dependent Sumoylation Harel-Bellan, A., Kouzarides, T. et al. (2002) The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase. EMBO J. 21, 2682–2691. 13. Pichler, A., Gast, A., Seeler, J. S., Dejean, A., and Melchior, F. (2002) The nucleoporin RanBP2 has SUMO-1 E3 ligase activity. Cell 108, 109–120. 14. Uchimura, Y., Nakao, M.,and Saitoh, H. (2004) Generation of SUMO1 modified proteins in E. coli: towards understanding the biochemistry/structural biology of the SUMO-1 pathway. FEBS Lett. 564, 85–90. 15. Jakobs, A., Koehnke, J., Himstedt, F., Funk, M., Korn, B., Gaestel, M., and Niedenthal, R. (2007) Ubc9 fusion-directed sumoylation (UFDS): a method to analyze function
79
of protein sumoylation. Nat. Methods 4, 245–250. 16. Jakobs, A., Himstedt, F., Funk, M.,
Korn, B., Gaestel, M., and Niedenthal, R. (2007) Ubc9 fusion-directed SUMOylation identifies constitutive and inducible SUMOylation. Nucleic Acids Res. 35(17):e109. Epub 2007 Aug 20. 17. Ehrhardt, C., Schmolke, M., Matzke, A., Knoblauch, A., Will, C., Wixler, V., and Ludwig, S. (2006) Polyethylenimine, a cost-effective transfection reagent. Signal Transduction 6, 179–184.
Chapter 6 In Vivo Detection and Characterization of Sumoylation Targets in Saccharomyces cerevisiae Helle D. Ulrich and Adelina A. Davies Abstract Ni-NTA affinity chromatography under denaturing conditions has proven to be a powerful method for the isolation of SUMO conjugates from total cell extracts, as it minimizes deconjugation and excludes noncovalent interactions. This chapter describes the use of both His-tagged SUMO and a His-tagged target protein for the characterization of the sumoylation process in the budding yeast Saccharomyces cerevisiae. Two well-studied model substrates, the septin Cdc3 and the replication clamp protein PCNA, are used as examples, but the protocol can easily be adapted to other targets and organisms. Key words: SUMO, PCNA, septins, Ni-NTA affinity chromatography, budding yeast.
1. Introduction The identification of target proteins remains one of the major challenges for SUMO research. In vitro sumoylation reactions are particularly helpful to study conjugation mechanisms or to demonstrate that a particular protein can in principle serve as a target; however, the validation of a protein as a physiologically relevant substrate of the SUMO conjugation pathway requires in vivo evidence, and regulatory control mechanisms that address the conditions under which a particular protein is modified are also best studied in the relevant organism. For this purpose, this chapter demonstrates the use of a strategy that is generally applicable for the detection of sumoylated proteins in vivo. The method is described for the budding yeast Saccharomyces cerevisiae because of the flexibility of this model system with regard to
Helle D. Ulrich (ed.), Methods in Molecular Biology: SUMO Protocols, vol. 497 © 2009 Humana Press, a part of Springer Science + Business Media, New York, NY Book doi: 10.1007/978-1-59745-566-4
81
82
Ulrich and Davies
the use of epitope tags and mutants, but can easily be applied to other organisms with a few modifications. Ni-NTA chromatography of His-tagged proteins has so far proven the most powerful approach for the identification of new SUMO targets (1–10). The method uses His-tagged SUMO, which can easily be expressed in yeast or mammalian cells. In contrast to most other epitopes, the His-tag allows the bulk purification of target proteins under completely denaturing conditions, which minimizes the problems of deconjugation during extract preparation and excludes noncovalent interactions. Novel targets can be identified in the eluate by mass spectrometry, but the presence of a particular conjugate can also be directly monitored with an appropriate antibody or by using a yeast strain in which the protein of interest is marked with an epitope tag for detection. If higher molecular weight species of a protein have been detected, the use of the His-tagged SUMO gives immediate confirmation of the modifier’s identity, because of the size difference between the untagged and the His-tagged SUMO. In case of large proteins, however, the identification of the modification by means of its size shift will be difficult. In this situation, NiNTA chromatography is again helpful to determine the presence of the modifier on the target protein. Likewise, the pull-down of conjugates may allow the detection of a modification in cases where the abundance of the modified form is too low to be visible in total extracts. Overexpression of the tagged SUMO might also enhance the modification beyond the level of that achieved by the endogenous SUMO, resulting in better detection. As an alternative to the His-tagged SUMO, Ni-NTA chromatography can also be used to detect rare conjugates of a protein of interest if that protein itself is fused to a His-tag. Here, the pull-down step simply serves to enrich the target protein, thus overcoming the problem of detecting low levels of modified forms against a background of total cellular protein. The identity of the modifier can then be determined with antibodies against SUMO. This chapter demonstrates the use of both methods, applying antibodies against the target proteins as well as the epitope tags and also against the modifier itself. While the method of cell lysis is optimized for yeast, the pull-down protocol itself can be applied to other organisms. 1.1. Sumoylation of the Yeast Septins
The very first SUMO targets identified in budding yeast were the septins, i.e., scaffold proteins that localize in a ring-shaped structure to the yeast bud neck and contribute to cytokinesis (11). Three of the five septin proteins are modified by the SUMO ligase Siz1 at multiple sumoylation consensus sequences, ΨKX(E/D) (where Ψ denotes a bulky aliphatic and X any amino acid), during the G2 phase of the cell cycle. Mutants unable to sumoylate the septins display very subtle phenotypes that mainly affect the
Detection of Sumoylation Targets in Yeast
83
morphology of the septin ring itself, without major effects on the cell cycle or cytokinesis. The physiological significance of this reaction is therefore still a matter of debate. However, septins are one of the few cytoplasmic SUMO targets. The E3-dependence and cell cycle regulation of the modification (12,13) makes them a useful model to study the in vivo sumoylation process in yeast. In this chapter, we will describe the use of an epitope-tagged version of the yeast septin Cdc3 and analyze its Siz1-dependent SUMO modification. 1.2. PCNA as a Target of SUMO Conjugation
Proliferating cell nuclear antigen (PCNA), encoded in yeast by the POL30 gene, is an essential processivity factor for replicative DNA polymerases, which encircles the DNA as a sliding clamp and serves as an interaction platform for a variety of proteins involved in several DNA repair pathways, chromatin assembly, and cell cycle regulation (14). In many eukaryotic species, PCNA undergoes mono- as well as polyubiquitylation in a damage-dependent manner, but PCNA from S. cerevisiae is also a target for modification by SUMO (15,16). The modification is detectable during S phase, and a conserved lysine K164 serves as the major attachment site. Notably, the sequence around this residue does not correspond to the consensus motif ΨKX(E/D) that is used for sumoylation in many other proteins. This motif is instead found at a second, minor modification site K127, which is less conserved in other species. Sumoylation of PCNA at replication forks recruits the helicase Srs2, which blocks access of the recombination machinery and thereby prevents the formation of spontaneous crossovers during DNA replication (17–19). The modification enhances the affinity of PCNA for Srs2 through a SUMO-interaction motif at the C terminus of the helicase, irrespective of whether SUMO is attached to K164 or to K127 of PCNA. The presence of multiple modifications on a single lysine of PCNA makes this molecule an interesting object for mechanistic studies of ubiquitylation and sumoylation (20). This chapter will demonstrate the detection and differentiation of the in vivo modified forms at the individual SUMO acceptor lysines.
2. Materials 2.1. Cultivation of Yeast Strains
1. YPD medium (liquid): 1% (w/v) Bacto-yeast extract, 2% (w/v) Bacto-peptone, 2% (w/v) glucose in water. Sterilize by autoclaving and store at room temperature.
84
Ulrich and Davies
2. YPD plates: YPD medium as above, containing 2% (w/v) Bacto-agar. 3. SC medium (liquid): synthetic complete medium lacking uracil, tryptophane, or leucine. Available from various suppliers (e.g., Sigma-Aldrich), but can also be prepared in the lab (21). 4. SC plates: SC medium as above, containing 2% (w/v) Bacto-agar. 5. CuSO4 stock solution: 100 mM in water. Filter-sterilize. 6. Disposable Petri dishes (90 mm). 7. Culture tubes and flasks in sizes of 15 and 125 ml. 8. Incubators for plates and shake flasks and tubes at 30°C. 2.2. Strain Constructions
1. Plasmids: pYM3, YEplac181, YEp181-CUP-His7-Smt3, pBL243, YIp128-P30-His6-POL30, and mutant vectors bearing pol30(K164R), pol30(K127R), and pol30(K127/164R), respectively (see Note 1). 2. Oligonucleotide primers: CDC3-tag-down, 5′-CCAATGTTAACCACTCCCCCGTCCCTACAAAGAAGAAGGGATTTTTACGTCGTACGCTGCAGGTCGAC-3′; CDC3-tag-up, 5′-TAATAATATTTAATAGTGTATGTTTGAAATTTTTATATGTCTTTATTTCGATCGATGAATTCGAGCTCG-3′ (see Note 2). 3. Reagents and equipment for polymerase chain reaction (PCR): thermostable polymerase (Vent polymerase, New England Biolabs or alternatives) and matching buffer, dNTPs, thermocycler, PCR tubes. 4. Reagents and equipment for agarose gel electrophoresis (see Note 3). 5. Sodium acetate solution: 3 M, pH 5.2. 6. Ethanol: absolute and 70% (v/v) in water. 7. LiT: 100 mM lithium acetate, 10 mM Tris-HCl, pH 7.4; sterilize by autoclaving. 8. PEG/LiT: dissolve 100 g polyethylene glycol 3350 (Sigma-Aldrich) in 100 ml LiT; sterilize by autoclaving (see Note 4). 9. TE buffer: 10 mM Tris-HCl, pH 8.0, 1 mM EDTA, pH 8.0. 10. HT DNA: 10 mg/ml herring testes DNA (e.g., Sigma type XIV – see Note 5). 11. Rotating wheel for microfuge tubes, Vortex mixer. 12. Heat block or water bath at 42°C.
Detection of Sumoylation Targets in Yeast
2.3. SDS-PAGE and Western Blot Analysis
85
1. Electrophoresis system for small-scale vertical gels (e.g., BioRad Mini-Protean 3) with power supply and semi-dry blotting apparatus. 2. NuPAGE 4–12% Bis-Tris gradient gels (1.0 mm), matching electrophoresis apparatus, and MOPS SDS running buffer, 20X (Invitrogen). 3. Acrylamide solution: 30% solution of acrylamide/bisacrylamide (37.5:1), available from various suppliers (e.g., BioRad). Store at 4°C. 4. Separating buffer (4X): 1.5 M Tris-HCl, pH 8.8, 0.4% (w/v) sodium dodecyl sulfate (SDS). Store at room temperature. 5. Stacking buffer (4X): 0.5 M Tris-HCl, pH 6.8, 0.4% (w/v) SDS. Store at room temperature. 6. APS solution: 10% (w/v) ammonium peroxodisulfate in H2O. This solution can be stored in 1 ml aliquots at −20°C. Each aliquot is stable at 4°C for several weeks. 7. TEMED (N,N,N′,N′-Tetramethylethylenediamine): Store at 4°C. 8. SDS running buffer: 25 mM Tris-HCl, pH 8.8, 200 mM glycine, 0.1% (w/v) SDS. This buffer can be prepared as a 5X stock solution in large quantities and stored at room temperature. 9. Molecular weight marker: prestained, e.g., PeqGold Protein Marker IV (Peqlab). 10. Blotting buffer I: 300 mM Tris-HCl, pH 10.4, 15% (v/v) methanol. 11. Blotting buffer II: 30 mM Tris-HCl, pH 10.4, 15% (v/v) methanol. 12. Blotting buffer III: 25 mM Tris-HCl, pH 9.4, 40 mM 6-aminocaproic acid, 15% (v/v) methanol. 13. PVDF membrane (Millipore or equivalent). 14. Gel blotting paper: extra thick (1.2 mm), e.g., Whatman GB005. 15. TBS: 50 mM Tris-HCl, pH 7.5, 150 mM NaCl. 16. TBST0.1: TBS + 0.1% (v/v) Tween 20. 17. TBST0.1/milk: TBST0.1 + 3% (w/v) skimmed milk powder. This solution can be stored at 4°C for a few days. 18. Primary antibodies: 12CA5 (mouse monoclonal anti-HA), anti-His-tag (mouse monoclonal, available from Qiagen or other suppliers), anti-Smt3 (rabbit polyclonal), anti-Pol30 (rabbit polyclonal, affinity purified) (see Note 6). 19. Secondary antibodies: Goat anti-mouse and goat anti-rabbit horseradish peroxidase conjugates.
86
Ulrich and Davies
20. Chemiluminescence detection kit: ECL (GE Healthcare) or equivalent and autoradiography film (e.g., Amersham Hyperfilm ECL). 2.4. Preparation of Total Cell Extracts by TCA Lysis
1. NaOH/BME: 1.85 M NaOH, 7.5% (v/v) 2-mercaptoethanol. Prepare immediately before use from a 2 M NaOH stock solution by adding 2-mercaptoethanol to a final concentration of 7.5%. 2. TCA solution: 55% (w/v) trichloroacetic acid in H2O. 3. HU buffer: 8 M urea, 200 mM Tris-HCl, pH 6.8, 1 mM EDTA, 5% (w/v) SDS, 0.1% (w/v) bromophenol blue, 1.5% (w/v) dithiothreitol. This buffer should be stored in 1 ml aliquots at −20°C. 4. Neutralizing buffer: 1.5 M Tris-HCl, pH 8.8.
2.5. Denaturing Ni-NTA Affinity Chromatography
1. Buffer A: 6 M guanidine HCl, 100 mM sodium phosphate, pH 8.0, 10 mM Tris-HCl, pH 8.0. Store at 4°C. 2. Buffer C: 8 M urea, 100 mM sodium phosphate, pH 6.3, 10 mM Tris-HCl, pH 6.3. Store at 4°C. 3. Tween-20: 10% (w/v) stock solution in H2O. Store at room temperature. 4. Ni-NTA agarose: Qiagen or equivalent. 5. Imidazole: 1 M stock solution in H2O. Store at 4°C.
3. Methods 3.1. General Methods 3.1.1. Yeast Transformation
1. An exponentially growing yeast culture (see Note 7) in YPD medium is pelleted by centrifugation at 3,000g for 5 min. Aliquots of 10–15 ml per transformation are sufficient. Alternatively, 700 µl of a fresh overnight culture in YPD medium can be used (harvest in a microcentrifuge tube at 16,000g for 15 s). Transformation efficiencies will be somewhat higher with exponential cultures. 2. Completely remove the medium and resuspend the cells in 100 µl LiT solution per transformation. Mix the PCR product or plasmid DNA with 10 µl of HT DNA and add the mixture to the cell suspension. Vortex briefly. 3. Add 500 µl of PEG/LiT, vortex for several seconds, and incubate on a rotating wheel for 15–30 min at room temperature. 4. Add 50 µl of DMSO and incubate 15 min in a 42°C heat block. Shorter incubation times can be used for temperature-sensitive strains.
Detection of Sumoylation Targets in Yeast
87
5. Pellet the cells by centrifugation at 500g for 30 s, resuspend in 75 µl water, and spread onto a selective SC plate. Incubate the plate for 2–3 days at 30°C. 3.1.2. SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
1. Prepare a separating gel solution of the desired acrylamide concentration by mixing appropriate volumes of 30% acrylamide solution with water, 1.25 ml separating buffer, and 50 µl APS solution to make a total volume of 5 ml. Add 5 µl of TEMED and immediately pour into a prepared set of plates. Leave space for the stacking gel. Carefully pipet a layer of water on top of the acrylamide layer and allow polymerization for a minimum of 20 min. 2. Pour off the layer of water from the separating gel. Prepare a 6% stacking gel solution by mixing 400 µl acrylamide solution, 500 µl stacking buffer, 20 µl APS, and 1.08 ml water. Add 2 µl of TEMED and immediately pour the solution on top of the separating gel to fill the space completely. Insert a comb and allow polymerization for at least 20 min. 3. Transfer the gel to the electrophoresis chamber and fill with SDS running buffer. Alternatively, omit Steps 1 and 2 and use precast NuPAGE 4–12% Bis-Tris gradient gels with MOPS SDS running buffer. 4. Load the denatured samples alongside an appropriate molecular weight marker (see Note 8) and run the gel at 150 V for 1 h or until the blue loading dye has reached the bottom of the gel.
3.1.3. Western Blot Analysis
1. Prepare a sheet of PVDF membrane in the size of your gel by soaking briefly in methanol, rinsing in water, and then incubating for several minutes in blotting buffer II (see Note 9). 2. Prepare six sheets of blotting paper per gel to fit the size of the gel. Soak two sheets in blotting buffer I and place onto the anode (+) of a semi-dry blotting apparatus. Soak one sheet in blotting buffer II and add to the stack. Add the PVDF membrane on top of this, and then carefully place the acrylamide gel onto the membrane, ensuring that its position does not change once it has touched the membrane (see Note 10). Soak three sheets of blotting paper in blotting buffer III and stack onto the gel. Roll over the surface of the stack with a glass pipette or test tube to remove any bubbles from between the layers. 3. Cover the gel stack with the cathode (−) of the blotting apparatus, set the maximum voltage to 25 V, and blot at 40 mA for 75 min (see Note 11). 4. Disassemble the blotting apparatus and block unspecific binding sites on the membrane by incubation on a rocking platform in TBST0.1/milk for 30 min at room temperature. 5. Incubate with primary antibody in TBST0.1/milk for a minimum of 1 h at room temperature or overnight at 4°C.
88
Ulrich and Davies
6. Wash the membrane three times for 10 min in TBST. 7. Incubate with secondary antibody in TBST0.1/milk for 1 h at room temperature. 8. Wash the membrane as done before, and then incubate for 5 min in TBS. 9. Detect the signals by chemiluminescence using the detection kit according to the manufacturer’s instructions. Obtain several different exposures of the membrane (see Note 12). 3.1.4. Small-Scale TCA Lysis
1. Harvest ca. 4 × 107 yeast cells (see Note 7) by centrifugation at 16,000g for 15 s. 2. Aspirate the supernatant and resuspend the pellet in 500 µl water. Place the tube on ice. 3. Add 75 µl of NaOH/BME, vortex, and incubate for 15 min on ice. 4. Add 75 µl of TCA solution, vortex, and incubate for 10 min on ice. 5. Centrifuge at 16,000g for 10 min at 4°C. 6. Aspirate the supernatant and centrifuge again briefly (30 s) in order to collect the residual buffer. Remove the last drops of liquid by aspiration. 7. Resuspend the pellet in 30 µl of HU buffer. If the pellets are not sufficiently dry, the suspension will turn green or yellow. In this case, add 1 µl of neutralizing buffer and make sure the resulting suspension turns blue. 8. Denature the sample at 60°C for 10 min. 9. Centrifuge briefly before analyzing by SDS-PAGE. Samples can be stored at −20°C, but it is important to completely solubilize the SDS, after thawing the samples, before loading on a gel.
3.1.5. Denaturing Ni-NTA Pull-Down
1. Harvest ca. 109 cells of the desired yeast culture (see Note 7) by centrifugation at 3,000g for 5 min (see Note 13). Remove the supernatant and place the tube on ice. Add 5 ml of icecold water, then 0.8 ml of NaOH/BME, resuspend the pellet by vortexing, and incubate on ice for 20 min. 2. Add 0.8 ml of TCA solution, vortex, and incubate on ice for 20 min. 3. Centrifuge at 8,000g for 20 min at 4°C. 4. Remove the supernatant and centrifuge again for 2 min in order to collect residual buffer. Remove the last drops of liquid by aspiration. 5. Resuspend the pellet in 1 ml of buffer A, transfer to a microcentrifuge tube, and incubate in a shaking heat block at room temperature for 1 h to solubilize the precipitate completely.
Detection of Sumoylation Targets in Yeast
89
6. Centrifuge at 16,000g for 10 min at 4°C and transfer the supernatant to a fresh tube. Discard the pellet (see Note 14). 7. Prepare a 20 µl aliquot of Ni-NTA agarose by washing three times with buffer A containing 0.05% Tween-20. When preparing several aliquots, these can be washed together and distributed into individual tubes at the last wash step (see Note 15). 8. Add the prepared cell extract to the tube containing the agarose. Then add 5 µl of 10% Tween-20 and 15 µl of imidazole solution (see Note 16). Incubate overnight at room temperature on a rotating wheel. 9. Centrifuge the agarose beads at 200g for 15 s and remove the supernatant. Wash the pellet twice with 1 ml of buffer A containing 0.05% Tween-20 and four times with 1 ml of buffer B containing 0.05% Tween-20. Remove the supernatant completely after the last wash. 10. Add 30 µl of HU buffer and denature the sample at 60°C for 10 min. Centrifuge briefly before analyzing by SDS-PAGE. Samples can be stored at −20°C, but need to be reheated before loading in this case. 3.2. Detection of Siz1-Dependent Cdc3HA Sumoylation via HisSmt3
Septin sumoylation will be analyzed by Ni-NTA chromatography from a strain carrying an episomal vector for expression of His7-tagged Smt3 and endogenously HA-tagged Cdc3 (11). Sumoylated Cdc3 will be detected by Western blot using an HA-specific antibody. Control extracts from strains lacking Histagged Smt3, expressing untagged Cdc3, or carrying a deletion of the SUMO ligase Siz1 will be examined in parallel. This section will describe the construction of an epitope-tagged CDC3 allele, the introduction of the expression vector for His-tagged Smt3, and the use of the resulting strains in pull-down experiments. The protocol can easily be adapted to the analysis of an alternative target.
3.2.1. Construction of Yeast Strains
In a wild-type (WT) and a siz1 (12,13) strain background, a sixfold HA epitope is appended to the CDC3 open reading frame in its native genomic context in order to allow the detection of the protein with a commercial antibody with minimal disturbance of expression or activity patterns (Fig. 6.1A). The resulting strains are called CDC3HA and CDC3HA siz1, respectively. An episomal expression vector YEp181-CUP-His7-Smt3 is then introduced for overexpression of His7-tagged Smt3 under control of a copper-inducible promoter (Fig. 6.1B). As a negative control, an “empty” vector YEplac181 (22) is transformed in parallel. Both vectors are also introduced into the untagged parent WT strain. When analyzing your gene of interest, adapt the gene-specific primer sequence to the relevant open reading frame (see Note 2).
90
Ulrich and Davies
Fig. 6.1. Construction of yeast strains for in vivo analysis of Cdc3HA sumoylation. (A) As a first step, a cassette bearing the epitope tag, followed by a transcriptional terminator (TT) and the TRP1 marker from Kluyveromyces lactis (klTRP1), is amplified from pYM3 by PCR with primers that incorporate 50 nt of homology to the carboxy terminus of CDC3 on either side (see Notes 1 and 2). WT yeast cells are transformed with the PCR product and transformants are selected by growth on medium lacking tryptophane. The regions of homology at the ends of the PCR product will direct the integration of the cassette into the genome by recombination (indicated by grey shading). This results in a strain with the 6HA-tag appended in-frame to the CDC3 gene. (B) Episomal vector for expression of His SMT3 under control of the CUP1 promoter (YEp181-CUP-His7-Smt3, see Note 1). The yeast 2µ replication origin is shown. All vectors shown here are shuttle vectors bearing an E. coli replication origin (ori) and the gene encoding β-lactamase for ampicillin resistance (Ampr).
Alternatively, if an antibody against the protein of interest is available, omit Steps 1–5 of this section. 1. Amplify the 6HA cassette including the klTRP1 marker from the plasmid pYM3 (23) in standard 100 µl PCR reactions using the primers CDC3-tag-down and CDC3-tag-up. Set
Detection of Sumoylation Targets in Yeast
91
up two reactions of 100 µl each and program the machine for 30 cycles, using an annealing temperature of 56°C, and an extension time sufficient for amplification of a 1.3 kbp fragment. 2. Combine the two reactions and analyze a 5 µl aliquot on a 0.8% agarose gel to verify the presence of a ∼1.5 kbp band. 3. Precipitate the PCR product by adding 20 µl of sodium acetate solution and 500 µl of absolute ethanol. Mix well and store at −20°C for 20 min. Recover the DNA by centrifugation at 16,000g for 10 min at 4°C. Aspirate the supernatant, add 750 µl of 70% ethanol, centrifuge again for 2 min, remove the supernatant completely, and dry the pellet at room temperature for 15 min. Resuspend the DNA in 20 µl of water. 4. Transform WT and siz1 yeast cells with 10 µl of the PCR product each (see Sect. 3.1.1). Spread the cells onto SC-Trp plates and incubate for 2–3 days at 30°C. 5. Inoculate several isolated colonies of the two transformations into 2 ml of liquid SC-Trp medium each, incubate with shaking overnight at 30°C, and examine the expression of epitope-tagged Cdc3 by small-scale TCA preparations, PAGE (8% gels), and anti-HA Western blot analysis (see Sects. 3.1.2–3.1.4). Use the untagged WT parent strain (grown in SC-complete medium) as a negative control. An example result is shown in Fig. 6.2A. Restreak one positive clone each, now designated as CDC3HA and CDC3HA siz1, onto a fresh SC-Trp plate, incubate at 30°C for 2–3 days, and select an isolated colony each for further experiments. 6. Use the plasmids YEplac181 and YEp181-CUP-His7-Smt3 (see Note 1) for transformation of WT, CDC3HA, and CDC3HA siz1. Spread the cells onto SC-Leu plates and incubate at 30°C for 2–3 days. 7. Grow 2 ml overnight cultures of isolated colonies in SC-Leu medium, supplemented with 100 µM CuSO4, at 30°C. Use one colony of the strain transformed with YEplac181 and 3–4 colonies each of the strains transformed with YEp181-CUPHis7-Smt3. Prepare small-scale TCA lysates as described above and analyze 5 µl aliquots by PAGE on 12% gels and Western blot, using antibodies against yeast Smt3 and the His-tag in order to confirm overexpression of tagged Smt3. Select clones that show good overexpression of the tagged construct (as shown in Fig. 6.2B) and restreak one colony each of the resulting strains on SC-Leu plates: - WT + YEplac181 - CDC3HA + YEplac181 - CDC3HA siz1 + YEplac181
92
Ulrich and Davies
Fig. 6.2. Analysis of Cdc3HA and HisSUMO by Western blot. (A) Anti-HA blot of total cell lysates showing expression of the 6HA-tagged CDC3 allele. An untagged WT strain is shown as a negative control. Note that the extent of sumoylation is too low to be detected on this blot. (B) Effect of HisSMT3 overexpression on the total cellular SUMO conjugates. The anti-Smt3 blot shows yeast SUMO conjugates in the strains used subsequently for Ni-NTA pull-downs, where “–” denotes the “empty” vector YEplac181. Note that HisSMT3 expression is observable even without addition of CuSO4, and the total level of conjugates does not increase significantly after induction of the CUP1 promoter, even though their size distribution changes (see Note 17). Reduced SUMO conjugate levels are found in the siz1 mutant.
Detection of Sumoylation Targets in Yeast
93
- WT + YEp181-CUP-His7-Smt3 - CDC3HA + YEp181-CUP-His7-Smt3 - CDC3HA siz1 + YEp181-CUP-His7-Smt3 3.2.2. Pull-down of HisSmt3 under Denaturing Conditions
1. Use the strains listed above to inoculate 5 ml cultures in SCLeu medium containing 100 µM CuSO4. Shake overnight at 30°C. 2. Use the overnight cultures to inoculate 50 ml cultures in the same medium at a starting cell density of OD600 ≈ 0.5. Shake at 30°C until the OD600 has just exceeded 1.0. At this stage the culture is actively growing in exponential phase. 3. Harvest 109 cells and perform denaturing Ni-NTA pulldowns as described in Sect. 3.1.5. 4. In parallel, prepare small-scale TCA lysates of each culture as described in Sect. 3.1.4. 1. Prepare 7.5% polyacrylamide gels for the analysis of the samples as described in Sect. 3.1.2.
3.2.3. Detection of SUMO Conjugates
2. Load the TCA lysates and the eluates from the pull-down onto both gels, run them as described in Sect. 3.1.2, and blot onto PVDF membranes as described in Sect. 3.1.3. 3. Use an anti-HA antibody to detect Cdc3HA in the TCA lysates and the pull-down samples. Fig. 6.3 shows a representative blot on which not only the mono-sumoylated form of Cdc3HA but also the longer poly-SUMO chains specific for Cdc3HA are visible in the positive sample. In this example the distinction between positive signals and background is evident, but care has to be taken in cases where the abundance of the relevant conjugates is low. As the total level of the HisSUMO conjugates depends on the expression level of the HisSMT3 gene (see Fig. 6.2B), the control strains have to be treated in parallel under identical conditions (see Note 17).
3.3. Detection of His PCNA Sumoylation by Endogenous Smt3
PCNA sumoylation will be detected using His-tagged POL30 alleles and endogenous yeast Smt3 (15–18). In this example, the Ni-NTA pull-downs serve to enrich the modified forms of PCNA against a background of nonspecific bands cross-reacting with the anti-PCNA antibody. This procedure significantly enhances the sensitivity of detecting low-abundance conjugates and allows the visualization of poly-SUMO chains on PCNA using an antiSmt3 antibody (20). We will detect the sumoylation pattern on WT PCNA as well as mutants in the two major SUMO acceptor sites, K127 and K164. A control strain, harboring untagged POL30, is processed in parallel to account for nonspecific signals from the antibodies.
94
Ulrich and Davies
Fig. 6.3. Analysis of Cdc3HA sumoylation by Ni-NTA pull-down in vivo. (A) Anti-HA Western blot of pull-down samples, indicating Cdc3HA-SUMO conjugates. A cross-reacting band is marked by an asterisk. (B) Anti-HA Western blot of total TCA lysates showing the presence of Cdc3HA in the relevant strains.
3.3.1. Construction of Yeast Strains
His-tagged versions of WT or mutant POL30 are first introduced into the LEU2 marker of WT yeast on integrative vectors bearing the tagged alleles under control of the POL30 promoter (16,17). Endogenous PCNA is then deleted using a plasmid knockout construct that replaces the open reading frame with the URA3 marker pBL243 (see Note 18). The strategy, along with possible alternative schemes, is outlined in Fig. 6.4. 1. Digest YIp128-P30-His6-POL30 and mutant versions (K127R, K164R, and K127/164R) (see Note 1) with AflII and use ca. 0.5 µg of digested DNA for transformation of WT yeast cells as described in Sect. 3.1.1. Spread the cells onto SC-Leu plates and incubate at 30°C for 2–3 days. 2. Inoculate several 2 ml cultures in liquid SC-Leu medium with isolated colonies, shake overnight at 30°C, and prepare TCA lysates for analysis by anti-PCNA Western blot (see Sects. 3.1.2–3.1.4). For each allele of POL30, select
Fig. 6.4. Strategies for the construction of His-tagged POL30 alleles for in vivo analysis of sumoylation (see also Notes 1 and 18). Recombination events are indicated by grey shading. (A) Transformation with an integrative plasmid bearing HisPOL30 (YIp128-P30-His6-POL30) into the LEU2 marker and subsequent deletion of endogenous POL30 by a hisG-URA3-hisG construct (pBL243). (B) Two-step replacement by integration of HisPOL30 into the POL30 locus and subsequent counterselection for loss of the URA3 marker and retention of the tagged allele. (C) One-step replacement by insertion of a cassette bearing HisPOL30 flanked by the selectable LEU2 marker.
Detection of Sumoylation Targets in Yeast 95
96
Ulrich and Davies
a colony that shows an additional band of equal intensity above endogenous PCNA, corresponding to the His-tagged protein (Fig. 6.5A, lane 2). Restreak these colonies onto a fresh SC-Leu plate and incubate at 30°C for 2–3 days. 3. For each of the POL30 alleles, inoculate an overnight culture in liquid YPD medium and use this for transformation with ca. 1 µg each of MluI/KpnI-digested pBL243 (24). Spread onto SC-Ura plates and incubate at 30°C for 2–3 days. 4. Inoculate several 2 ml cultures in liquid SC-Ura medium with isolated colonies, shake overnight at 30°C, and prepare TCA lysates for analysis by anti-PCNA Western blot as above. For each POL30 allele, select a clone that has lost the endogenous, untagged PCNA (Fig. 6.5A, lane 3). Restreak this clone onto a fresh SC-Ura plate and incubate at 30°C for 2–3 days.
Fig. 6.5. Construction and analysis of the strains used for detection of PCNA sumoylation in vivo. (A) Construction of a yeast strain bearing a His-tagged POL30 allele, followed by anti-PCNA Western blot analysis of TCA lysates. The blot shows extracts from yeast cells before introduction of the HisPOL30 allele, after insertion of HisPOL30, and after deletion of endogenous POL30. (B) Detection of SUMO (upper panel) and PCNA (lower panel) in total cell extracts of the strains used for the pull-down assays. Note that the SUMO conjugates at K164 in the POL30 (lower arrow) and HisPOL30 (upper arrow) strain are abundant enough to be detectable among the total SUMO conjugates. Their positions are marked by arrows.
Detection of Sumoylation Targets in Yeast 3.3.2. Pull-down of HisPCNA under Denaturing Conditions
97
1. Use the clones described above (Fig. 6.5A), together with an unmodified WT strain, for inoculation of 5 ml cultures in YPD and shake at 30°C overnight. 2. Use the overnight cultures to inoculate 50 ml cultures in the same medium at a starting cell density of OD600 ≈ 0.5. Shake at 30°C until the OD600 has just exceeded 1.0. 3. Harvest 109 cells and perform denaturing Ni-NTA pulldowns as described in Sect. 3.1.5. 4. In parallel, prepare small-scale lysates of each culture as described in Sect. 3.1.4.
3.3.3. Detection of SUMO Conjugates
1. Prepare two 10% polyacrylamide gels for the analysis of the samples as described in Sect. 3.1.2. Load 5 µl aliquots of the TCA preparations and the pull-down eluates onto each gel. Also assemble a NuPAGE 4–12% Bis-Tris gradient gel and load the pull-down samples twice, placing the molecular weight marker into the middle to separate the two sets of samples. Run the gels as described above and blot onto PVDF membranes. 2. Develop one of the membranes derived from the 10% gels with anti-PCNA and the other one with anti-Smt3 antibodies. Cut the membrane corresponding to the gradient gel samples along the marker lane and develop one half with anti-PCNA and the other half with anti-Smt3 antibodies. 3. The Western blots of the TCA lysates should result in a picture similar to that shown in Fig. 6.5B. As its abundance in vivo is quite high, PCNA sumoylated at K164 may be detectable as a distinct band even on anti-SUMO blots of total conjugates, recognizable by its absence in the Hispol30(K164R) and Hispol30(K127/164R) and a size shift between POL30 and HisPOL30. 4. The analysis of the pull-down samples by SDS-PAGE and Western blot exemplifies the sensitivity of the detection method (Fig. 6.6). The anti-SUMO blots allow detection of poly-SUMO conjugates of high molecular weight that are not visible on the PCNA-specific blots, because the antiSUMO antibody naturally favors higher order polymers of SUMO. The architecture of the conjugates shown here has been described and interpreted in detail elsewhere (20). 5. When images derived from 10% gels versus gradient gels are compared side-by-side, a characteristic complexity of the running behavior of SUMO conjugates on polyacrylamide gels is revealed (Fig. 6.6). Despite an identical molecular weight, attachment of SUMO to K164 of PCNA results in a species with a mobility different from that of a conjugate at K127, and the relative mobilities vary with the gel system
98
Ulrich and Davies
Fig. 6.6. Analysis of PCNA sumoylation in vivo. (A) Detection of SUMO (upper panels) and PCNA (lower panels) in the eluate from Ni-NTA beads. The Western blots represent samples separated on 10% polyacrylamide gels. (B) The same samples were separated on 4–12% Bis-Tris gradient gels. Positions of the major SUMO conjugates are labeled on both blots. The asterisks indicate the positions of PCNA di- and tri-sumoyated at K164.
used. As a rule, SUMO conjugates generally tend to exhibit lower mobilities than expected based on their molecular weights. This often allows detection of a size shift even in cases of high molecular weight conjugates.
4. Notes 1. pYM3 (23) encodes a 6HA-epitope flanked by a selectable marker (klTRP1) for preparing tagged alleles (Fig. 6.1A). Various other tags and markers are equally suitable (23,25). YEp181-CUP-His7-Smt3 is an episomal vector based on the yeast shuttle vector YEplac181 (22), carrying the LEU2 marker and His7-tagged SMT3 (in its processed form without the C-terminal extension) under the control of the cop-
Detection of Sumoylation Targets in Yeast
99
per-inducible CUP1 promoter (Fig. 6.1B). pBL243 (24) is useful for disruption of the POL30 gene by a hisG-URA3hisG marker that can be removed by counterselection on 5-fluoroorotic acid (Fig. 6.4). YIp128-P30-His6-POL30 and mutant derivatives (16,17) are integrative vectors carrying the LEU2 marker and His6-tagged POL30 under the control of its own promoter (Fig. 6.4). 2. The primer sequences given here are compatible with a series of widely used tagging and deletion cassettes (23,25). The underlined sequence is specific for the gene of interest, while the 3′ terminus of each primer is used to amplify the desired cassette. The gene-specific sequence should be at least 45 nt in length. We routinely use 50 nt for efficient in vivo recombination. 3. Reagents and equipment as well as protocols for agarose gel electrophosesis are not given here in detail, but can be found in general laboratory manuals for molecular biology and cloning (26). 4. It is important to use polyethylene glycol of the correct molecular weight range (PEG 3350). The solution is quite viscous and has to be pipetted slowly. It is sterilized by autoclaving. During this process, a white precipitate may form that will eventually settle at the bottom of the flask. This does not affect transformation efficiency. 5. This solution is commercially available (e.g., Sigma D7290), and can also be prepared in the lab. To prepare this solution, use Type XIV sodium salt (Sigma D6898) and dissolve in TE buffer at 10 mg/ml. Shear the DNA by pulling the solution repeatedly through a narrow-gauge needle and by sonication with ultrasound until it is no longer viscous. Extract three times with equal volumes of TE-equilibrated phenol, once with a 25:25:1 mixture of TE-equilibrated phenol:chloroform:isoamyl alcohol and once with a 25:1 mixture of chloroform:isoamyl alcohol. Precipitate the DNA with 0.1 volume of 3 M sodium acetate, pH 5.2, and 10 volumes of absolute ethanol at 4°C for 30 min. Centrifuge the precipitate at 8,000g for 10 min, remove the supernatant, wash the pellet with 70% ethanol, centrifuge again briefly, remove the supernatant, and dry the pellet at room temperature for several hours. Redissolve the DNA (incubation with shaking overnight might be required). Heat-denature at 95°C for 10 min before use. The preparation can be stored at −20°C, but should be reheated from time to time in order to maintain the denatured state. 6. While the HA- and His-specific antibodies are commercially available, the antibodies specific for yeast SUMO and
100
Ulrich and Davies
PCNA have been generated in our lab (17). Similar antibodies are available from a number of yeast labs. Antibodies raised against mammalian PCNA react poorly with the yeast protein and are not suitable for the detection of PCNA modifications. 7. The number of yeast cells in a culture can be roughly determined by the optical density at 600 nm (OD600). Although the ratio between OD600 and cell number depends on the size of the cells, an approximate calculation can be performed using the ratio: 1 0D600 ≈ 2 × 107 cells/ml. For accurate measurements of optical densities, yeast cultures should be diluted to a reading not exceeding OD600 = 0.3. Cultures grown in YPD remain exponential up to OD600 ≈ 2. In SC medium they should not exceed an OD600 of 1. 8. When loading samples in HU buffer, ensure that equal volumes of the buffer are loaded into empty wells in order to obtain a straight running pattern. If this is not done, the high concentration of urea in the HU buffer will promote a spreading of the corresponding lanes into adjacent urea-free regions of the gel. Samples in other loading buffers, such as the molecular weight markers, need to be mixed with HU buffer for loading in order to avoid being “squeezed” by adjacent urea-containing lanes during the run. 9. PVDF membranes are preferable to nitrocellulose membranes because of their better physical stability and the lower propensity of proteins to run through the membrane during blotting. These membranes need to be wetted with methanol due to their hydrophobicity. Once wet, they should never be allowed to dry during the blotting and detection process. 10. If the gel is moved after having touched the membrane, spurious signals are likely to appear on the film. This is particularly relevant for gels bearing pull-down samples, because some proteins are highly enriched by this procedure and may leave an imprint on the membrane on first contact. 11. We describe here a semi-dry blotting procedure. For very large proteins, tank blotting may be preferable. We use a discontinuous buffer system in order to minimize the loss of proteins from “run-through”. 12. The chemiluminescence signal can be quantified on an imager (e.g., Fuji LAS-3000), but it has to be borne in mind that the signal strength is usually not proportional to the amount of protein on the blot. Accurate quantification will require comparison to samples of known concentrations. 13. Depending on the abundance of the target protein and the extent of its modification, smaller amounts of cells can often be used for the pull-down. Isolation of tagged proteins from
Detection of Sumoylation Targets in Yeast
101
the lysates under the conditions described here is not quantitative, but the amount recovered in the eluate is roughly proportional to the number of cells used for preparing the lysate. 14. Incomplete removal of the supernatant of this step will result in lower pull-down efficiencies because of an inappropriately low pH due to TCA carry-over. To avoid this, the pH of the solution can be checked at this point and, if needed, adjusted. However, if the supernatant after TCA precipitation is removed completely by two steps of centrifugation and aspiration, adjustment should not be necessary. 15. Agarose beads should be centrifuged at low speed to avoid crushing them. All wash solutions should contain some detergent, which prevents the beads from sticking to the sides of the tube. For distributing them with a pipette, cut the tip from the plastic pipette tip. Magnetic Ni-NTA beads are also available and are easier to handle, but, in direct comparisons, we have found that their binding capacity is significantly lower. 16. Addition of low concentrations of imidazole significantly reduces the background signal arising from nonspecific binding to the Ni-NTA beads. However, concentrations higher than 15 mM are not recommended, as they will reduce the pull-down efficiency. 17. As shown in Fig. 6.2B, the amount and distribution of the total cellular HisSUMO conjugates depends on the expression levels of the HisSMT3 allele, and addition of CuSO4 does not automatically result in increased conjugation of the tagged protein, even though the total abundance of SUMO is much higher than in the absence of copper. Omission of CuSO4 may sometimes result in improved detection of some His SUMO conjugates, but this needs to be empirically determined for each candidate substrate. 18. We describe here just one of several strategies to replace an endogenous gene with a His-tagged allele. This method is simple and works with high efficiency for any gene, and mutant alleles can be introduced with the same ease. The disadvantage is the use of two selectable markers: one by the integrative vector and the other one for the deletion construct. However, in this example, the knockout construct for POL30, pBL243, carries the URA3 marker flanked by tandem repeats of a sequence derived from the E. coli hisG gene (pol30::hisG-URA3-hisG), which allows the subsequent removal of URA3 by counterselection on 5-fluoroorotic acid (5FOA). An alternative approach is the integration of the tagged allele on a URA3-based plasmid into the target locus itself and subsequent selection on 5FOA for loss of the
102
Ulrich and Davies
untagged open reading frame by spontaneous recombination between the two alleles. This strategy leaves no marker behind in the genome, but the integration of mutant alleles is less efficient, because recombination may occur anywhere within the open reading frame, thus separating the His-tag from the site of the mutation. A third option would be the insertion of a selectable marker adjacent to the tagged open reading frame on a plasmid carrying the gene with its flanking regions and the use of this construct for a one-step replacement of the endogenous gene. All three options are schematically depicted in Fig. 6.4.
Acknowledgments The authors would like to thank E. Johnson for providing the strain CDC3HA, P. Burgers for plasmid pBL243, and M. Knop for plasmid pYM3. Work in this lab is supported by Cancer Research UK.
References 1. Denison, C., Rudner, A. D., Gerber, S. A., Bakalarski, C. E., Moazed, D., and Gygi, S. P. (2005) A proteomic strategy for gaining insights into protein sumoylation in yeast. Mol. Cell. Proteomics 4, 246–254. 2. Ganesan, A. K., Kho, Y., Kim, S. C., Chen, Y., Zhao, Y., and White, M. A. (2007) Broad spectrum identification of SUMO substrates in melanoma cells. Proteomics 7, 2216–2221. 3. Hannich, J. T., Lewis, A., Kroetz, M. B., Li, S. J., Heide, H., Emili, A., and Hochstrasser, M. (2005) Defining the SUMOmodified proteome by multiple approaches in Saccharomyces cerevisiae. J. Biol. Chem. 280, 4102–4110. 4. Manza, L. L., Codreanu, S. G., Stamer, S. L., Smith, D. L., Wells, K. S., Roberts, R. L., and Liebler, D. C. (2004) Global shifts in protein sumoylation in response to electrophile and oxidative stress. Chem. Res. Toxicol. 17, 1706–1715. 5. Panse, V. G., Hardeland, U., Werner, T., Kuster, B., and Hurt, E. (2004) A proteomewide approach identifies sumoylated substrate proteins in yeast. J. Biol. Chem. 279, 41346–41351. 6. Rosas-Acosta, G., Russell, W. K., Deyrieux, A., Russell, D. H., and Wilson, V. G. (2005)
7.
8.
9.
10.
11.
12.
A universal strategy for proteomic studies of SUMO and other ubiquitin-like modifiers. Mol. Cell. Proteomics 4, 56–72. Vertegaal, A. C., Ogg, S. C., Jaffray, E., Rodriguez, M. S., Hay, R. T., Andersen, J. S., Mann, M., and Lamond, A. I. (2004) A proteomic study of SUMO-2 target proteins. J. Biol. Chem. 279, 33791–33798. Wohlschlegel, J. A., Johnson, E. S., Reed, S. I., and Yates, J. R. 3rd. (2004) Global analysis of protein sumoylation in Saccharomyces cerevisiae. J. Biol. Chem. 279, 45662–45668. Zhao, Y., Kwon, S. W., Anselmo, A., Kaur, K., and White, M. A. (2004) Broad spectrum identification of cellular small ubiquitin-related modifier (SUMO) substrate proteins. J. Biol. Chem. 279, 20999–21002. Zhou, W., Ryan, J. J., and Zhou, H. (2004) Global analyses of sumoylated proteins in Saccharomyces cerevisiae. Induction of protein sumoylation by cellular stresses. J. Biol. Chem. 279, 32262–32268. Johnson, E. S. and Blobel, G. (1999) Cell cycle-regulated attachment of the ubiquitinrelated protein SUMO to the yeast septins. J. Cell Biol. 147, 981–994. Johnson, E. S. and Gupta, A. A. (2001) An E3-like factor that promotes SUMO conjugation to the yeast septins. Cell 106, 735–744.
Detection of Sumoylation Targets in Yeast 13. Takahashi, Y., Kahyo, T., Toh-E, A., Yasuda, H., and Kikuchi, Y. (2001) Yeast Ull1/Siz1 is a novel SUMO1/Smt3 ligase for septin components and functions as an adaptor between conjugating enzyme and substrates. J. Biol. Chem. 276, 48973–48977. 14. Jónsson, Z. O. and Hübscher, U. (1997) Proliferating cell nuclear antigen: more than a clamp for DNA polymerases. BioEssays 19, 967–975. 15. Hoege, C., Pfander, B., Moldovan, G. L., Pyrowolakis, G., and Jentsch, S. (2002) RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 419, 135–141. 16. Stelter, P. and Ulrich, H. D. (2003) Control of spontaneous and damage-induced mutagenesis by SUMO and ubiquitin conjugation. Nature 425, 188–191. 17. Papouli, E., Chen, S., Davies, A. A., Huttner, D., Krejci, L., Sung, P., and Ulrich, H. D. (2005) Crosstalk between SUMO and ubiquitin on PCNA is mediated by recruitment of the helicase Srs2p. Mol. Cell 19, 123–133. 18. Pfander, B., Moldovan, G. L., Sacher, M., Hoege, C., and Jentsch, S. (2005) SUMOmodified PCNA recruits Srs2 to prevent recombination during S phase. Nature 436, 428–433. 19. Robert, T., Dervins, D., Fabre, F., and Gangloff, S. (2006) Mrc1 and Srs2 are major actors in the regulation of spontaneous crossover. EMBO J. 25, 2837–2846.
103
20. Windecker, H. and Ulrich, H. D. (2008) Architecture and assembly of poly-SUMO chains on PCNA in Saccharomyces cerevisiae. J. Mol. Biol. 376, 221–231. 21. Guthrie, C. and Fink, G. R. (1991) Guide to Yeast Genetics and Molecular Biology. Academic Press, San Diego, CA. 22. Gietz, R. D. and Sugino, A. (1988) New yeast-Escherichia coli shuttle vectors constructed with in vitro mutagenized yeast genes lacking six-base pair restriction sites. Gene 74, 527–534. 23. Knop